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Abstract 
Introduction  
Accurate risk stratification of ED patients with infection is vital for informing priorities of 
investigation and treatment, disposition location, and communication to patients, families and 
inpatient specialists. Risk stratification systems for ED patients with infection exist in the form of 
‘sepsis syndromes’ classifications and clinical prediction rules derived through mathematical 
modelling. However most studies designed to validate these risk stratification tools have examined 
patient cohorts assembled using discharge coding, critical care admission or administrative 
databases, or re-analyse data from studies conducted for another purpose. These factors can 
contribute to multiple types of bias and questionable applicability.  
The aims of this thesis are to demonstrate that (1) with foreknowledge of contributors to bias, a 
quality Australian ED dataset comprising patients with a wide spectrum of disease severity can be 
compiled, and 2) validations of risk stratification and clinical prediction models with these data can 
provide valuable insights relevant to practising ED physicians and researchers. 
Methods 
Consecutive ED patients with infection admitted to a tertiary metropolitan hospital were enrolled 
in a prospective observational database. Concurrence between ED and admitting inpatient 
clinicians that infection was the most likely cause for admission was the primary inclusion 
criterion. Detailed data were recorded regarding suspected source, physiology and treatment in 
the ED, investigations, co-morbidities, admission location and length of stay. Mortality outcomes 
were sourced from a national database. Data enabled classification according to sepsis syndromes 
and established clinical outcome prediction models. Chapter 2 details methods as published. 
Results 
Data were collected over 162 weeks. The study cohort comprised 9719 admissions with overall 30-
day mortality 3.7%. Four papers, comprising the basis of chapters 3-6 of this thesis were 
published, each examining an aspect of risk stratification of ED patients admitted with infection. 
Sepsis syndromes: Chapter 3 examined risk stratification using ‘sepsis syndromes’ (infection 
without SIRS, sepsis, severe sepsis and septic shock). A 2016 reclassification examining large 
administrative databases advocated abandoning SIRS, proposed sequential organ function 
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assessment (SOFA) based criteria to determine organ dysfunction, and conceived ‘q’(quick) SOFA 
to screen for patients with sepsis outside ICU. The paper in this chapter reported SIRS was 
associated with increased risk of organ dysfunction (RR 3.5) and mortality in patients without 
organ dysfunction (OR 3.2). SIRS and qSOFA displayed equivalent discrimination for organ 
dysfunction (AUROCs 0.72 vs 0.73), but SIRS provided greater sensitivity at determined operating 
points (72.3% vs 29.2%). Substantial variation was revealed in mortality associated with SOFA-
determined dysfunction in various organ systems. A hybrid system of classification was proposed, 
consisting infection without SIRS, sepsis (infection with SIRS), severe sepsis (infection with organ 
dysfunction) and septic shock (infection with cardiovascular dysfunction). 
Septic shock is the subject of chapter 4, with stark contrast demonstrated between consecutive, 
unselected patients with this condition in the study database and cohorts enrolled in recent RCTs 
recruiting ED patients with septic shock. Increasing severity of illness and mortality was 
demonstrated for patients satisfying lactate, hypotension, and both diagnostic criteria for septic 
shock (mortality 14.8%, 21.3% and 27.5% respectively). Most patients with septic shock (62.7%) 
were not admitted to ICU, and mortality for patents admitted to ICU was lower than for patients 
treated on wards (12.1% vs 20.8%). 
Severity scores: Established clinical prediction models [MEDS, SOFA, APACHE II, SAPS II and a new 
‘Severe Sepsis Score’ were validated in chapter 5, most for the first time in Australian ED patients. 
Spectrum bias was explored through repeated analysis in varied patient groups. MEDS showed 
optimal performance (AUROC 0.92), however some MEDS variables were compromised by 
subjective interpretation and information bias. Older scores such as APACHE II and SAPS II 
discriminated well (AUROC for both 0.90), but displayed poor calibration, consistently 
overestimating mortality.  
Community-acquired pneumonia (CAP). Several CAP clinical prediction models have progressed to 
later developmental stages including impact assessment and incorporation into guidelines. Patient 
disposition location is informed through prediction model stratification in several national 
guidelines. The final paper (chapter 6) assessed performance of established CAP scores, some for 
the first time in Australian patients. Newer scores such as SMARTCOP, CURXO and IDSA/ATS 2007 
minor criteria showed higher discrimination (AUROCs 0.84-0.87) than older scores (0.70 for both 
PSI and CURB65).  Performance of low scores was assessed for prediction of brief admission (≤ 48 
hours), potentially to an ED short stay unit. No score performed sufficiently to justify this 
indication (AUROCs 0.64-0.74). 
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Conclusions 
Through analysis of detailed prospective data from consecutive ED patients admitted with 
infection of all severities, new perspectives have emerged to challenge established constructs 
derived from convenience or selective sources such as administrative or RCT data. Examples 
include prognostic import of SIRS and insensitivity of qSOFA in the ED, and interactions between 
hyperlactataemia and hypotension in septic shock. Performance of severity scores was shown to 
be influenced by cohort selection, and endpoints. Appraisal of research examining risk 
stratification tools should take account of representativeness of the study cohort.       
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Chapter 1: Introduction and Literature Review 
Section 1.1 - Introduction 
 
1.1.1 – The Challenge 
The patient was moved from triage to an empty emergency department (ED) cubicle shortly after 
arrival. Brian’s general practitioner had referred him to the ED after an illness of about ten days’ 
duration, consisting fatigue, malaise, back and right hip pain. There were no fevers, but this 
morning he had appeared slightly confused and sweaty. The only relevant aspects of Brian’s 
medical history were quiescent ischaemic heart disease after a myocardial infarct and two stents 
the previous year, and longstanding arthritis in his right hip. Regular medications were aspirin and 
an antihypertensive only. After a successful career in accounting, he had just retired at age 67 to 
spend more time with his wife and family. Life was good. 
  
Today he did not look well: sweaty, subtly dyspnoeic, and with cool peripheries. He was responsive 
and oriented but spoke little. Chest pain was denied. Brian’s respiratory rate was 28 breaths per 
minute with supplemental oxygen required for oximetry values greater than 90%. Auscultation 
revealed bibasal coarse crepitations. Radial pulses were strong and revealed new atrial fibrillation 
at 120 beats / minute. Blood pressure was 130/80 and bedside venous lactate mildly elevated at 
3.4 mmol/L. Abdominal exam revealed generalised mild discomfort without peritonism, and there 
were no rashes. The right hip was moderately painful on active movement with only a mildly 
reduced range of motion. Temperature and blood glucose measurements were normal. 
 
It was appreciated early that Brian’s unwellness was likely sepsis, with differential diagnoses 
including myocardial ischaemia and pulmonary embolism. Blood and urine cultures were 
collected, and antibiotic therapy commenced within the first hour comprising gentamicin and 
flucloxacillin in appropriate doses. Results of basic investigations showed a new acute kidney 
injury (creatinine 347) and normal peripheral leucocyte and platelet counts. A chest radiograph 
revealed bilateral patchy basal infiltrates, raising the possibility of pneumonia.  
 
Brian was later admitted to the ICU, but rapidly deteriorated within hours of admission. He 
became confused, soon after somnolent, with respiratory failure requiring mechanical ventilation. 
Persistent hypotension despite intravenous fluids required escalating doses of multiple inotropic 
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and vasopressor medications, and renal replacement therapy was commenced. Multiple blood 
cultures returned positive within six hours indicating bacteraemia with Staphylococcus aureus, 
later shown sensitive to the flucloxacillin given promptly in the ED and now administered by 
continuous infusion. All Brian’s organs were failing, and his condition was deteriorating hourly 
despite maximal therapy. His shocked and disorientated family kept a despairing vigil by his 
bedside. Brian died of overwhelming sepsis and multiple organ failure, less than 36 hours after his 
arrival at hospital.  
 
I was the emergency physician who treated Brian (not his real name) in the ED that day almost 10 
years ago. Although it was apparent at the time that Brian very likely had sepsis, and that he was 
sufficiently sick to require admission to the ICU, I had not judged him (at least during his initial 
phase of treatment) to be at very high risk of short-term mortality. There was evidence in the ED 
of dysfunction in two organ systems (respiratory and renal), but Brian’s temperature and 
leucocyte counts were normal, cognition and blood pressure were normal, and lactate not 
elevated to the level at that time associated with shock (≥4 mmol/L). Were there other data 
relevant to prognosis? My reading at the time identified two broad types of framework related to 
prediction of outcome for ED patients with sepsis:  
 
1) The sepsis risk stratification system in general use (sepsis, severe sepsis, septic shock) and 
endorsed by international authorities such as the ‘Surviving Sepsis Campaign’. This construct will 
be introduced in the next sub-section but discussed in more detail in chapters three and four of 
this thesis.   
 
2) Derived clinical prediction models.  The mathematical derivation of prediction models will be 
reviewed in section 1.2. 
 
Assessment of these methods to classify and risk-stratify ED patients with sepsis of all severities 
provides the basis of this thesis. 
  
26 
 
1.1.2 - Sepsis, Severe Sepsis, Septic Shock 
The term ‘sepsis’ has been used for thousands of years and generally accepted to represent a 
complicated infection [1]. However, it was not until the closing decade of the last millennium that 
efforts to define the term gained traction [2]. 
  
The ‘Surviving Sepsis Campaign’ (SSC) [3], has provided a straightforward and widely recognised 
risk stratification system (infection without sepsis, sepsis, severe sepsis, and septic shock) based 
on the systemic inflammatory response syndrome (SIRS) [4] and organ dysfunction. This 
stratification was based on expert opinion, rather than data, and was not universally acclaimed. 
Some clinicians disagreed with the relevance of SIRS [5] and the means by which organ 
dysfunction should be determined was not specified by the SSC. Perhaps the most controversial 
aspect of the SSC guidelines at the time pertained to the highest risk category, septic shock. 
Guideline criteria for the definition (and treatment) of septic shock were adopted directly from a 
sole, single-centre randomised controlled trial conducted in the US [6] in which the baseline in-
hospital mortality for septic shock presenting to the ED was 46.5%. This figure was thought to be 
substantially higher than for the condition in Australia, but the only available data to support this 
assertion came from retrospective studies based on discharge [7] or ICU [8] diagnosis coding, 
which estimated the mortality for septic shock presenting to the ED in Australia to be ≤ 30%. A 
prospective Australian ED observational study published in 2009 [9] found the in-hospital mortality 
rate for septic shock to be 23.1%. However, limitations of that study included enrolment of a 
convenience sample and use of a number of surrogate markers to indicate septic shock rather 
than the established SSC criteria. At that time there were no prospective data benchmarking the 
incidence or outcome of patients presenting to Australian EDs with the range of sepsis severity 
syndromes (sepsis, severe sepsis, and septic shock). 
  
One aim of the first half of this thesis is to correct that deficit. The paper forming the basis of 
chapter three was originally designed to estimate the relative size and mortality outcome of the 
patient subgroups with: infection without sepsis, sepsis (infection with ≥2 SIRS criteria), severe 
sepsis (sepsis with organ dysfunction), and septic shock, all as defined by the 2008 SSC guidelines 
(Table 1-1). Of particular interest were the role of SIRS in sepsis prognostication and implications 
of the use of a modified ‘Sequential Organ Function Assessment’ (SOFA) [10] based system to 
classify organ dysfunction.  
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Table 1. 1: Surviving Sepsis Campaign 2008 sepsis risk stratification 
 
Classification Definition 
 
Infection without sepsis 
 
Infection with <2 SIRS criteria 
Sepsis 
Infection + ≥2 SIRS criteria: 
Temperature <36 or >38.3 degrees C 
Leucocyte count <4 or >14 x10 
Respiratory rate ≥20 breaths/minute 
Heart rate ≥90 beats/minute 
Severe sepsis 
 
Sepsis with organ dysfunction 
 
Septic shock 
 
Sepsis with either: 
Hypotension unresponsive to fluid 
Lactate ≥4mmol/L 
 
 
 
 
In 2016, an influential group of predominantly US and European critical care physicians published 
a proposed revision of the definitions for sepsis severity classes [11]. Substantial changes were 
detailed, including discarding SIRS, introduction of a new construct (‘qSOFA’ or ‘quick’ SOFA) for 
screening patients at risk of sepsis, and defining organ dysfunction in terms of a two-point 
increase in SOFA score. These changes were considered sufficiently important to incorporate into 
the published paper comprising chapter three of this thesis, providing an early appraisal of the 
implications of the proposed changes with prospectively collected ED data.   
 
The second broad source of prognostic information for patients with sepsis can be found within a 
range of clinical prediction models (CPM), reviewed in the next section.  
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Section 1.2 - Clinical Prediction Models 
 
1.2.1 - What are Clinical Prediction Models? 
Clinical prediction models (also known as clinical prediction rules, risk prediction scores or clinical 
prediction scores) are mathematically-derived tools that facilitate an evidence-based approach to 
clinical information or decision making [1]. Using established data, historical, clinical, and 
investigational variables are identified in a systematic fashion and combined in a model to 
estimate the probability of an outcome. Advantages of clinical prediction models (CPM) include 
incorporation of larger amounts of clinical information than the human brain would otherwise be 
able to consider, and greater accuracy than human clinical judgement alone [2]. Clinical prediction 
models have a variety of clinical and research-oriented uses, with several listed in Table 1-2 below.  
 
Table 1. 2: Uses of clinical prediction rules 
 
Domain Specific circumstances for clinical prediction model use 
Clinical  
 Quantification of risk to patients, families, caregivers 
 Structured communication of risk to fellow clinicians 
 Therapeutic decisions (e.g. broad-spectrum antibiotics, activated protein C)  
 Disposition decisions (e.g. home vs inpatient vs intensive care admission) 
Research  
 Inclusion in randomised controlled trials 
 Comparison of cohorts  
 Covariate and confounder adjustment 
 
 
Despite understandable concerns about maintenance of quality, standards and applicability of 
clinical prediction models [3], and slow uptake by clinicians [2], their number continues to rise [4]. 
Toll et al. demonstrated a doubling in the number of Medline listed papers discussing clinical 
prediction rules between 1995 and 2005 [4]. Figure 1-1 shows the number of papers identified by 
an Embase search restricted to title field using the terms “predictive model” OR “prognostic 
model” between 1985 and 2015. 
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Figure 1. 1: Publications per year identified by an Embase search using title field and terms 
“Prediction rule” OR “Prognostic rule” between 1986 and 2016. 
           
 
1.2.2 - Types of clinical prediction model 
Various methods of developing clinical prediction models exist. These methods have been 
classified as follows [5]: 
 
a) Predictor variables and their weightings determined by univariate and multivariate analysis, 
usually resulting in a scoring system that assigns a weighted value to each identified predictor 
variable, the total then determining the expected result. This method has the advantage of 
relative simplicity, but may not capture complex inter-relationships between predictor variables. 
Examples are common in sepsis literature, such as the Mortality in Emergency Department Sepsis 
score (MEDS) [6], summarised in Table 1-3. 
 
b) Nomograms. These are graphical calculating devices, with advantage of simplicity in the final 
product, facilitating use at the bedside. These models generally rely on relationships between 
variables and values created with straight lines across the nomogram. A non-sepsis example of this 
type of prediction model would be the Siggaard-Anderson nomogram used in the diagnosis of 
acid-base disorders [7]. 
c) Neural networks. In these models, multiple data points are input to software programme which 
analyses all in the context of the others, culminating in dichotomous or a probability output. By 
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entering observed output data, the neural network recalibrates and ‘learns’ how to improve 
predictions [1]. Neural networks have several drawbacks, including complexity, unsuitability for 
use at the bedside, and ‘overfitting’ of data. Advantages include utilisation of large amounts of 
data from electronic health records, and automated recalibration [8]. Examples of neural networks 
or ‘machine learning’ models have been proposed for prediction of mortality for ED patients with 
sepsis [9]. 
 
Table 1. 3: Variables, weightings and predicted outcomes in the Mortality in Emergency 
Department Sepsis score [6]. 
Variable Points 
Rapidly terminal comorbid illness 6 
Age >65 years 3 
Tachypnoea or hypoxia 3 
Septic shock 3 
Platelets <150,000/mm3 3 
Neutrophil bands >5% 3 
Nursing home resident 2 
Altered mental state 2 
Lower respiratory tract infection 2 
  
Points range Predicted 28-day mortality (%) 
0 to 4 0.9 
5 to 7 2 
8 to 12 7.8 
13 to 15 20.2 
>15 50 
 
 
d) Classification and regression tree (CART) analysis is used to generate a ‘decision tree’, whereby 
data are sequentially divided into subgroups based on values of each predictor variable. [5]. The 
impact of later variables is therefore modified by the values of variables used at earlier points in 
the decision tree. CART analysis has been found less accurate than logistic regression based 
models [10]. Several examples of CART analysis use in sepsis research exist [11, 12].  
 
1.2.3 – Stages of clinical prediction model development 
The four stages of clinical decision model evolution are briefly outlined as follows [1]: 
 
1. Development – proceeds with analysis of data and formulation of contributor variables and 
individual weightings or position that will determine the impact or importance of that 
31 
 
characteristic in the final model. Internal validation may be performed to demonstrate the model 
effectively represents the data from which it was derived [13]. 
2. Validation – in this process the performance of a CPM is assessed in patients other than those in 
which it was derived. This process determines the generalisability or transportability of the CPM to 
other groups of patient and settings. Over time the CPM may be updated or modified with 
additional variables or recalibrated to reflect different performance at a later time or in different 
patient groups.  
3. Impact analysis – a determination of the overall benefit (clinical, financial or both) associated 
with a period of clinical care during which decisions are guided by the CPM.   
4. Widespread implementation – CPM-based guidelines may be adopted and endorsed by 
authoritative clinical or administrative advisory groups for implementation over a geographic or 
health-care speciality related area.   
 
The theoretical evolution of each CPM through each stage of development ensures mature and 
robust models with widespread applicability are used to optimise the clinical and/or financial 
implications of decisions [4]. However, most studies on clinical prediction models describe 
development of new models [14]. Relatively few papers report on the external validation of CPMs, 
and evidence of models reaching the final two stages of impact analysis and widespread 
implementation is rare. Contributions to the CPM external validation literature have been made 
within the later chapters of this thesis. Chapter five includes a review and validation of several 
sepsis severity CPMs, including the MEDS score outlined above. Severity scores for community-
acquired pneumonia are unusual in that several have progressed through the later stages of 
impact analysis [15] and widespread recommendation, if not implementation [16]. These CPMs 
are examined in chapter six. 
 
Section 1.3 Validation of Clinical Prediction Models 
 
The second stage of development for clinical prediction models is validation in patients other than 
those in which the model was derived. Validation in this sense refers to an assessment of the 
performance of the model, which is usually assessed in two domains, discrimination and 
calibration [1]. 
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1.3.1 – Discrimination 
An essential function of a clinical prediction model is the ability to discriminate between patients 
with and those without the endpoint of interest (often mortality within a specified timeframe for 
sepsis severity scores). The most commonly used measure of overall discrimination for clinical 
prediction rules is the concordance (c) statistic, which for binary outcomes is equal to the area 
under the receiver operating curve (AUROC) [2]. The receiver operating curve is described by 
plotting sensitivity (true positive rate) against 1 – specificity (false positive rate) for each of the 
possible clinical prediction model values (Figure 1-2) [3].  
 
Figure 1. 2: Receiver operating characteristic (ROC) curves for several predictive models 
                                          
Each curve represents the plot of sensitivity versus (1-specificity) for all the possible model values. The 
trade-off between sensitivity and specificity is well demonstrated. Optimal performance is obtained by the 
point closest to the top left corner of the plot. A commonly-used summary measure of discrimination is the 
area under the receiver operating curve, which for binary outcomes is equivalent to the ‘c’ (concordance) 
statistic. 
 
 
In practice, an operating point for the prediction model is chosen optimising the combination of 
sensitivity and specificity [2]. A completely non-informative model (pure chance, such as a coin 
flip) is represented by the diagonal line running from bottom left to top right of the figure (AUROC 
= 0.5), and larger AUROC (approaching 1.0) indicates greater overall discrimination. The ‘c’ statistic 
(or AUROC) is also equal to the probability that a random patient with the outcome of interest is 
assigned a higher CPM score value than a randomly selected patient without the outcome of 
interest [4]. 
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1.3.2 – Calibration 
Calibration refers to the comparison of predicted and observed event rates in groups of patients 
[5]. A plot of predicted versus observed outcomes for patients with each CPM score or risk group 
demonstrates calibration graphically, with a line at 45 degrees indicating perfect predictions. 
Additional strategies for assessing calibration include the Hosmer Lemeshow goodness-of-fit test 
[6] or plotting results from linear regressions of observed and predicted values [7], in which a well 
calibrated model will produce slope close to unity and an intercept not statistically different from 
zero. 
 
1.3.3 – Types of validation studies 
Three types of validation study are recognised to form a hierarchy of increasing generalisability, or 
transportability [8]. A temporal validation study is performed in similar patients at the same 
location or institution (and potentially with the same investigators) as the original derivation 
study, but at a later time [9]. Geographical validation studies assess the performance of a CPM in 
similar patients but in a geographically distinct location (another hospital, or country). Domain 
validation refers to assessments conducted in patients with different characteristics to those in 
which the CPM was originally derived. Examples may include validating a model derived in ED 
patients in ICU patients and vice versa. Given the increasing opportunity for factors and 
circumstances to impact on the measured performance characteristics of clinical prediction 
models when assessed at different times, locations and types of patients, domain validation is 
regarded as the most robust and exacting measure of a model’s generalisability [8]. 
 
1.3.4 – Assessing the quality of validation studies 
Despite concerns about a general lack of external validation studies [10], the recent publication of 
a series of systematic reviews assimilating substantial numbers of such assessments of both ED 
sepsis [11] and community-acquired pneumonia [12-14] clinical prediction scores suggests 
researchers and clinicians are increasingly aware of the importance of this stage of model 
development. Together with these changes, checklists have been devised to facilitate assessments 
of validation study methodological quality and risk of bias. Several reviewers have based these 
quality and risk-of-bias assessments on a structure proposed by Hayden et al. [15], known as the 
Quality in Prognostic Studies (QUIPS) tool [12,14]. Six domains were specified (study participants 
and attrition, prognostic factor and outcome measurement, identified confounders, and statistics 
/reporting) and associated risk of bias reported as either low, medium or high. A similar 
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framework has been employed by Whiting and colleagues [16] in their 2011 Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS-2) tool. Here four domains are specified (patient selection, 
index test, reference standard, and flow/timing) in each of which signalling questions are 
suggested to facilitate judgement of risk of bias (high, low or unclear) and for the first three 
domains, applicability (sources of variation). Researchers from the Prognosis Methods Group of 
the Cochrane Collaboration have recently formulated a new tool for assessing bias in prediction 
studies, PROBAST (prediction model risk of bias assessment tool), designed to improve on prior 
tools such as QUIPS and QUADAS [17]. The PROBAST framework adopted the domain and 
signalling question approach that was deemed successful in the QUADAS model. Table 1-4 outlines 
the domains, data, and signalling questions in each of the three bias assessment tools.  
 
A combined tool was constructed for the purpose of assessing quality and risk of bias in the two 
reviews of validation studies included in this thesis (sections 5.2 and 6.2), based on the tools 
reviewed above. Four domains were included: 1) Study participants representative of the 
population of interest, 2) Index tests consistently applied, 3) endpoints measured accurately and 
consistently, and 4) appropriate statistical analysis.  
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 Table 1. 4: Comparison of operating domains in risk of bias assessment tools. 
 
Assessment tools 
QUIPS [15] QUADAS-2 [16] PROBAST [17] 
Participants Patient selection Participant selection 
Eligible participants enrolled Methods of patient 
selection defined 
Appropriate data sources used? 
(ie cohort, RCT, case-control 
study data) 
Source population described 
Study sample described Description of patients 
Sampling timeframe 
Period and place Consecutive patients? Appropriate inclusions and 
exclusions? Inclusion and exclusion Case-control avoided? 
Study Attrition Inappropriate exclusions 
avoided?  
Participants all in similar state 
of health, or confounders 
recorded? 
Response rate 
Efforts to optimise responses Could selection of study 
patients have introduced a 
bias? 
Loss to follow-up patients 
described  
 
Prognostic factor (PF) 
measurement 
Index test Predictors 
Clear definition of PF Description, how 
conducted and interpreted 
Adequately described and 
interpreted for all? Cut-offs determined  
Method of measurement 
same for all participants 
Index determined without 
knowledge of reference?  
Made without knowledge of 
outcome data? 
Missing data reported Threshold specified? All predictors available at the 
time of assessment? Techniques for accounting for 
missing data reported 
 
Outcome measurement Reference standard Outcome 
Clear definition Description, how 
conducted and interpreted 
Prespecified? 
Valid and reliable Independent of predictors? 
Same for all participants Correct classification of 
target condition? 
Determined similarly for all 
participants? Study confounding 
Definitions provided Conducted without 
knowledge of the index? 
Determined without knowledge 
of predictors? Confounders measured 
Measurements valid and 
reliable 
 Sample size and participant flow 
and timing 
Missing data accounted for Flow and Timing Enough outcomes? 
Confounders accounted for in 
study design and analysis 
Did all patients receive 
both index and reference? 
Interval between predictors and 
outcome appropriate? 
Statistical analysis and 
reporting 
Different intervals or 
interventions between 
index and reference? 
All participants included in 
analysis and missing data 
handled appropriately? 
Data presented to allow 
judgement of adequacy 
All patients received the 
same reference? 
Analysis 
Suitable framework for model 
construction 
All patients in analysis? Complexities in data accounted 
for? 
Statistics sufficient  Discrimination, calibration? 
Non-selective data reporting  Recalibration? 
 
QUIPS = quality in prognostic studies, QUADAS = quality in diagnostic accuracy studies, PROBAST = 
prediction model risk of bias assessment tool, RCT = randomised controlled trial. Domains are in blue and 
signalling questions are displayed in orange. 
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Section 1.4 - Summary and Conclusions 
 
The case report at the commencement of this chapter demonstrated the difficulties of risk 
assessment in patients presenting to the emergency department with the complex and potentially 
fatal disease process referred to as sepsis. Two broad classes of risk stratification framework were 
introduced, the sequentially more deadly “sepsis syndromes” (infection without sepsis, sepsis, 
severe sepsis, and septic shock), and mathematically derived constructs known as clinical 
prediction models. The relative lack of Australian data validating the “sepsis syndromes” hierarchy 
was revealed. 
 
 Clinical prediction models were then reviewed, starting with the rationale, types and methods of 
derivation for these risk stratification tools then proceeding to the important aspect of external 
validation. The assessment of quality and risk of bias in validation studies was examined, as a 
background to the assessment of validation studies in later chapters and to help minimise bias and 
optimise applicability in subsequent validation studies forming parts of the thesis. 
 
A central theme of this thesis is the identification of shortcomings in previous validations of risk 
stratification frameworks, and to provide Australian validations of both the ‘sepsis syndromes’ 
classification and selected clinical prediction models used in sepsis. Examination of quality and bias 
in validation studies has revealed the sentinel importance of the data used for analysis. The 
cornerstone of this thesis is therefore the prospective, observational database described in the 
next chapter.  
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Chapter 2: Methods 
 
Section 2.1 – Synopsis 
 
This chapter opens with a review of potential methods used to assess the performance of risk 
stratification systems or clinical prediction models in emergency department patients with 
infection (section 2.2). Using the framework established in the previous chapter, bias and 
applicability associated with various methods used in previous observational and validation 
studies are identified. These findings have informed the methodology employed in the creation of 
the database that underpins the published studies in this thesis. In section 2.3, thesis database 
methods are described in detail as they appear in a published paper titled “A prospective registry 
of emergency department patients admitted with infection”. Section 2.4 summarises some 
advantages of the chosen methods and outlines specifics such as personnel collecting data and 
time frames over which patients were recruited and the database completed.   
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Section 2.2 – Bias and variation in observational and validation studies 
 
This section will explore the dual challenges of minimising bias and maximising applicability in the 
design of an observational database. Bias is defined as a systematic deviation from the truth in 
measured values. Characteristic and predictable biases that may limit the internal validity of 
observational studies are well recognised [1]. Applicability (or external validity) is determined by 
the degree of similarity between participants, processes and procedures in the study and those in 
another environment [1]. Using the domains specified in the PROBAST tool [2], potential methods 
to identify and analyse a suitable cohort will be discussed, particularly with respect to risk of bias 
and extent of applicability of findings to other similar environments.  
 
2.2.1 – Participants 
The key questions posed in this thesis relate to risk stratification and prediction of outcomes for 
emergency department patients with infection. To optimise applicability (or external validity), the 
enrolled cohort would ideally comprise consecutive emergency department patients with 
infection of all severities. Identifying this group with acceptable sensitivity and specificity presents 
significant challenges, not least because the diagnosis of ‘infection’ is often a subjective one made 
by clinicians at points in time when available information is incomplete. 
  
The use of positive microbial culture has the appeal of specificity but is confounded by the fact 
that even in the sickest patients with septic shock, blood cultures are positive in only 30-40% of 
cases and cultures from all sites (blood, urine, sputum, swabs) positive in 60-70% [3, 4]. Further 
complicating the issue, positive cultures identify not only pathogenic organisms but also 
contaminants (in some studies incidence of blood culture contamination is greater than the 
incidence of pathogenic organisms [5]) and colonising organisms (positive urine cultures in the 
presence of a urethral catheter, positive sputum cultures in chronic suppurative lung disease) 
which often require detailed clinical correlation to establish. Additionally, results of cultures are 
not available for hours or even days after presentation, so can only be used to identify ED patients 
with infection retrospectively. The main advantage of using positive cultures to identify a study 
cohort is clarity and therefore repeatability, and examples of these studies exist [6]. However, bias 
associated with necessary retrospectivity [7] and lack of general applicability are substantial 
drawbacks. Specificity also will be reduced, given cultures are not routinely collected from all 
patients with suspected infection. 
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Several studies have been published using a large prospective database in which participating ED 
patients with infection were identified through ordering of a blood culture [8, 9]. This method has 
the advantage of relative simplicity and repeatability, but is compromised by a lack of widely 
accepted criteria that indicate in what circumstances a blood culture should be performed [10, 
11]. Patients who have had a blood culture ordered are likely to have met some clinician-
determined threshold for requirement, therefore the resulting cohort may not include some 
patients with a lower severity of illness. The consequent spectrum bias may influence results of 
analyses with these data [12].  
 
The lack of reliable gold-standard test for ‘infection’ necessitates the use of subjective clinical 
impression for the identification of emergency patients with infection of all severities. The use of 
hospital discharge codes to retrospectively identify emergency patients admitted with infection 
has been extensively used to study incidence and outcome of sepsis syndromes and other 
prognostic determinants [13, 14]. However, a variety of discharge codes have been used in 
different studies, and substantial differences have been found between patients identified by 
different codes [15, 16]. Hospital discharge codes have also been found specific but very 
insensitive for infection as determined by manual chart review [17, 18]. The influence of financial 
incentives on discharge coding may also influence coding behaviour [19]. Massive electronic 
hospital discharge databases understandably appeal to researchers attempting to identify and 
study patients admitted with infection. Despite this, the questionable accuracy with which 
discharge codes identify patients of interest, combined with biases associated with inherent 
retrospectivity combine to reduce the value of such methods.  
 
Intensive care unit admission has also been extensively used to identify emergency patients 
admitted with infection [20, 21]. Spectrum bias [1] results as only unwell patients are generally 
admitted to intensive care units. Additionally, important groups of patients with severe infection 
but determined not to be suitable for intensive care support (on the basis of dependence, poor 
quality of life, or significant co-morbid illness) are excluded, introducing selection bias [7]. It has 
been appreciated that intensive care admission policies and practices vary across health care 
systems [22], potentially reducing wider applicability of findings from studies using these methods.  
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 Similar spectrum and selection bias issues limit the utility of studies using databases containing 
emergency department patients with severe sepsis or septic shock treated according to an 
established ‘severe sepsis bundled care’ pathway [23]. Such databases are usually prospectively 
maintained and contain rich and detailed data, but similar to intensive care cohorts, will contain 
only the sickest patients with infection and systematically exclude an important subgroup with 
limitations to treatment [24-26]. 
 
In an effort to enrol emergency patients representing the full spectrum of sepsis severity, some 
investigators have based processes of enrolment closer to the emergency phase of care. In a 
United States hospital, Howell and colleagues [27] enrolled emergency department patients based 
on the ED admission diagnosis indicating infection. Similar methods have been employed by 
researchers working at single sites in Denmark [17], England [28], and Holland [29], while 
admission from the ED to an infectious diseases unit was used to identify patients in a study 
conducted in Sweden [30]. In these papers, researchers have attempted to enrol cohorts of 
patients with the full spectrum of infection severity using overall clinical impression of ‘ED 
diagnosis’ suggesting or indicating infection. While these methods have greater sensitivity than 
methods using hospital discharge diagnosis [31], limitations include both enrolment of patients 
ultimately shown not to have infection [32], as well as missing patients ultimately shown to have 
infection that were incorrectly diagnosed or labelled in the ED. A selection bias is also introduced 
through not including patients with infection who were discharged home from the ED. 
 
No method of identifying and enrolling consecutive ED patients with the full spectrum of infection 
severity is without potential for multiple biases and application difficulties. Methods utilising 
hospital discharge diagnosis codes are insensitive with high risk of misclassification bias. Spectrum 
and selection bias are limitations to methods utilising large ICU or severe sepsis databases, despite 
the convenience of large amounts of existing data. Enrolment of patients in the ED has the 
advantage of greater sensitivity and opportunity to identify a cohort with a full spectrum of 
disease severity to optimise applicability to clinical applications. Disadvantages include 
misclassification bias and the labour-intensive nature of data collection within the ED 
environment.    
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2.2.2 – Index tests 
The ‘index tests’ under consideration are the criteria which define the sepsis syndromes (systemic 
inflammatory response syndrome and organ dysfunction) or variables that comprise the clinical 
prediction models under review. Because this thesis concerns risk stratification and prognostic 
determinants in the emergency department, the data to determine values of these index tests 
should be limited to those obtained or available in the ED. Among studies, variation exists 
regarding the timing of recorded physiological observations and laboratory data that may 
contribute to systemic inflammatory response syndrome (SIRS) or clinical prediction models (such 
as APACHE II or SAPS II) in the ED. Initial data [17, 28] and worst data in ED [27, 33] approaches 
have both been utilised. The timing of these observations has been shown to influence resulting 
scores [34], underlining the importance of reporting in detail the methods used in each study.  
 
An important limitation of observational data is the variable completeness and accuracy of 
patients’ data available for abstraction [35]. The effects that unavailable and inaccurate data 
would have on a prediction model with variables based on co-morbidities (MEDS and APACHE are 
examples) would vary in different datasets, and influence on diagnostic accuracy is uncertain [12].   
 
Definitions for contributor variables such as ‘immunosuppression’, ‘organ dysfunction’, and 
‘confusion’, used in validation papers frequently differ from those used in guidelines or initial 
score development papers. This may affect score performance and affect generalisability of 
results. Unavailability of an entire variable (for example absence of neutrophil band count in some 
MEDS validation papers [36]) will bias scores and reduce applicability further.  
 
Subjectivity in a clinical prediction score variable is likely to introduce substantial variation in 
interpretation and results. The MEDS variable ‘terminal illness’ was defined in derivation as 
‘metastatic cancer or a disease condition with a >50% likelihood of predicted fatality within 30 
days’. Doctors’ prognostications even in advanced disease are recognised to be often inaccurate 
[37]. Another concern is the severity of presenting illness and evolution of the presenting 
complaint in the ED may influence the subjective determination of this variable (especially so if the 
patient dies in the ED). In this example of ‘incorporation bias’ [1], the reference test outcome 
(death, or an increasing likelihood of this) influences the value of the index test variable.  
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Determination of ‘not for resuscitation’ (NFR) status may also be influenced by clinical course in 
the ED, so observed associations between NFR status in the ED and mortality outcome may be 
subject to information bias. 
 
2.2.3 – Reference test or outcome 
Mortality is the outcome reported by most studies examining prognosis of emergency patients 
with infection. While mortality itself has the advantages of undoubted clinical relevance and 
unrivalled certainty, the frequently reported surrogate of in-hospital mortality does have 
limitations. Differential verification bias [1] is arguably present as patients discharged alive from 
hospital are assumed to be alive for study outcome purposes, as two groups of patients were 
effectively subject to different reference tests. Patients discharged alive but subsequently 
deceased within a timeframe of interest (usually 28-30 days) are subject to misclassification bias. 
This is potentially a greater issue when patients from nursing homes are discharged sooner than 
would otherwise be the case for non-nursing home patients. Mortality within a specified 
timeframe as determined by an independent database such as a national or state registry of 
deaths would remove these biases. 
 
2.2.4 – Data analysis 
Two aspects of observational and validation study methodology that may introduce bias and 
variation in applicability are missing data and patient groups systematically excluded from 
enrolment and analysis. The degree to which data that should have contributed to risk 
stratification scores or clinical prediction models is missing and the means by which this is 
accounted for in statistical analysis should be reported. An assessment of the reasons data are 
missing should influence statistical approach.  
 
Systematic exclusion of patients has been addressed in the preceding section on participant 
selection. Studies enrolling only those patients judged suitable for unrestrained resuscitation or 
ICU admission will lack applicability for clinicians faced with a broader spectrum of patients, and 
findings will not necessarily apply to excluded patients. 
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2.2.5 – Conclusions 
This section has outlined some of the many difficulties associated with observational and 
diagnostic accuracy research. Bias in its many forms is impossible to exclude, and challenging to 
minimise. Very large electronic hospital discharge or ICU databases can provide appealingly 
precise results with but without accuracy or applicability to the question of prognostic 
determinants in the ED. Several investigators have used ED clinical impression or admission 
diagnosis to identify patients, but these methods may sacrifice some specificity for greater 
applicability. The prognostic models and risk-stratification criteria under investigation are 
sometimes complex with clinical variables that risk some association with outcomes. Some data 
will always be missing, and transparency regarding quantity and type of missing data as well as 
methods to account for this are required. 
 
No methods will be perfect. The following section describes in detail the methods used to create 
the database which comprises the foundation on this thesis. The methods were determined after 
review of available studies based on similar data, and prioritised accurate patient selection, 
enrolling a representative spectrum of emergency patients with infection of all severities, and 
reliable outcomes.  
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2.3.1 - Abstract 
 
Background: Patients with infections account for a significant proportion of Emergency 
Department (ED) workload, with many hospital patients admitted with severe sepsis initially 
investigated and resuscitated in the ED. The aim of this registry is to systematically collect quality 
observational clinical and microbiological data regarding emergency patients admitted with 
infection, in order to explore in detail the microbiological profile of these patients, and to provide 
the foundation for a significant programme of prospective observational studies and further 
clinical research. 
  
Methods/design:  ED patients admitted with infection will be identified through daily review of the 
computerised database of ED admissions, and clinical information such as site of infection, 
physiological status in the ED, and components of management abstracted from patients’ charts. 
This information will be supplemented by further data regarding results of investigations, 
microbiological isolates, and length of stay (LOS) from hospital electronic databases. Outcome 
measures will be hospital and intensive care unit (ICU) LOS, and mortality endpoints derived from 
a national death registry.  
 
Discussion: This database will provide substantial insights into the characteristics, microbiological 
profile, and outcomes of emergency patients admitted with infections. It will become the nidus for 
a programme of research into compliance with evidence-based guidelines, optimisation of empiric 
antimicrobial regimens, validation of clinical decision rules and identification of outcome 
determinants. The detailed observational data obtained will provide a solid baseline to inform the 
design of further controlled trials planned to optimise treatment and outcomes for emergency 
patients admitted with infections.      
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2.3.2 – Background 
 
Emergency department and infections 
Patients with infections ranging in severity from uncomplicated cellulitis to fulminant septic shock, 
account for a significant proportion of Emergency Department (ED) workload [1]. Furthermore, 
studies based in the intensive care unit (ICU) reveal that the majority of patients with severe 
infections are admitted after first presenting to the ED and receiving initial diagnostic workup and 
treatment [2]. Given the key role of the ED in diagnosis, risk stratification and initial treatment of 
patients with infection, it is clear that ED clinicians are ideally placed to significantly contribute to 
research in this area. Collecting rigorous, quality observational data in this setting will provide the 
foundation for a significant programme of clinical research.  
 
Potential uses and benefits of a prospective sepsis registry 
The benefits of establishing a comprehensive and detailed prospective database on patients 
admitted with infection are numerous. These data can provide a baseline measurement of 
important cohort characteristics, spectrum of disease severity, and outcomes for various 
subgroups. By collecting data on the investigations and treatment initiated, compliance with 
established best-practice guidelines can be assessed, and changes may be quantified post 
implementation of quality-improvement initiatives. Comprehensive data on microbiological 
isolates and associated sensitivities will enable the formulation of locally-valid guidelines for 
empirical antimicrobial therapy.  
 
It is only with a large, quality database that prognostic associations between variables and 
outcome can be sought, facilitating the validation of scoring systems and decision rules 
established elsewhere, and the development of locally-derived scoring systems and decision rules. 
A critical examination of the patterns and trends in observational data may generate hypotheses 
and provide the basis for further experimental trials. In many circumstances observational data 
provide the only evidence to guide future management (e.g. time to antibiotics in septic shock) 
[2], because it would be unethical to test certain hypotheses within a randomised trial design. This 
important role of well-designed studies using detailed prospective observational data in advancing 
our knowledge and understanding of complex clinical issues has recently been emphasised [3].    
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Methodological standards for clinical registries 
A clinical register is defined as a database of systematically collected health-related information, 
and together with the system governing the register, is known as a registry [4].   Guidelines for the 
structure of this type of clinical registry exist, outlining necessary characteristics such as the 
collection of variables for risk adjustment, indicators to assess quality of care, and outcome data. 
The “Operating Principles and Technical Standards for Australian Clinical Quality Registries” [4] 
exhaustively specifies further desirable characteristics of clinical registries regarding the mode of 
data collection, data elements, risk-adjustment factors, data security and quality, organisation and 
governance, ethics and privacy. Our database has been designed to comply with as many of these 
characteristics as is practically possible.   
 
Review of previous studies 
There are many examples of quality observational databases that contribute significantly to the 
knowledge and understanding of complex clinical problems, and provide a framework from which 
to direct scientific enquiry. These include the National Traumatic Coma Database [5] and the 
Australian and New Zealand Intensive Care Society Adult Patient Database [6]. Most clinical 
databases of patients with infections include only those with severe sepsis or septic shock [7,2] 
and are often multi-centred and/or ICU-based. Databases of ED patients with infections of all 
severities are less common, but examples do exist and are represented in numerous studies that 
have contributed significantly to the ED literature.    
 
Researchers at the Beth Israel Deaconess Medical Centre in Boston have collected rigorous 
prospective data on emergency patients admitted with infection over several discrete time 
periods. Using the ordering of blood cultures by the treating emergency physician as an indicator 
of suspected infection, data were collected on a series of 3,179 patients between February 2000 
and February 2001. A number of studies have since been published between 2003 and 2010 using 
this dataset, including a paper describing the derivation of the Mortality in Emergency Department 
Sepsis (MEDS) score [8]. This is a severity scoring system that was subsequently validated at one 
year [9] and was the subject of a recent complimentary review [10]. A further dataset publication 
provided evidence that the Charlson Co-morbidity score [11], a four-point score developed to 
objectively quantify the burden of co-morbid illness, also predicted one year mortality in these 
patients [12]. A 2006 paper explored the prognostic implications of organ dysfunction and the 
presence of the Systemic Inflammatory Response Syndrome (SIRS) [13], and a recent publication 
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found a poor association between abnormal temperature or leucocytosis and subsequently 
proven bacteraemia [14].   
 
Data on several large cohorts of emergency patients admitted with clinical suspicion of infection 
were again collected at Beth Israel Deaconess Medical Centre between 2003 and 2006. At least 
seven studies have been published using these data, advancing our knowledge and understanding 
of emergency patients with infections and the associated determinants of outcome. Several 
severity scoring systems have been validated [15] and the association between lactate and poor 
outcome has been explored in detail [16, 17]. Donnino et al. [18] concluded co-incident treatment 
with “statins” (hydroxy-methyl-glutaryl co-enzyme A inhibitors) was associated with improved 
outcomes in patients admitted with infections, and a rule comprising weighted risk factors for 
poor outcome in elderly patients admitted with infection was derived and validated [19]. In 
recently published studies, early abnormalities in coagulation system parameters were 
independently associated with poor outcome [20], and factors associated with clinical 
deterioration and transfer to ICU after admission to a ward were identified [21]. 
 
The productivity of the investigators at Beth Israel Deaconess Medical Centre summarised above 
demonstrates that the creation and maintenance of a large database of detailed information on 
emergency patients with the full spectrum of disease severity is achievable and can substantially 
contribute to our understanding of this complex disease process and its management. Large 
observational databases should ideally be multi-centred, national or even international in scope in 
order to maximise power and generalisability [4]. However, the labour-intensive process of data 
abstraction from paper ED records and the large number of patients included in a database of 
patients admitted with all severities of infection render a single-centre registry at least practical, 
and relevant, respectively. 
       
Objective 
The objective of this paper is to describe the creation of a comprehensive, systematic and detailed 
database of the way in which patients with infections present and are treated at a typical inner 
city university hospital ED. Data regarding microbiological isolates and their associated sensitivities 
will enable the optimisation of empirical guidelines for antimicrobial therapy.  Together with 
accurate outcome data, it will be possible to assess compliance with established guidelines and 
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best practice, validate scoring systems, investigate factors of prognostic significance, and provide 
solid baseline data to inform further studies and quality improvement initiatives.      
 
2.3.3 – Methods / Design 
 
Setting and study population 
This study will be conducted in the ED of an adult inner city university hospital in Australia, with an 
annual census of over 72,000. Patients eligible for inclusion will be those presenting to the ED and 
subsequently admitted to hospital with a primary diagnosis indicating clinical suspicion of 
infection. Those patients transferred from another hospital or under the age of 17 years will be 
excluded. 
 
Data collection process 
On a daily basis, trained data abstractors will scrutinise the hospital electronic database record of 
emergency patients admitted over the 24-hour period to midnight the night before. Those 
patients with an admission diagnosis indicating or suggestive of infection according to ICD-10 
coding will be listed (see additional file 1: admission diagnoses potentially indicating infection), 
and the charts of the patients thus identified will be examined to assess suitability for study 
inclusion. Only those patients that are judged to have infection as the most likely cause for their 
admission according to both the treating ED senior medical officer and the admitting team will be 
enrolled.  
 
Data will be abstracted from the charts of enrolled patients, with information recorded on case 
report forms and subsequently entered into a secure computerised study database (Access, 
Microsoft, Redmond, WA). We have shown with pilot data that with appropriate training, our data 
abstractors achieve a high degree of inter-rater agreement (97%). At a later date this clinical 
information will be supplemented by further information from other hospital electronic databases, 
regarding pathology and microbiology results and hospital length of stay (LOS). Mortality outcome 
data will be obtained from periodic interrogation of the Australian Institute of Health and Welfare 
National death index [22]. This registry records vital status data for all individuals deceased within 
Australia. 
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Variables recorded  
Table 1 lists the variables recorded in the database. Clinical details such as site of infection, 
physiological status and treatment in ED and co-morbid conditions will be abstracted directly from 
the hospital paper chart. Values recorded for physiological status will be the most abnormal value 
recorded in the ED, and missing physiological values will be recorded as such and assumed to be in 
the normal range for analysis purposes. Results of laboratory tests and microbiological assays will 
be transferred manually from hospital electronic databases. 
 
 
Table 2. 1: Variables recorded in the database 
 
Data type Variables recorded 
Demographics Age, gender, postcode 
Site of infection 
Classified: respiratory, urinary tract, abdominal/pelvic, 
soft tissue, skeletal, neurological, vascular, unknown 
source. 
Aetiological agents identified 
Results of positive cultures, serology, antigen tests, 
nucleic acid amplification. 
Physiological status in ED 
SIRS criteria, initial and lowest systolic blood pressure, 
oliguria (urine output less than 0.5ml/kg/hour for 2 
consecutive hours), oximetry values. 
Pathology tests in ED 
Results of biochemistry and haematology profiles. Further 
data may also be available such as results of blood gas 
analyses and coagulation profiles.  
Treatment in ED 
Amount and type of fluid administered 
Type and timing of antimicrobial therapy 
Other variables 
Limitations on therapy (e.g. not for ICU admission) 
Nursing home status 
Antibiotics prior to admission 
Hospital admission in the past month 
Severity of illness 
MEDS score  
SAPS II score [23] 
Co-morbid illness Charlson Co-morbidity score 
Organ dysfunction Modified SOFA [24] score 
Outcomes 
Hospital length of stay 
ICU length of stay (where applicable) 
Date of death (where applicable) 
ED = emergency department, ICU = intensive care unit, SIRS = systemic inflammatory response syndrome, 
MEDS = mortality in emergency department sepsis, SAPS II = simplified acute physiology score, SOFA = 
sequential organ failure assessment. 
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Microbiological isolates cultured from samples taken in the ED and up to 48 hours after 
presentation will be deemed potentially relevant causative organisms. A more liberal approach 
will be taken regarding results from other tests such as serology, antigen tests and nucleic acid 
amplification assays. Cases in which clinical interpretation is required in order to clarify issues such 
as site of infection and relevance of microbiological isolates will be referred to a panel comprising 
an Emergency Physician, Intensivist, and Infectious Disease Physician/Microbiologist for 
adjudication.  
 
Derived variables 
A number of derived variables or scores will also be recorded in the database. The Mortality in 
Emergency Department Sepsis (MEDS) score sums nine weighted components (age > 65 years, 
terminal illness, tachypnoea/hypoxia, shock, thrombocytopaenia, bands >5%, altered mental 
status, nursing home residence, and lower respiratory tract infection) and has been validated as 
an accurate mortality-risk stratification tool in ED patients with infection [15, 25]. Our laboratory 
does not routinely measure leukocyte bands, so effectively a modified MEDS score comprising the 
remaining eight components will be recorded.  
 
The Simplified Acute Physiology Score [23] was originally developed as a predictive tool in 
intensive care patients and has subsequently been shown to have utility in ED patients [26, 27]. 
This score is a function of 17 weighted clinical variables and estimates the probability of hospital 
mortality. The Charlson Co-morbidity score is a frequently-used index of co-morbid illness burden, 
which has been validated in a similar cohort of emergency patients with infection [12]. The 
calculation of these three scores will enable score validation in our cohort, allow comparison of 
our patients to those in other studies, and facilitate adjustment for severity of illness and burden 
of co-morbidity in regression analyses. 
 
Indices of Organ Dysfunction 
A modified SOFA score [24] will be used to indicate and quantify organ dysfunction across six 
organ systems (see table 2). The SOFA score is a validated and widely used tool for quantifying 
organ dysfunction in patients with infection, and is a preferred method listed by the Surviving 
Sepsis Campaign consensus guidelines [28]. Several modifications to the score as originally 
published have been made for the purposes of this study. The published SOFA cardiovascular 
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system (CVS) score incorporates the potential use of a variety of vasopressor and inotropic agents, 
including noradrenaline, adrenaline, dopamine and dobutamine. The modified SOFA 
cardiovascular system score reflects local practice of using noradrenaline almost exclusively as the 
vasopressor of choice in patients with septic shock. Adrenaline will be considered equivalent to 
noradrenaline for the purposes of calculating the cardiovascular system score, and vasopressor 
infusion must be required for at least one hour for both agents.  
    
 
Table 2. 2: Modified Sequential Organ Function Assessment (SOFA) score 
 
 Modified SOFA score 
Organ 
system 
 
Determinants 
0 1 2 3 4 
RESP PaO2/FiO2 
SpO2% 
≥400 
>94% (RA) 
<400 
<300 
<90% (RA) 
<200 <100 
CVS Blood pressure, 
 
Vasopressor 
requirement 
SBP ≥90 
mmHg 
always 
SBP ≥90 mmHg 
only after fluid 
bolus 20-30 ml/kg 
SBP <90 
despite 
fluid bolus. 
NA<5 
NA 5-10 NA>10 
HAEM Platelet count 
(x109/l) 
≥150 <150 <100 <50 <20 
GIT Bilirubin 
(mmol/l) 
≤20 20-32 33-101 102-204 >204 
CNS Glasgow Coma 
Scale (GCS) 
score 
15 13-14 10-12 6-9 3-5 
RENAL Creatinine 
(mmol/l) 
Urine output 
(ml/kg/hour) 
≤120 
>120 
Or 
UO <0.5 for 2 
hours 
>170 >300 >440 
RESP = respiratory, CVS = cardiovascular, HAEM = haematological, GIT = gastro-intestinal, CNS = central 
nervous system, PaO2 = arterial partial pressure of oxygen, FiO2 = fraction inspired oxygen, SaO2 = oxygen 
saturation, RA = room air, SBP = systolic blood pressure, NA = noradrenaline, UO = urine output.  
 
 
Our respiratory system score utilises the ratio of arterial partial pressure of oxygen to fractional 
inspired oxygen (PaO2/FiO2) as originally published, with the addition of SpO2>94% on room air 
indicating no respiratory dysfunction, and SpO2<90% on room air indicating a respiratory SOFA 
score of 2. These additions were made to reflect the fact that many ED patients will not have an 
arterial blood gases analysis performed, but SpO2% readings will be obtained in almost all patients.  
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Lastly, creatinine concentration cut-offs have been slightly adjusted at the lower scores to reflect 
the local laboratory reference range, and oliguria (defined as urine output less than 0.5ml/kg/hour 
for 2 consecutive hours) scoring 2 points has replaced an impractical series of daily urine balances 
as detailed in the original SOFA score. The other organ system SOFA scores (haematology, central 
nervous system, and gastrointestinal) remain unchanged from the original SOFA score gradings.       
 
The proposed dataset includes a comprehensive description of all relevant characteristics of 
patients with infections that are routinely measured at the time of ED assessment. The recording 
of SIRS criteria and SOFA scores enables stratification of database patients into the categories of 
sepsis, severe sepsis and septic shock as defined by the Surviving Sepsis Campaign consensus 
guidelines [28]. The collection of sufficient data to calculate MEDS and SAPS II scores for each 
patient will facilitate validation of these scores, and comparison of patients in studies ensuing 
from this database with other patient studies.     
  
Data integrity 
A number of strategies will be introduced to ensure the quality of the data entered in the registry 
 
1. All individuals collecting the data for the registry will be trained in data collection and data 
entry methods 
2. The database incorporates validation fields which provide warnings if a data value falls 
outside the expected range 
3. The database will be checked on a monthly basis for completeness. A report of missing 
data will be printed and provided to the data collection team for follow-up 
4. A data audit will be conducted every 6 months. Within this audit, the following data checks 
will be conducted 
a. Every field will be checked for values outside the standard reference range. 
Extreme values will be investigated for accuracy 
b. All data will be rechecked against original paper-based data. 
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Data security 
The registry is a Microsoft Access document that is stored on a protected network drive, which is 
only accessible to authorised users.  Individuals with access to the network drive must enter a 
second password to allow them entry to the database. There are two levels of access to the 
database.  
 
1) User access. This access is available to data collectors and only allows data entry. 
2) Super-user access. This access enables users to view and modify all sections of the 
database.  
 
The database contains a separate file that links the patient’s study ID number to their hospital 
identification number, which will enable re-identification of the data if necessary. This file is only 
accessible to super-users and requires a separate password to be opened. 
 
Ethics approval 
The collection of this data as described above has been approved by the Royal Brisbane and 
Women’s Hospital Human Research Ethics Committee (HREC). A waiver for informed consent was 
obtained due to the entirely observational nature of the project. Ethics approval will be sought for 
further studies conducted using the database.    
 
Limitations 
Our reliance on the diagnosis field of the ED admissions database to identify potential study 
candidates may result in some eligible patients admitted with infection being missed. It is possible 
to enter in the ED diagnosis field a major symptom such as abdominal pain or headache, rather 
than an established diagnosis. During data collection, an attempt to list and peruse the charts of 
all patients that are admitted will be made, not just those with clear diagnoses indicating infection, 
but also those admitted with symptoms that may be suggestive of infection. It is, in this way 
planned to maximize the representative nature of our enrolled cohort, but it is acknowledged 
there may be inadvertent omissions. It is also possible that patients may be included but 
ultimately discharged with a diagnosis other than infection. Inadvertent inclusions will be 
minimized by enrolling only those patients with both ED and admitting team diagnosis indicating 
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infection. The acquisition of data from patients’ charts may potentially result in incomplete or 
incorrect data, especially regarding relevant co-morbid conditions. However, the abstraction of 
data with access to patients’ full hospital records as planned will minimise the effects of this.   
 
2.3.4 – Discussion 
 
This database will provide substantial insights into the characteristics, microbiological profile, and 
outcomes of emergency patients admitted with infections. It will provide the substrate for a 
programme of research into compliance with evidence-based guidelines, the validation of clinical 
decision rules and the identification of outcome determinants. 
 
The detailed observational data obtained will provide solid baseline data with which to modify 
empiric antimicrobial regimes and to inform the design of further controlled trials planned to 
optimise treatment and outcomes for emergency patients admitted with infections.      
 
 
Additional Material 
Additional file 1:  
‘ED admission ICD-10 codes potentially indicating infection’  
Excel file of 240 diagnoses accessible via on-line version of published article. 
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Section 2.4 – Methods: summary and conclusions 
 
In the previous section, methods to identify and enrol consecutive emergency patients with 
infection of all severities were detailed. Sensitivity was optimised by screening for suitable 
participants each day using a broad range of emergency admission diagnoses indicating or 
suggesting infection or organ dysfunction. Specificity was enhanced by inclusion of only those 
patients that were determined to have infection as the most likely cause for hospitalisation by 
both emergency and admitting medical teams. Through these means, selection and spectrum 
biases were controlled in the enrolment of broad and representative study cohort. Patients 
discharged home with presumed infections were not enrolled. This was justified on the basis that 
these patients were effectively primary care patients, most of whom would have been suitably 
and safely assessed by general practitioners. Discharged patients could not fulfil the study criteria 
of both ED and inpatient teams concurring with the diagnosis of infection. Amounts of missing 
data would have been a significant limitation with enrolment of discharged patients, as ED 
investigations were likely not performed for many of those discharged. The paper charts of 
admitted patients were available at the bedside or on the ward, thus immediately accessible to 
data abstractors on the day of admission. In contrast, paper charts for discharged patients were 
returned to medical records, increasing the difficulty of access. Similar research datasets have also 
excluded discharged patients [1-4]. 
 
Careful review and data abstraction occurred using each enrolled patient’s paper chart (including 
documentation of previous hospitalisations and clinic reviews) at the time of admission. This 
facilitated collection of the most accurate data available at that time regarding physiology and 
treatment in the ED and co-morbid conditions. Hospital electronic databases were searched to 
provide laboratory data. All this occurred without knowledge of each patient’s subsequent clinical 
course, helping to separate index and reference testing and minimising information bias. The 
challenges of limiting information and incorporation biases in cases of severely unwell patients 
with substantial co-morbidities and limitations to therapy, and particularly in cases of death within 
the ED phase of care, have been discussed. Further discussion will follow analysis of data for 
patients with septic shock, in chapter four.  To exclude partial verification bias associated with in-
hospital mortality as an outcome (reference test), a national database of deaths was searched to 
determine mortality at 30 days (and one year). Sample size calculations did not occur given the 
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variety of different analyses that were planned using the database – however cohort size in 
previous similar studies were used as a guide. 
 
2.4.1 – Assembly and completion of the database 
The first year of data collection was unfunded and carried out by the candidate and a colleague 
(emergency registrar at the time). Two further years of data collection were funded by the 
Queensland Emergency Medicine Research Foundation. Over these years data were collected by 
funded nursing abstractors (who were blinded to the aims of the planned studies) during the 
working week and by the candidate on the weekends, public holidays and vacation periods. The 
total data collection period comprised just over three years (162 weeks), concluding in mid-2011. 
Over the following two years, the candidate continued to enter and clean data for the enrolled 
9,719 ED patients admitted with presumed infection into the study access database. 
Microbiological data were sourced from hospital electronic databases and entered together with 
assessments of administered antimicrobial adequacy based on cultures of presumed source of 
infection in the ED at the time of enrolment. Chest X-ray (CXR) radiologist reports were coded and 
entered for those patients with a presumed respiratory source. 
 
2.4.2 – The studies 
A series of papers were planned and have now been completed, based on the thesis theme of 
prognosis and risk-stratification of ED patients with infection. The first two papers (on which 
chapters three and four are based) explored aspects of the ‘sepsis syndromes’ risk stratification 
scheme embraced and propagated by the Surviving Sepsis Campaign [5], and the remaining two 
papers (on which chapters five and six are based) have assessed established severity scores based 
on clinical prognostic models. 
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Chapter 3: SIRS, qSOFA and Organ Dysfunction 
 
Section 3.1 – Synopsis 
 
This chapter examines the validity of the risk-stratification structure for sepsis that originated with 
Roger Bone’s foundational paper of 1989 [1], evolved through several iterations and culminated in 
the recently proposed ‘Sepsis-3’ framework of 2016 [2]. For most of that period, clinicians and 
researchers have defined sepsis syndromes largely according to the structure proposed in the 
Sepsis Definitions Consensus Conference of 1992 [3], in which sepsis was defined as infection with 
systemic inflammatory response syndrome (SIRS), severe sepsis was organ dysfunction 
consequent to sepsis, and septic shock was defined as cardiovascular failure due to sepsis. SIRS 
was defined as ≥ 2 of:    
Temperature higher than 38°C or lower than 36°C 
Heart rate higher than 90/min 
Tachypnoea defined by respiratory rate > 20/min or PaCO2 < 32 mmHg 
White blood cell count higher than 12,000 cells/μl or lower than 4,000/ μl 
 
It was recognised at further consensus conferences in 2001 [4] and 2008 [5] that these criteria 
lacked sensitivity and specificity, leading to expansion of candidate SIRS criteria to a variety of 
systemic abnormalities, (optimistically) pending the discovery of biomarkers with improved 
diagnostic accuracy for ‘sepsis’. However almost two decades on, the search for suitable 
biomarkers continues while evidence for (or against) therapies has been founded on SIRS-based 
enrollment criteria for large clinical trials (for example Rivers et al. [6], PROWESS [7], CORTICUS 
[8], VASST [9], VISEP [10], ALBIOS [11], SEPSISPAM [12], ProCESS [13], ARISE [14], ProMISe [15]) 
and large non-randomised studies of patients managed with ‘protocolised therapy’ [16]. Despite 
SIRS being clearly postulated as a severity indicator, criticism persists that SIRS is insensitive and 
non-specific for the diagnosis or infection [17, 18]. Studies conducted in intensive care have 
demonstrated that SIRS contributes relatively little to prognosis in that environment, and that 
severe infection can occur without SIRS [19]. Surprisingly few studies have examined the 
prognostic utility of SIRS in the emergency department. 
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3.1.1 – SEPSIS-3 proposals 
Authors of the recently proposed revision of sepsis definitions (‘Sepsis-3’) retrospectively 
examined a large, multicentre database consisting mostly electronic records from US hospitals 
with substantial missing data, to derive and validate their new framework. The resulting system 
has  discarded SIRS and introduced ‘q (quick) SOFA’ as a means to screen for organ dysfunction in 
patients with infection outside the intensive care unit [2]. The Sepsis-3 authors have determined 
that ≥ 2 of three criteria: 
 Blood pressure ≤ 100 mmHg  
 Respiratory rate ≥ 22 breaths / minute 
 Glasgow Coma Score (GCS) ≤ 13 
be used to identify patients at risk of organ dysfunction for further investigation. Sepsis-3 has 
furthermore determined organ dysfunction be determined by an increase in total sequential organ 
failure assessment (SOFA) [20] score of two or more. Familiarity with the SOFA score is limited 
outside the critical care environment, and the system has not undergone calibration since creation 
by consensus in 1996. Stipulation of defined criteria for organ dysfunction is a welcome change, 
however this approach differs from those used by previous researchers. Most studies to date have 
used separate criteria to determine dysfunction in each organ system, albeit with some variation 
in criteria between studies. The new Sepsis-3 organ dysfunction can be satisfied with minor 
dysfunction (a SOFA score of one) in two or more organs. 
 
Sepsis-3 has been presented as an evidence-based solution to the persistent problem of 
determining clinical criteria which approximate conditions that have no gold-standard definition. 
While basing proposals on data is clearly commendable, previous sections of this thesis have 
established that datasets and observation studies based on them can have substantial limitations 
and biases potentially compromising internal validation and (importantly for Sepsis-3 proposals) 
external validation or accessibility. The Sepsis-3 authors recognised that validation in other 
settings was required. The published paper in the next section represents one of the first such 
external validations of Sepsis-3 criteria in the emergency department setting.     
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3.2.1 – Abstract 
 
Background: A proposed revision of sepsis definitions has abandoned the systemic inflammatory 
response syndrome (SIRS), defined organ dysfunction as an increase in total Sequential Organ 
Function Assessment (SOFA) score of ≥ 2, and conceived “qSOFA” (quick SOFA) as a bedside 
indicator of organ dysfunction. We aimed to (1) determine the prognostic impact of SIRS, (2) 
compare the diagnostic accuracy of SIRS and qSOFA for organ dysfunction, and (3) compare 
standard (Sepsis-2) and revised (Sepsis-3) definitions for organ dysfunction in ED patients with 
infection.  
 
Methods: Consecutive ED patients admitted with presumed infection were prospectively enrolled 
over 3 years. Sufficient observational data were collected to calculate SIRS, qSOFA, SOFA, 
comorbidity, and mortality.  
 
Results: We enrolled 8,871 patients, with SIRS present in 4,176 (47.1%). SIRS was associated with 
increased risk of organ dysfunction (relative risk [RR] 3.5) and mortality in patients without organ 
dysfunction (odds ratio [OR] 3.2). SIRS and qSOFA showed similar discrimination for organ 
dysfunction (area under the receiver operating characteristic curve 0.72 vs 0.73). qSOFA was 
specific but poorly sensitive for organ dysfunction (96.1% and 29.7%, respectively). Mortality for 
patients with organ dysfunction was similar for Sepsis-2 and Sepsis-3 (12.5% and 11.4%, 
respectively), although 29% of patients with Sepsis-3 organ dysfunction did not meet Sepsis-2 
criteria. Increasing numbers of Sepsis-2 organ system dysfunctions were associated with greater 
mortality.  
 
Conclusions: SIRS was associated with organ dysfunction and mortality, and abandoning the 
concept appears premature. A qSOFA score ≥ 2 showed high specificity, but poor sensitivity may 
limit utility as a bedside screening method. Although mortality for organ dysfunction was 
comparable between Sepsis-2 and Sepsis-3, more prognostic and clinical information is conveyed 
using Sepsis-2 regarding number and type of organ dysfunctions. The SOFA score may require 
recalibration. 
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3.2.2 - Introduction  
 
Infectious diseases have plagued mankind for millennia [1] and remain a major cause of morbidity 
and mortality [2]. Despite this, the complex pathophysiological response to infection remains to be 
fully elucidated, and a gold standard test for serious infection (or colloquially, “sepsis”) does not 
currently exist. In the absence of a gold standard test, several groups have attempted to provide 
clinical criteria for the identification of infected patients at risk of significant mortality.  
 
Consensus conferences in 1991 [3] and 2001 [4] proposed that sepsis be defined as infection with 
systemic inflammatory response syndrome (SIRS), and severe sepsis as sepsis with consequent 
organ dysfunction. The Sequential Organ Function Assessment (SOFA) [5] score was a suggested 
means to quantify dysfunction in each of six organ systems. Within this framework, sepsis 
research has advanced with promulgation of evidence based guidelines for sepsis management 
[6], and global sepsis mortality has been reduced [7]. A recently proposed revision of sepsis 
definitions (Sepsis-3) [8] has discarded SIRS, with concerns that most patients with SIRS do not 
have infection [9] and that SIRS is absent in some patients with infection in a critical care setting 
[10]. Sepsis-3 has also redefined organ dysfunction as an increase in the total SOFA score of ≥ 2 
rather than the previous convention of using specified criteria to determine dysfunction in each of 
several organ systems. A new construct, quick (q)SOFA, has also been introduced in Sepsis-3 as a 
means to screen for organ dysfunction at the bedside using respiratory rate, blood pressure, and 
conscious state. 
 
However, the original definitions intended SIRS be regarded as a potential severity indicator in 
patients with suspected infection rather than a screening test for infection. In the ICU, SIRS is 
common [11] and contributes minimally to mortality risk [12]. As noted in a recent editorial critical 
of the revised definitions [13], SIRS is more likely to be useful in the ED, where patients with 
infection are common and a parsimonious means to screen for those at higher risk of mortality is 
required. There are few studies specifically examining the prognostic utility of SIRS in ED patients 
with infection, and the SOFA and qSOFA scores remain to be evaluated in those patients. The 
purpose of this study was to determine the following in ED patients with suspected infection: (1) 
the prevalence and prognostic impact of SIRS, (2) the diagnostic accuracy of SIRS and qSOFA for 
organ dysfunction, and (3) the characteristics and utility of the current (Sepsis-2) and proposed 
(Sepsis-3) SOFA-based organ dysfunction criteria. 
63 
 
3.2.3 – Methods 
 
Study Design and Setting  
The prospective observational database used for this study was designed to examine the 
performance of SIRS and SOFA-based organ dysfunction as originally described for Sepsis-2. 
Following the recent publication of the proposed Sepsis-3 definitions, the study scope was 
expanded retrospectively to include analysis of the new definitions. The study was undertaken in 
the ED of a tertiary university-affiliated Australian hospital with an annual census of > 72,000 adult 
presentations. Data were collected over two discrete periods, October 2007 to December 2008 
(unfunded pilot) and June 2009 to May 2011 (funded period), totalling 162 weeks. The Royal 
Brisbane and Women’s Hospital Human Research Ethics Committee approved the study 
(HREC/09/QRBW/226) and determined that patient consent was not required. 
 
Participants, Methods, and Measurements 
Methods have been described in detail [14] but are briefly summarized here. On a daily basis, 
patients seen in the ED and subsequently admitted with a diagnosis indicating presumed or 
potential infection were identified. The charts of those patients were examined by trained data 
collectors. Patients were enrolled if the ED and admitting medical staff both indicated that 
infection was the most likely reason for admission. Patients transferred from other hospitals or 
aged < 17 years were not enrolled. 
 
Data were abstracted from the paper chart at the time of each patient’s enrollment and included 
physiological measurements and treatment in the ED, presumed source of infection, and 
comorbidities. At a later time, results of hematologic and biochemical tests were obtained from 
computerized hospital databases. Data were entered into a Microsoft Access database and stored 
on a password-protected secure hospital drive. Regular automated checks for out-of-range entries 
were conducted, and the principal investigator reviewed accuracy of the data for all patients. The 
database was designed to comply with the components of the Strengthening the Reporting of 
Observational studies in Epidemiology statement.  
 
For each physiological parameter, the most abnormal measurement in the ED was recorded. SIRS 
was defined as two or more of the following: heart rate > 90 beats/min, respiratory rate > 20 
breaths/min or arterial carbon dioxide pressure < 32 mm Hg, leukocyte count > 12,000/mL or < 
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4,000/mL, and temperature < 36°C or ≥ 38°C. The recorded components of qSOFA were 
respiratory rate ≥ 22/min, systolic blood pressure ≤ 100 mm Hg, and Glasgow Coma Score (GCS) ≤ 
13. Organ function was assessed using a modified SOFA score (Table 3-4 = ex Supplementary Table 
1). Hospital records relating to previous admissions and outpatient and ED encounters were used 
to assess and record baseline organ function, which was assumed to be normal in the absence of 
such data. Consistent with definitions in place during data collection (Sepsis-2), acute organ 
dysfunction was defined for primary analyses as an increase in SOFA score of ≥ 2 in any discrete 
organ system. For comparison, the proposed new definition of acute organ dysfunction (Sepsis-3) 
was an increase in total SOFA score of two or more. Shock was defined as hypotension (systolic 
blood pressure < 90 mm Hg) persisting despite at least a 1,000-mL fluid bolus or vasopressor 
infusion in the ED (corresponding to a cardiovascular SOFA score of ≥ 2). The Charlson score [15] 
was calculated to quantify comorbidity. The primary outcome measure was 30-day mortality, and 
the secondary outcome was 1-year mortality. Both were obtained from a national death registry.  
 
Analysis 
Analyses were performed using Stata, version 14 (StataCorp LC). In cases of readmission within 90 
days, a single representative admission was selected at random from within that period for 
inclusion in the study data set. Baseline characteristics of the study sample were reported by vital 
status at 30 days. Risk ratios and risk differences (with 95% confidence intervals [CI]) were 
calculated to identify the prognostic utility of SIRS for mortality in patients with and those without 
organ dysfunction. ORs adjusted for age and comorbidity were also reported. Because of the 
nonlinear relationship between age and mortality, age was stratified into 10-year categories for 
computation of adjusted ORs. The Charlson comorbidity index was stratified into 0, 1 to 2, 3 to 4, 
and ≥ 5 as originally described [15]. 
 
Discrimination of SIRS and qSOFA scores for organ dysfunction and mortality was quantified using 
receiver operating curves. Sensitivity and specificity corresponding to SIRS ≥ 2 and qSOFA ≥ 2 were 
reported. Adjusted ORs for mortality were calculated for each of the SIRS and qSOFA criteria, each 
individual (Sepsis-2) organ system dysfunction, Sepsis-2 and Sepsis-3 organ dysfunction, and 
cumulative (Sepis-2) organ dysfunction.  
 
A number of sensitivity analyses were conducted. First, analyses were repeated using multiple 
imputation of missing data to identify whether the assumption of normality in the primary analysis 
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resulted in biased estimates. This resulted in imputation for 21 patients (0.2%) with missing white 
cell count data and 242 patients (2.7%) with any missing SOFA score components. Analyses 
conducted using multiple imputation yielded similar estimates so were not reported. Second, to 
inform discussion regarding definitions of acute organ dysfunction, mortality was computed for 
different SOFA score thresholds. 
 
3.2.4 – Results 
 
Patient recruitment and classification into groups according to SIRS and organ dysfunction is 
outlined in Figure 3.1. The study cohort comprised 8,871 admissions of patients with presumed 
infection over the total study duration of 162  weeks, after exclusion of 846 readmissions within 
90 days. Numbers and characteristics of included and excluded representations are detailed in 
Table 3.5 (ex Supplementary Table 2). Table 3.1 details characteristics of the study cohort. SIRS 
was present in 4,176 patients (47.1%), and the prevalence of acute organ dysfunction varied 
according to definition (Sepsis-2: 1,534 [17.3%]; Sepsis-3: 2,166 [24.4%]) (Table 3.1). However, 
mortality associated with organ dysfunction using Sepsis-2 and Sepsis-3 was similar at 30 days 
(Sepsis-2: 12.5%; 95% CI, 10.8%-14.2%; Sepsis-3: 11.4%; 95% CI, 10.1%-12.8%; difference, 1.0%; 
95% CI, –1.1 to 3.2%) and at 1 year (Sepsis-2: 25.5%; 95% CI, 23.3%-27.7%; Sepsis-3: 26.3%; 95% 
CI, 24.4%-28.2%; difference, 0.8%; 95% CI, –2.1 to 3.6%). Table 3.2 compares the prevalence and 
prognostic implications of SIRS in subgroups with and without organ dysfunction and with shock.  
 
In the overall cohort, SIRS was associated with increased risk of (Sepsis-2) organ dysfunction 
(relative risk [RR], 3.5; 95% CI, 3.1-3.8) and increased odds of mortality in patients without (Sepsis-
2) organ dysfunction (OR, 3.2; 95% CI, 2.2-4.7). SIRS had similar implications when Sepsis-3 was 
used to determine organ dysfunction. SIRS was present in 1,157 patients (75.4%) with (Sepsis-2) 
organ dysfunction and was associated with increased odds of mortality compared with the 377 
patients (24.6%) without SIRS (OR, 1.8; 95% CI, 1.2-2.7). Similarly, in those with Sepsis-3 organ 
dysfunction (n = 1,561 with SIRS and 605 without SIRS), SIRS was associated with increased odds of 
30-day mortality (OR, 2.2; 95% CI, 1.5-3.1). However, at 1 year, there was no association between 
SIRS and prognosis in patients with organ dysfunction according to either definition. In patients 
with shock, SIRS was present in 89% and was not associated with increased mortality at either end 
point. Table 3.2 also allows comparison of sepsis subgroups according to Sepsis-2 and Sepsis-3 
definitions (column 2). 
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Figure 3. 1: Patient recruitment and classification according to SIRS and organ dysfunction. 
                                 
Organ dysfunction (current definition or Sepsis-2) is defined as an increase in the Sequential Organ 
Function Assessment (SOFA) score of two or more, and shock is defined as cardiovascular system organ 
dysfunction. SIRS = systemic inflammatory response syndrome. 
 
 
As defined in this study, patients with Sepsis-2 organ dysfunction composed a subgroup of those 
with Sepsis-3 organ dysfunction. The 632 patients that met Sepsis-3 but not Sepsis-2 criteria for 
organ dysfunction presented with an acute increase in total SOFA score of ≥ 2, but that increase 
occurred in different organ systems. Mortality for those patients was significantly less than for 
those with Sepsis-2 organ dysfunction at 30 days (difference 3.6%; 95% CI, 0.8%-6.4%) but not at 
one year (difference –2.6%; 95% CI, –6.8 to 1.5%).  
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Table 3. 1: Characteristics of the study cohort, by mortality at 30 days 
 
  Total Alive at 30 days  Deceased 30 days 
Entire cohort  8871 8544 (96.3%) 327 (3.7%) 
Males 4453 (51.3%) 4369 (51.1%) 184 (56.3%) 
Age in years - median (IQR) 49 (30-69) 47 (29-67) 79 (69-86) 
ED LOS in hours – median (IQR) 8.3 (5.5-12.2) 8.2 (5.4-12.2) 8.7 (6.0-12.0) 
Charlson score - median (IQR) 1 (0-3) 1 (0-3) 4 (2-6) 
Total SOFA – median (IQR) 1 (0-2) 1 (0-2) 5 (3-7) 
SIRS    
SIRS <2 4695 (52.9%) 4621 (54.1%) 74 (22.6%) 
SIRS ≥2 4176 (47.1%) 3923 (45.9%) 253 (77.4%) 
     SIRS leucocyte count 3933 (44.3%) 3726 (43.6%) 207 (63.3%) 
     SIRS temperature 2797 (31.5%) 2654 (31.1%) 143 (43.7%) 
     SIRS respiratory  2009 (22.5%) 1797 (21.0%) 212 (64.8%) 
     SIRS heart rate 4505 (50.8%) 4274 (50.0%) 231 (70.6%) 
qSOFA    
qSOFA <2 7966 (89.8%) 7803 (91.3%) 163 (49.8%) 
qSOFA ≥2 905 (10.2%) 741 (8.7%) 164 (50.2%) 
     GCS ≤13 454 (5.1%) 326 (3.8%) 128 (39.1%) 
     Respiratory rate ≥22 1868 (21.1%) 1667 (19.5%) 201 (61.5%) 
     SBP ≥100  2379 (26.8%) 2203 (25.8%) 176 (53.8%) 
SEPSIS-2 organ dysfunction    
No organ dysfunction 7337 (82.7%) 7201 (84.3%) 136 (41.6%) 
Organ dysfunction 1534 (17.3%) 1343 (15.7%) 191 (58.4%) 
       Cardiovascular  218 (2.5%) 166 (1.9%) 52 (15.9%) 
       Respiratory  779 (8.8%) 650 (7.6%) 129 (39.4%) 
       Renal  279 (3.1%) 214 (2.5%) 65 (19.9%) 
       Haematological  203 (2.3%) 189 (2.2%) 14 (4.3%) 
       Gastrointestinal  400 (4.5%) 375 (4.4%) 25 (7.6%) 
       Central nervous system  129 (1.5%) 86 (1.0%) 43 (13.1%) 
SEPSIS-3 organ dysfunction    
No organ dysfunction 6705 (75.6%) 6625 (77.5%) 80 (24.5%) 
Organ dysfunction 2166 (24.4%) 1919 (22.5%) 247 (75.5%) 
IQR = inter-quartile range, ED LOS = Emergency Department length of stay, SIRS = systemic inflammatory 
response syndrome, SOFA = sequential organ function assessment, qSOFA = “quick” SOFA, GCS = Glasgow 
Coma Score, SBP = systolic blood pressure (mmHg). 
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Table 3. 2: Mortality for sepsis subgroups according to SEPSIS-2 and SEPSIS-3 and the prognostic 
impact of SIRS in patients with and without organ dysfunction. 
 
    
SIRS vs no SIRS: 
 
SIRS vs no SIRS: 
Classification Subgroup n =  
30-day 
mortality (%) 
Mortality 
difference 
Adjusted 
OR 
one year 
mortality (%) 
Mortality 
difference 
Adjusted 
OR 
SEPSIS-2                 
All SIRS<2 infection 4695 1.6 (1.2-2.0) 
  
8.4 (7.6-9.2) 
  No OD, SIRS≥2 sepsis 3019 3.2 (2.6-3.9) 2.3%                   
(1.6-2.9) 
3.2              
(2.2-4.7) 
11.2 (10.1-12.4) 4.2%                              
(2.5-5.5%) 
1.5                          
(1.2-1.7) No OD, SIRS<2 
 
4318 0.9 (0.7-1.2) 7.0 (6.3-7.8) 
OD, SIRS≥2 severe sepsis 1157 13.6 (11.6-15.7)      4.6 %             
(1.1-8.1) 
1.8              
(1.2-2.7) 
26.1 (23.6-28.7)  2.5%                                   
(-2.5-7.5%) 
1.2                              
(0.9-1.7) OD, SIRS<2 
 
377 9.0 (6.3-12.4) 23.6 (19.4-28.2) 
Shock, SIRS≥2 septic shock 194 23.7 (17.9-30.3) -1.3%                        
(-19.6-17.0) 
0.9             
(0.3-3.0) 
37.6 (30.8-44.9) -8.2%                                   
(-29.3-12.9%) 
0.7                              
(0.2-1.9) Shock, SIRS<2 
 
24 25.0 (9.8-46.8)  45.8 (25.6-67.2) 
SEPSIS-3                 
No OD infection 6705 1.2 (0.9-1.5) 
  
6.9 (6.3-7.6) 
  No OD, SIRS≥2 
 
2615 2.0 (1.5-2.6) 1.3%             
(0.7-1.9) 
2.8           
(1.8-4.5) 
8.6 (7.5-9.7) 2.7%              
(1.4-4.0) 
1.4             
(1.1-1.7) No OD, SIRS<2 
 
4090 0.7 (0.5-1.0) 5.9 (5.2-6.7) 
OD sepsis 2166 11.4 (10.1-12.8) 
  
26.3 (24.4-28.2) 
  OD, SIRS≥2 
 
1561 12.9 (11.3-14.6) 5.3%                 
(2.6-8.0) 
2.2           
(1.5-3.1) 
26.7 (24.5-29.0) 1.6%                    
(-2.5-5.7) 
1.2             
(1.0-1.6) OD, SIRS<2 
 
605 7.6 (5.6-10.0) 25.1 (21.7-28.8) 
OD SEPSIS-3 but not SEPSIS-2 632 8.8 (6.8-11.3) 
  
28.1 (24.6-31.8) 
  COMBINATION                 
No OD, SIRS<2 infection 4318 0.9 (0.7-1.2) 
  
7.0 (6.3-7.8) 
  No OD, SIRS≥2 sepsis 3019 3.2 (2.6-3.9) 
  
11.2 (10.1-12.4) 
  OD (SEPSIS-2) severe sepsis 1534 12.5 (10.8-14.2) 
  
25.5 (23.3-27.7) 
  Shock septic shock 218 23.9 (18.4-30.1) 
  
38.5 (32.0-45.3) 
   
SIRS = systemic inflammatory response syndrome, OD = organ dysfunction, OR = odds ratio, adjusted for 
age and co-morbidity (Charlson Score). Figures in parentheses are 95% confidence intervals. ‘SEPSIS-2’ 
refers to established definitions [4] and ‘SEPSIS-3’ to recently proposed definitions [8]. ‘COMBINATION’ 
refers to a potential framework which recognises SIRS is associated with substantially increased mortality 
only in the absence of organ dysfunction.  
 
 
The relationships between study groups according to Sepsis-2 and Sepsis-3 definitions are 
illustrated graphically in Figure 3.2. The last four rows of Table 3-2 and Figure 2D represent a 
potential compromise structure that recognizes that SIRS is associated with increased mortality in 
patients without organ dysfunction but is prognostically less important when organ dysfunction or 
shock is present.  
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Figure 3. 2: Relationships between sepsis subgroups 
 
SIRS = systemic inflammatory response syndrome, SEPSIS-2 and SEPSIS-3 represent patients satisfying 
organ dysfunction criteria according to respective definitions. Panel A demonstrates SHOCK (cardiovascular 
dysfunction) being a subset of SEPSIS-2 organ dysfunction, which in turn is a subset of SEPSIS-3 organ 
dysfunction. Each of these groups contains patients with and without SIRS. Panel B represents established 
sepsis definitions [4], with “sepsis” (infection + SIRS) in grey and “severe sepsis” (sepsis + organ 
dysfunction) cross-hatched. Panel C approximates the proposed Sepsis-3 [8] definitions, with “sepsis” 
(infection with organ dysfunction) in grey and “septic shock” cross-hatched. SIRS plays no role in this 
construct. Panel D represents a potential compromise, recognising SIRS is associated with increased 
mortality in the absence or organ dysfunction, and organ dysfunction (including shock) carries significant 
mortality risk regardless of SIRS criteria. 
 
 
SIRS and qSOFA scores showed similar discrimination for Sepsis-3 organ dysfunction (area under 
the receiver operating curve, 0.72 vs 0.73; difference, 0.01; 95% CI, 0.0-0.03) (Fig 3-3). A qSOFA 
score ≥ 2 had high specificity for Sepsis-3 organ dysfunction but poor sensitivity (96.1%; 95% CI, 
95.7%-96.6% and 29.9%; 95% CI, 27.9%-31.8%, respectively). Specificity and sensitivity for SIRS ≥ 2 
were 61.1% (95% CI, 60.0%-62.3%) and 72.3% (95% CI, 70.3%-74.1%). Figure 3.4 (published e-
Figure 1) shows results using the end point of 30-day mortality.  
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Figure 3. 3: Receiver operating curves for SIRS and qSOFA prediction of (Sepsis-3) organ 
dysfunction 
 
SIRS = systemic inflammatory response syndrome, qSOFA = “quick” sequential organ function assessment, 
AUC = area under curve, CI = confidence interval. Discrimination for SIRS and qSOFA were similar (AUC 
difference 0.01, 95%CI 0-0.03). Larger symbols indicate diagnostic characteristics for operating points 
SIRS≥2 and qSOFA ≥2. Using GCS≤14 rather than GCS≤13 in qSOFA increases AUROC to 0.76 (95%CI 0.75-
0.77) with sensitivity 36.5% and specificity 95.4% (p<0.01 for both). 
 
 
Using Sepsis-2, the odds of mortality increased with a greater number of organ system 
dysfunctions (Fig 3.4). Substantial variation was seen in the odds of mortality associated with 
dysfunction in individual organ systems (Table 3.3). CNS dysfunction was associated with the 
greatest mortality risk (OR, 11.2; 95% CI, 7.1-17.7), with hematologic dysfunction lowest and 
failing to achieve statistical significance (OR, 1.6; 95% CI, 0.9-2.9). Table 3.6 (ex Supplementary 
Table 3) examines the implications of defining Sepsis-2 organ dysfunction at varying SOFA scores in 
each organ system. Mortality odds for each of the SIRS and qSOFA components are also presented 
in Table 3-3. Among these, altered conscious state was again the most powerful predictor. 
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Table 3. 3: Mortality odds associated with individual SIRS and qSOFA criteria, and organ 
dysfunctions. 
 
SIRS criteria 
 n = OR 30-day mortality 
unadjusted 
OR 30-day mortality 
adjusted 
SIRS respiratory  2009  6.9 (5.5-8.7) 3.7 (2.9-4.8) 
SIRS heart rate 4505  2.4 (1.9-3.1) 2.7 (2.1-3.4) 
SIRS leucocyte count 3933  2.2 (1.8-2.8) 2.2 (1.7-2.8) 
SIRS temperature 2797  1.7 (1.4-2.2) 1.6 (1.3-2.0) 
qSOFA criteria    
GCS ≤13 454 16.2 (12.7-20.8) 8.7 (6.6-11.4) 
Respiratory rate ≥22 1868  6.6 (5.2-8.3) 3.6 (2.9-4.6) 
SBP ≤100 2379 3.4 (2.7-4.2) 3.3 (2.6-4.2) 
Organ system dysfunction    
Central nervous 129 14.9 (10.1-21.9) 11.2 (7.1-17.7) 
Cardiovascular 218 9.5 (6.8-13.3) 6.3 (4.3-9.1) 
Renal 279 9.7 (7.1-13.1) 4.6 (3.3-6.4) 
Respiratory 779 7.9 (6.3-10.0) 4.4 (3.4-5.7) 
Gastro-intestinal 400 1.8 (1.2-2.7) 1.9 (1.2-3.0) 
Haematological 203 2.0 (1.1-3.4) 1.6 (0.9-2.9) 
 
Organ system dysfunction was defined as increase in sequential organ function assessment (SOFA) score of 
2 or more in a single organ system. Figures in parentheses are 95% confidence intervals. OR = odds ratio, 
with figures in final column adjusted for age and co-morbidity (Charlson Score). SIRS = systemic 
inflammatory response syndrome, qSOFA = “quick” SOFA, GCS = Glasgow Coma Score, SBP = systolic blood 
pressure (mmHg). 
 
3.2.5 – Discussion 
 
In this large prospective study of ED patients with suspected infection of all severities, SIRS was 
found to be a useful marker of organ dysfunction and mortality, whereas qSOFA had high 
specificity for organ dysfunction but poor sensitivity. Organ dysfunction was associated with 30-
day mortality slightly > 10%, without a significant difference between values obtained with Sepsis-
2 and those obtained with Sepsis-3. Using Sepsis-2, an increasing number of discrete organ system 
dysfunctions increased mortality, but dysfunction in individual organ systems was associated with 
a wide variation in mortality risk. 
 
SIRS in the ED 
Previous investigators have found that SIRS is not useful for predicting which patients in hospital 
wards [9] or the ED [16, 17] have infection. While some components of SIRS may contribute to a 
clinician’s judgment regarding the presence of infection, that assessment is ultimately based on a 
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range of physiological, investigational, and heuristic criteria because a gold standard does not yet 
exist. This paper examines the role of SIRS as a prognostic marker in ED patients with suspected 
infection. There are few previous studies with this aim. Shapiro et al [18] found no relationship 
between SIRS and mortality in ED patients with suspected infection and no organ dysfunction (OR, 
0.8; 95% CI, 0.4-1.6). The 3,102 patients in that study were identified on the basis of blood culture 
requests and included patients discharged home from the ED. More recently, a larger Danish study 
[19] also used blood culture requests to identify 5,499 ED patients admitted with infection and 
found that SIRS was associated with increased mortality (HR, 1.5; 95% CI, 1.2-1.7). Marchick and 
Jones [20] also found SIRS to be associated with significantly greater mortality in a cohort of 1,031 
ED patients with suspected infection (6.5% vs 1.4%; P = .02), but those investigators expanded SIRS 
criteria to include hyperglycemia and altered mental state. Our study examined the largest 
prospective cohort of ED patients with suspected infection to date and found SIRS to be associated 
with increased risk of organ dysfunction and mortality at 30 days and 1 year. The proposed Sepsis-
3 definitions discarded SIRS and nominated organ dysfunction as an indicator of deleterious and 
dysregulated response to infection. Our results establish that SIRS is also associated with increased 
risk of deleterious response to infection and mortality. 
 
SIRS in patients with organ dysfunction 
Depending on the method used, we found that 24.6% (Sepsis-2) to 27.9% (Sepsis-3) of patients 
with organ dysfunction did not have SIRS. Other investigators have reported similar figures 
[18,21,22]. In our study, SIRS was associated with a modest increase in 30-day mortality risk in 
patients with infection and organ dysfunction, but this effect was not evident at 1 year. We could 
identify only one previous study designed to examine the prognostic effect of SIRS in patients with 
infection and organ dysfunction seen in the ED. In that study, Henriksen et al [22] found that SIRS 
was present in 75.8% of 1,169 patients seen in the ED and admitted with infection and organ 
dysfunction, and did not confer increased mortality risk (adjusted HR, 1.17; 95% CI, 0.84-1.64). 
Studies in patients with infection in the ICU have concluded that SIRS adds little to the prognosis in 
the context of organ dysfunction and shock [12]. Kaukonen et al [10] examined a large database of 
ICU patients with serious infection (mortality, 23.4%), finding SIRS to be present in 87.9% and not 
associated with mortality in an adjusted analysis. In our study, patients with shock (mortality, 
23.8%) had SIRS in 89% of cases, with SIRS also not associated with mortality. 
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Organ dysfunction 
Overall organ dysfunction according to both Sepsis-2 and Sepsis-3 provided similar estimates of 
mortality risk. The capacity to denote dysfunction in each of the six SOFA organ systems (Sepsis-2) 
allowed the identification of patients with dysfunction in multiple organ systems. This 
classification was important prognostically, with mortality increasing according to the number of 
organs affected; it could also provide relevant clinical information that may indicate the 
requirement for particular interventions and organ support. Increasing mortality with cumulative 
organ dysfunction was also observed in the study from Shapiro et al [18] although the criteria used 
to determine organ dysfunction were not SOFA based. Our analyses found that mortality 
associated with each individual organ dysfunction varied widely (Table 3.3) despite the same SOFA 
threshold (increase of 2 or more) applying to each. Table 3.5 (Supplementary Table 2) enables 
comparison of mortality in each organ system as the threshold is increased from one to four. A 
CNS SOFA cut-off of 1 (any reduction in consciousness) is associated with outcomes similar to 
dysfunction in the other major organ systems. Furthermore, even at SOFA cut-offs of 3 or more, 
gastrointestinal and hematologic organ system dysfunction remains less important prognostically 
than dysfunction in other systems. The poor calibration of the SOFA score between organ systems 
seen in our study may be related to its use in the ED setting and the fact that the SOFA score dates 
from 1996. Limitations in the SOFA score will also affect Sepsis-3 organ dysfunction criteria and 
might be reduced by recalibrating the score with contemporary patient data. The 29% of patients 
with Sepsis-3 but not Sepsis-2 organ dysfunction presented with an increase in SOFA score by 1 in 
two or more different organ systems. Mortality in this group was less than with Sepsis-2 organ 
dysfunction at 30 days (but similar at 1 year), creating some uncertainty about whether these 
patients should be regarded to have organ dysfunction. 
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Figure 3. 4: 30-day mortality and adjusted odds ratio for mortality associated with organ 
dysfunction according to Sepsis-2 and Sepsis-3, and Sepsis-2 cumulative organ dysfunctions. 
 
Mortality = 30-day mortality (%), OR = odds ratio, adjusted for age and co-morbidity (Charlson Score) 
 
SIRS and qSOFA 
The qSOFA score has been proposed as a parsimonious bedside tool to screen patients with 
infection for those at risk of organ dysfunction and death [8]. Overall discrimination for organ 
dysfunction was similar for SIRS and qSOFA, but specificity and sensitivity differed at operating 
cut-offs of SIRS ≥ 2 and qSOFA ≥ 2. Despite qSOFA ≥ 2 being highly specific for Sepsis-3 organ 
dysfunction and mortality (96.1% and 91.3%, respectively), sensitivity was poor (29.7% and 49.1%) 
compared with sensitivity for SIRS ≥ 2 (72.1% and 76.7%, respectively). Given the relative 
insensitivity of a qSOFA score ≥ 2, it appears inferior to a SIRS score ≥ 2 as a screening test in the 
ED, where the timely identification of high-risk infected patients is paramount. 
 
Study limitations and strengths 
The methods used to identify patients may not have identified all ED patients admitted with 
infection, and not all included patients may have ultimately been shown to have infection. 
However, it is likely that any method chosen to identify patients with infection of all severities in 
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large enough numbers for meaningful analyses would have similar limitations. We aimed to 
minimize these issues by using a broad list of ED admission diagnoses indicating possible infection 
to screen for enrollment candidates and including only those in whom both ED and admitting 
teams concurred that infection was the most likely cause of admission. Our methods were entirely 
observational, and therefore data collected were limited to those generated in the course of 
standard investigation and treatment for each patient. Despite this, missing data were minimal as 
reported. Our study was undertaken at a single center, which may limit generalizability. We used a 
modified SOFA score for ED patients, and this may influence the number of patients categorized as 
having organ dysfunction. Derivation of the Sepsis-3 criteria incorporated a secondary end point of 
mortality or ICU admission of ≥ 3 days, or both. Consistent with the primary end point of mortality, 
our analyses have assessed the performance of Sepsis-3 criteria against mortality at 30 days and 1 
year but have not assessed this secondary end point. Strengths of our study include the 
prospective enrollment of a large cohort of ED patients admitted with suspected infection and 
reliable short-term and long-term mortality end points sourced from a national database. Use of 
the SOFA score has enabled a comparison between alternative definitions of organ dysfunction in 
the context of infection, and ours is the first assessment of the proposed Sepsis-3 criteria in the 
ED. 
 
Conclusions 
Our results indicate that SIRS is a useful screening tool for organ dysfunction and death in ED 
patients with suspected infection. SIRS contributed less to prognosis in the context of organ 
dysfunction or shock, arguing against including SIRS as a requirement for entry into trials enrolling 
patients with severe sepsis and septic shock. Patients with organ dysfunction according to either 
Sepsis-2 or Sepsis-3 criteria had similar mortality. Reporting multiple organ dysfunctions (Sepsis-2) 
allows a description containing more prognostic and clinically relevant information. The wide 
variation in mortality risk associated with a SOFA score of 2 in each organ system indicates that 
the SOFA score may require calibration for use in the ED. 
 
 
 
 
 
 
76 
 
Table 3. 4: Modified sequential organ function assessment (SOFA) score    
         
SOFA = sequential organ function assessment, RESP = respiratory system, PaO2 = arterial oxygen partial 
pressure (mmHg), FiO2 = fraction inspired oxygen, SpO2 = oximetry saturation, RA = room air, CVS = 
cardiovascular system, SBP = systolic blood pressure (mmHg), NA = noradrenaline, HAEM = haematological 
system, GIT = gastrointestinal system, CNS = central nervous system, RENAL = renal system, Cr = creatinine, 
UO = urine output.  
 
 
 
Table 3. 5: Comparison of included and excluded presentations for the 618 patients with 
readmissions within 90 days. 
 
 Included Presentations 
(884) 
Excluded presentations 
(846) 
p =  
SIRS ≥2 478 (54.1%) 472 (55.8%) 0.47 
qSOFA ≥2 129 (14.6%) 118 (13.9%) 0.70 
Sepsis-3 Organ Dysfunction 296 (33.5%) 280 (33.1%) 0.86 
Deceased at 30 days 39 (4.4%) 33 (3.9%) 0.60 
 
SIRS = systemic inflammatory response syndrome, qSOFA = “quick” sequential organ function assessment. 
In cases of readmissions within 90 days, a single admission was chosen at random from that period for 
inclusion. 472 patients had one representation excluded, 98 had 2 excluded, 27 had 3 excluded, and 19 had 
4 or more excluded (total 846 excluded presentations). 429 patients had one representation included, 128 
had 2 included, 41 had 3 included, and 18 patients had 4 or more representations included (total 884 
included presentations) in the study dataset. 
 
 
    SOFA SCORE 
Organ 
system 
Determinants 0 1 2 3 4 
RESP 
PaO2/FiO2 
SpO2% 
>400     
>94%(RA) 
<400 <300                              
<90%(RA) 
<200 <100 
CVS SBP, 
vasopressors 
SBP>90  SBP>90 post bolus SBP<90 post bolus  
+/- NA < 8mcg/min NA 8-15mcg/min NA >15mcg/min 
HAEM Platelet count   
(x109/L) 
≥150 <150 <100 <50 <20 
GIT Bilirubin 
(mmol/L) 
<20 20-32 33-101 102-204 >204 
CNS Glasgow Coma 
Score (GCS) 
15 13-14 10, 11, 12 6, 7, 8, 9 3, 4, 5 
RENAL Cr (mmol/L), 
Urine output 
<120 ≥120, UO <0.5 
ml/kg over 2 hours 
≥170 ≥300 ≥440 
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Table 3. 6: Mortality and odds ratios for mortality using different SOFA cut-offs to denote organ 
dysfunction in different organ systems. 
 
SOFA cut-off 
considered 
abnormal 
CVS CNS RESP HAEM GIT RENAL 
1+ 
n=614 
16.6% 
OR: 7.1                   
(5.5-9.1) 
n=789 
16.2% 
OR: 7.7                   
(6.1-9.7) 
n=1639 
13.5% 
OR: 10.5                  
(8.3-13.3) 
n=726 
4.8% 
OR: 1.4                    
(1.0-2.0) 
n=1750 
4.6% 
OR: 1.4                   
(1.1-1.8) 
n=701 
15.4% 
OR: 6.6                      
(5.2-8.5) 
2+ 
n=218 
23.9% 
OR: 9.5                     
(6.8-13.3) 
n=129 
33.3% 
OR: 14.9               
(10.1-21.9) 
n=779 
16.6% 
OR: 7.9                    
(6.3-10.0) 
n=203 
6.9% 
OR: 2.0                    
(1.1-3.4) 
n=400 
6.3% 
OR: 1.8                   
(1.2-2.8) 
n=279 
23.3% 
OR: 9.7                      
(7.1-13.1) 
3+ 
n=60 
21.6% 
OR: 7.5                     
(4.0-14.0) 
n=61 
36.1% 
OR: 15.7                    
(9.2-26.9) 
n=300 
20.3% 
OR: 8.0                    
(5.9-10.8) 
n=66 
9.1% 
OR: 2.6                      
(1.1-6.2) 
n=26 
7.7% 
OR: 2.2                       
(0.5-9.3) 
n=64 
25.0% 
OR: 9.1                     
(5.1-16.2)  
4 
n=33 
33.3% 
OR: 13.5                  
(6.5-28.1) 
n=17 
41.2% 
OR: 18.7                 
(7.1-49.4) 
n=72 
33.3% 
OR: 14.0                    
(8.5-23.2) 
n=28 
10.7% 
OR: 3.2                       
(1.0-10.5) 
n=6 
16.7% 
OR: 5.2                      
(0.6-45.0) 
n=25 
24.0% 
OR: 8.4                       
(3.3-21.1) 
 
SOFA = sequential organ function assessment, CVS = cardiovascular system, CNS = central nervous system, 
RESP = respiratory system, HAEM = haematological system, GIT = gastrointestinal system, RENAL = renal 
system, OR = (unadjusted) odds ratio. Table entries comprise number of patients with failure at each cut-
off, 30-day mortality and OR for 30-day mortality with 95% confidence intervals in parentheses. 
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Figure 3. 5 (published as e-figure 1): Receiver operating curves for SIRS and qSOFA prediction of 
30-day mortality 
 
 
SIRS = systemic inflammatory response syndrome, qSOFA = “quick” sequential organ function assessment, 
AUC = area under curve, CI = confidence interval. 
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Section 3.3 – Summary and context 
 
Sepsis-3 definitions were derived and validated in very large retrospective datasets from multiple 
locations. Many patients were identified through hospital discharge summaries, and inclusion 
criteria were culture of a bodily fluid, and treatment with antibiotics (although these events could 
be up to 72 hours apart) [1]. Key variables such as tachycardia, tachypnoea and hypotension were 
missing in >50% of episodes. Platelet count, PaO2/FiO2 ratio and bilirubin were missing in 15%, 
62% and 74% of encounters outside the ICU respectively. The composite endpoint used was in-
hospital mortality or ≥ 3 days in intensive care. Reporting centred predominantly on areas under 
receiver operating curves (AUROC) [1]. 
 
Review of methods for derivation and validation of prognostic scores in previous sections of this 
thesis reveals substantial potential for bias in the methods used to derive the Sepsis-3 criteria. 
Nonetheless, the authors used very large datasets and attempted to use rigorous methods despite 
inherent limitations of the data. Ultimately, as is acknowledged in the paper, external validation 
with good quality data is required to justify further use, particularly in the emergency department 
setting.  
 
Although enrolling far fewer patients, the prospective observational database underpinning the 
studies in this thesis is methodologically robust [2]. Findings of the published study in the previous 
section relate to emergency department patients with infection and can be summarised: 
 
1) SIRS is associated with greater risk of organ dysfunction, and mortality in patients 
without organ dysfunction.  
 
2) SIRS is not associated with greater mortality in patients with organ dysfunction or shock 
 
3) Although SIRS and qSOFA have very similar overall diagnostic accuracy for prediction of 
organ dysfunction (AUROC), sensitivity at the specified operating points (≥ 2 points for both 
scores) strongly favours SIRS as a screening test for organ dysfunction. 
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4) Using total increase of two SOFA points to define organ dysfunction creates two groups 
with different mortality risk – those with 2 points increase in one organ system and those 
with unitary SOFA increase in two different organ systems. 
 
5) The SOFA score likely requires some recalibration for use in the emergency department 
setting, with a wide range of mortality evident with different organ failures. 
 
Other studies examining the Sepsis-3 proposals have now been published [3-5], but most have 
focussed on the predictive validity of qSOFA using area under the receiver operating curve 
(AUROC). Raith and colleagues [3] examined retrospective data from over 185,000 intensive care 
unit admissions (2000-2015) in the Australian and New Zealand Intensive Care Society Adult 
Patient Database (ANZICS APD). Thirty-seven percent of included patients were admitted to 
intensive care from the emergency department, and study endpoint was hospital mortality 
(overall 18.7%). AUROC (for prediction of mortality) was greater for SOFA (0.75) than for qSOFA 
(0.61) or SIRS (0.59). Two smaller single-centre US intensive care based studies have similarly 
assessed diagnostic accuracy with hospital mortality endpoint. Finkelsztein et al. [4] 
retrospectively analysed data from 152 patients admitted to ICU with infection (67% from the ED), 
and measured qSOFA and SIRS using data generated in the eight hours prior to ICU admission. 
Again, AUROC for qSOFA (0.74) was found greater than that for SIRS (0.59) for prediction on in-
hospital mortality. Another retrospective chart review [5] analysed 214 emergency patients 
admitted to intensive care with severe infection. Data generated in the ED found AUROC for 
qSOFA (0.66) not different to AUROC for SIRS (0.65), for prediction of in-hospital mortality. 
  
At the time of writing, two published studies have assessed qSOFA outside the intensive care unit. 
A single-centre retrospective database of 30,677 patients with infection outside the intensive care 
unit (60% from the ED, overall mortality 5.4%) was analysed by Churpek et al [6]. For prediction of 
in-hospital mortality, the Modified and National Early Warning Scores (MEWS, NEWS) were far 
superior to both qSOFA (AUROC 0.69) and SIRS (0.65). qSOFA was found to be a late and 
insensitive indicator of deterioration. Lastly, an international prospective observational ED study 
(30 emergency departments over four weeks, 879 patients with infection, hospital mortality 8%) 
was conducted in Europe [7]. In-hospital mortality was more accurately predicted by qSOFA 
(AUROC 0.80) than by SIRS or SIRS + lactate ≥ 2.0 mmol/L (both 0.65). Patients with missing data 
(16%) were excluded from the study cohort. 
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Each of the papers outlined above have methodological drawbacks and all but the last paper 
described are not generally applicable to ED patients with infection of all severities. Our paper [8] 
remains the largest and most relevant to the research question, and raises several issues regarding 
the proposed Sepsis-3 structure other than discrimination of qSOFA and SIRS. Our paper is also the 
only study to assess SIRS and qSOFA for screening/prediction of organ dysfunction, a role clearly 
stipulated for qSOFA in the Sepsis-3 framework. Finally, we believe our suggested hierarchy 
consisting infection without SIRS, infection with SIRS (sepsis), infection with organ dysfunction 
(severe sepsis) and septic shock (infection with cardiovascular failure) is a sensible evolution of 
sepsis definitions that maintains SIRS as a severity indicator only in the absence of organ 
dysfunction.    
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Chapter 4: Septic Shock 
 
Section 4.1 – Synopsis 
 
In this chapter, the evolving concept of septic shock is explored. It commences with a short history 
of the term septic shock and proceeds with a summary of attempts to measure and characterise 
the condition in Australian cohorts.  
 
The published paper comprising the main section of this chapter (section 4.3) therefore analysed 
those patients in the thesis database that satisfied the definition of septic shock corresponding to 
criteria in use at that time. Direct comparisons were made between the patients in the study and 
cohorts enrolled in a series of randomised controlled trials investigating early goal directed 
therapy. Prognostic implications of hypotension and/or raised lactate in the ED, time to 
appropriate antibiotics and volume of fluid received during the resuscitation period were all 
explored using the study dataset. In the final section (section 4.4), results of the published paper 
will be further discussed together with implications for current practice and future research arising 
from analysis of the study cohort. 
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Section 4.2 – Defining and Measuring Septic Shock 
 
4.2.1 – Defining septic shock 
Highlights in the ongoing evolution of definitions for sepsis and sepsis syndromes have been 
reviewed in Chapter 3. The concept and definition of “septic shock”, as a distinct clinical syndrome 
signifying the sickest sepsis patients with severe and immediately life-threatening infection, has 
evolved in parallel with the broader definition of sepsis.  
  
The term “shock” is thought to have first appeared in the English-language medical literature in 
the translation of a treatise on gunshot wounds by French military surgeon Henri-François LeDran 
in 1740 [1]. In “Traité ou Reflexions Tire’es de la Pratique sur les Playes d’armes à feu” (A treatise, 
or reflections, drawn from practice on gun-shot wounds), LeDran observed that patients appearing 
stunned, agitated, or restless often succumbed to their injuries; he referred to this state using the 
word saisissemant which was translated to the English “shock”. Two authors published books on 
shock being the frequently-fatal culmination of a variety of insults in the 1860s, both ascribing the 
syndrome to neurological dysfunction [2, 3]. However, the invention of the sphygmomanometer 
by that time facilitated the recognition that hypotension was an objective and reliable feature of 
the syndrome.  
 
Alfred Blalock progressed understanding and classification of shock states with publication of his 
seminal 1936 paper “Shock and Hemorrhage” [4].  In a classification still in use today, Blalock 
described five shock states (Table 4-1) and was the first to define shock as a state of ‘diminished 
effective blood volume’, whether due to blood loss or pathological dilatation. Sepsis was 
recognised to cause a state of abnormal vasodilation despite low blood pressure similar to that 
observed with histamine. 
 
The search for circulating vasoplegic and myocardial depressant factors in septic shock has 
unearthed several candidates including endotoxin [5], tumour necrosis factor [6] and an increasing 
array of cytokines [7]. However, none of these mediators has proved sufficiently sensitive or 
specific for use as a gold-standard definition of septic shock. Consequently, contemporary 
diagnostic criteria involve clinical findings of hypotension or hypoperfusion refractory to fluids in 
the context of infection. 
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Table 4. 1: Blalock’s classification of shock states 
 
Shock type Definition, examples 
‘Hematogenic’ Diminution of blood volume, trauma. Also known as ‘hypovolaemic’ 
Neurogenic Vasodilation due to diminished neural vasoconstrictor tone 
Vasogenic Vasodilation mediated by circulating agencies. Also known as 
‘Distributive’ 
Cardiogenic Primary disturbance of the heart characterised by venous distension 
‘Other’ (modern classifications include ‘obstructive’ as a fifth shock type) 
 
 
‘Consensus’ conferences, Surviving Sepsis Campaign  
Roger Bone, an eminent critical care specialist and endotoxin researcher, proposed clinical 
definitions for sepsis and septic shock in 1989 [8]. Bone defined septic shock as sustained (at least 
one hour) systolic blood pressure (SBP) of ≤ 90 mmHg (or reduction in SBP of ≥ 40 mmHg from a 
known baseline) after adequate volume replacement, in the context of sepsis syndrome (abnormal 
temperature, tachycardia and tachypnoea as systemic manifestations of infection). This was 
essentially the definition of septic shock endorsed in the first and second sepsis ‘consensus 
conferences’ in 1991 [9] and 2001 [10] albeit with adjustments to the systemic inflammatory 
response (SIRS) criteria in each case. Recommendations made in the initial Surviving Sepsis 
Campaign (SSC) guideline for managing severe sepsis and septic shock in 2004 [11] were strongly 
influenced by a ground-breaking randomised controlled trial (RCT) conducted by Emanuel Rivers 
and colleagues [12] which enrolled patients with ‘severe sepsis and septic shock’, defined by 
infection, SIRS, and either hypotension unresponsive to fluid bolus or blood lactate ≥4.0 mmol/L. 
These criteria were adopted as the working definition of septic shock in the second (2008) and 
third (2012) iterations of the SSC guidelines [13, 14].  
 
The association of a working definition for septic shock (refractory hypotension or lactate ≥4.0 
mmol/L) with an endorsed management guideline (known as ‘early goal-directed therapy’, after 
the initial RCT) likely helped promote awareness and use of both the definition and the guideline. 
The fact that Rivers’ early goal directed therapy (EGDT) study was the first to document improved 
outcomes in septic shock for decades no doubt also increased interest and awareness [15]. An 
international registry was established by the SSC to which participant hospitals contributed data 
85 
 
regarding compliance with screening and treatment of patients satisfying the septic shock criteria 
[16]. Systems to screen for patients meeting these criteria and collection of data on compliance 
with sepsis management protocols were mandated in some jurisdictions [17], and ‘sepsis 
pathways’ were adopted by many other hospitals [18, 19]. Outcomes for patients treated on these 
pathways were reported to improve, with substantial reductions in mortality [20]. 
 
In 2014/15, three large multi-centre RCTs found no benefit from early goal-directed therapy 
applied to patients with sepsis and either hypotension or lactate ≥4.0 mmol/L [21 - 23]. In this 
context, Shankar-Hari et al. [24] suggested that the current definition for septic shock was 
inadequate, citing concerns such as the stepwise increase in mortality then seen in patients 
satisfying lactate only, hypotension only, and combined criteria [16, 21]. Subsequently in 2016 a 
group of critical care researchers from the United States and Western Europe published the “Third 
International Consensus Definitions for Sepsis and Septic Shock” (Sepsis-3), in which new criteria 
were proposed to identify patients with septic shock: vasopressor requirement to maintain a 
mean arterial blood pressure (MAP) ≥65 mmHg, and lactate ≥2.0 mmol/L, in the absence of 
hypovolaemia [25]. No emergency medicine representatives were involved in the formulation of 
the recently proposed definitions, despite most patients with septic shock first being assessed and 
treated in the ED [26]. The sepsis-3 authors were concerned that ‘septic shock’ should be 
associated with higher hospital mortality than the 29.9% and 30.1% seen respectively for sepsis 
patients in the SSC database with either lactate ≥4.0 mmol/L or fluid-resistant hypotension (and 
lactate ≤2.0 mmol/L) alone. The relevant figure to report for the hypotension-only group should 
have been 36.7% mortality for patients with fluid-resistant hypotension and lactate <4.0 mmol/L 
[16].  Mortality for SSC database patients with resistant hypotension and lactate ≥2.0 mmol/L was 
42.3%. 
 
4.2.2 – Septic shock outcomes in Australia 
The original early goal-directed therapy (EGDT) study [12] was indeed notable for its welcome 
positive findings in the context of a series of negative trials examining immunomodulation [27] 
and goal-directed haemodynamic protocols [28] in severe sepsis and septic shock. However, 
concerns were voiced about both internal and external validity of the EGDT study results [29]. 
There were no reliable Australian data on the outcome of patients with septic shock at that time, 
and many of the studies summarised below were framed and interpreted in the context of Rivers’ 
EGDT study and the 46.5% in-hospital mortality reported in the ‘standard-care’ arm of that study. 
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The following Australian studies in which outcomes for patients with septic shock have been 
quantified have been categorised according to broad methodological groups based on the way in 
which data were gathered in each case. Findings are summarised in Table 4-2. 
 
Hospital discharge codes 
Sundararajan et al [30] used discharge ICD-10 (International Classification of Diseases, version 10) 
codes denoting various forms of infection and organ dysfunction to identify hospital admissions 
with sepsis and severe sepsis in the state of Victoria over a four-year period (1999-2003). These 
methods identified 33,741 sepsis admissions with overall hospital mortality 18.4%. Patients were 
classified as severe sepsis (sepsis with organ dysfunction, mortality 31.1%) or non-severe sepsis 
(without organ dysfunction, mortality 10.2%). Mortality for patients with severe sepsis not 
admitted to ICU was reported to be lower than that for severe sepsis patients treated in the ICU 
(29.5% vs 32.7%, p<0.01). Although data for cardiovascular organ dysfunction were collected, no 
estimate of outcomes for patients with septic shock were made. The retrospective identification of 
patients using hospital discharge codes for infection, sepsis and organ dysfunction has provided 
estimates of outcomes in several large studies in the United States [31, 32]. While these methods 
capitalise on the efficiency of large pre-existing administrative databases, substantial inherent 
limitations have been appreciated [33, 34], including variation in codes used, funding and 
insurance reimbursement issues potentially influencing coding in some countries, difficulty 
determining nosocomial from community-acquired sepsis, and poor sensitivity. 
 
Intensive care admission  
Patients admitted to intensive care (ICU) are easily identified in hospital administrative databases 
and have detailed physiological and clinical data recorded at the bedside in the course of routine 
care. Finfer et al [35] prospectively screened for adult severe sepsis cases in 23 Australian and New 
Zealand ICUs over three months in 1999. Severe sepsis was defined as infection with SIRS and 
organ dysfunction (defined in turn as per the PROWESS [36] study, in which the criteria for 
cardiovascular comprised hypotension unresponsive to fluids or vasopressor requirement). Overall 
691 severe sepsis patients were identified with associated 28-day mortality 32.4%. Outcomes for 
patients with shock was not presented. The patients in this study included those with community 
acquired and nosocomial sepsis.  
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The Australia and New Zealand Intensive Care Society (ANZICS) has collected detailed data from all 
admissions to most ICUs in those countries for over two decades in their adult patient database 
(ANZICS APD). This database has been examined by several investigators for the purpose of 
quantifying outcomes for patients with severe sepsis and septic shock in Australia and New 
Zealand. A 2007 paper [37] used data from the ANZICS APD to retrospectively report on the 
characteristics and outcome of patients with sepsis admitted ICU after presentation to emergency 
departments over the period 1997-2005. Sepsis and shock were defined according coded ICU 
admission categories. These methods identified 7649 ICU patients with sepsis (hospital mortality 
26.7%), including 4001 patients with shock and associated hospital mortality of 36.2%. Authors of 
later retrospective study (published 2014) searched ANZICS APD data for ICU patients admitted 
with severe sepsis and septic shock over 13 years [38]. Mortality for patients with septic shock 
decreased from 40.3% to 22.0% from 2000 to 2012. As in the Finfer report [35], the cohort in this 
study included patients with both community-acquired and nosocomial sepsis. 
 
A substantial limitation shared by all studies restricted to ICU data is patients with sepsis not 
admitted to ICU will not be included. Patients with baseline dependence, multiple co-morbidities 
and poor quality of life are sometimes determined unlikely to benefit from aggressive 
resuscitation in ICU, and emergency physicians are increasingly aware of the importance of 
addressing symptoms control and dignity for such patients presenting with serious illness [39]. It is 
conceivable also that patients may meet criteria for septic shock in the ED but respond to initial 
care sufficiently to not require ICU admission. To capture data for all patients presenting with 
septic shock, studies need to enrol patients that meet specified criteria in the ED. 
 
Septic shock in the Emergency Department  
Ho and colleagues [40] aimed to identify adult ED patients that may have been eligible for EGDT 
(sepsis with hypotension unresponsive to fluid or lactate ≥ 4.0 mmol/L) in a retrospective single-
centre study published in 2006. Patients with an ED ICD-10 admission diagnosis potentially 
indicating infection were identified between 2000 and 2003. Patients without ‘not for 
resuscitation’ (NFR) orders and measured lactate ≥ 4.0 mmol/L (or surrogates: base deficit ≥ 4 
mEq/L or bicarbonate ≤ 20 mmol/L) were judged eligible for EGDT. Additionally, the charts of 
those patients admitted to monitored beds or deceased in hospital without NFR orders were 
examined for evidence of SIRS and refractory hypotension. Patients meeting these criteria were 
also deemed eligible for EGDT. With these methods, the authors identified only 52 patients judged 
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suitable for EGDT over 3.5 years, with in-hospital mortality 30.2%. Only one patient was identified 
with lactate ≥ 4.0 mmol/L suggesting lactate testing was not frequently used at the study hospital. 
The authors acknowledged the limitations of the retrospective design. 
 
A prospective ED-based study at the Royal Darwin Hospital also screened adult ED admission 
diagnosis codes for infection over 12 months (2007/08) [41]. Charts and data for all potential cases 
were reviewed for SIRS criteria and organ dysfunction (PROWESS criteria). Hospital mortality was 
1.5% for patients with non-severe sepsis and 17.1% for those with severe sepsis. No outcome data 
for shock patients were presented. Another prospective study examining biomarkers enrolled 240 
ED patients with sepsis from two West Australian centres from 2010 to 2013 [42]. The study 
cohort included 120 patients satisfying conventional criteria for septic shock (SIRS with refractory 
hypotension or lactate ≥ 4.0 mmol/L) and 30-day mortality 26%. The subjects in this study were 
recruited by research nurses working prescribed hours and consented to participate so may not 
represent all ED patients meeting septic shock criteria.  
 
To quantify and characterise all such patients was the aim of a prospective multicentre 
observational study conducted in 32 Australian emergency departments over a three-month 
period in 2006/7 [43]. Active screening in the ED and review of admissions databases were used to 
identify patients admitted with infection, SIRS, and either refractory hypotension or lactate > 4.0 
mmol/L. However the fluid challenge required to demonstrate refractory hypotension was only 
500mL and either anion gap > 20 mmol/L or bicarbonate < 16 mEq/L could be used in lieu of 
lactate measurement. In-hospital mortality for the 324 patients enrolled was 23.1%. Mortality was 
similar for patients admitted to ICU and the wards (24.7% vs 21.4%), and similar also for patients 
meeting either hypotension or lactate criteria (23.0% vs 26.9%). Fifty-one patients (15.7%) had a 
“do-not-resuscitate” order on presentation to the ED, and mortality in this group was 47.1%. By 
including all patients identified that met prescribed criteria, this carefully-designed study provided 
valuable information about ED patients admitted septic shock without several limitations apparent 
in previous work. However, the use of a smaller fluid bolus and surrogate metabolic markers to 
demonstrate shock provide some questions about validity of results. Table 4-2 summarises 
Australian data quantifying septic shock. 
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Table 4. 2: Australian studies quantifying severe sepsis / shock, stratified by methods. 
 
1st Author Cohort Findings, mortality 
Discharge coding  
Sundararajan [30] Retrospective, discharge coding based 
Identified 33,741 sepsis admissions in Victoria 
1999-2003 
Severe sepsis 31.1% 
Non-severe sepsis 10.2% 
Community and nosocomial 
Intensive care admission 
Finfer [35] Prospective, identified 691 severe sepsis cases in 
23 ICUs over 3 months in 1999. 
Severe sepsis 32.4% 
Community and nosocomial 
ANZICS APD [37] Retrospective ICU admissions database study 
7649 ICU admissions with sepsis / septic shock 
after ED presentation, multicentre 1997-2005. 
ICU sepsis 26.7% 
ICU septic shock 36.2% 
Community-acquired only 
Kaukonen [38] Retrospective ICU admissions database study 
101,064 ICU patients identified with severe sepsis 
in 171 ICUs over 2000-2012. 
 
Septic shock mortality 
decreased 40.3 – 22.0% over 
period 2000-2012. 
Community and nosocomial 
Admission from emergency department 
Ho [40] Retrospective, single centre, ED admission code 
consistent with infection. 52 patients judged 
eligible for EGDT after screening monitored 
admissions and biochemistry for lactate or 
equivalent. Study over 3.5 years from 2000-2003 
Septic shock 30.2% 
Community-acquired 
Davis [41] Prospective, single centre, ED admissions 
screened for sepsis. 1191 cases enrolled over 12 
months 2007/08 
Severe sepsis 17.1% 
Non-severe sepsis 1.5% 
Community-acquired 
MacDonald [42] Prospective 2 centres. Patients with sepsis, 
consented for enrolment in biomarker study. 
240 sepsis (incl. 120 septic shock) 2010-13  
Septic shock 26% 
Community-acquired 
Peake [43] Prospective, 324 patients with septic shock (with 
surrogate measures) enrolled from 32 EDs over 3 
months in 2006/7. Included patients NFR 
Septic shock 23.1% 
Community-acquired 
ARISE [23] Prospective international multicentre RCT 
enrolling septic shock patients suitable for EGDT. 
804 standard care patients, from 51 centres, over 
period 2008-2013. 
Septic shock (28d) 15.9% 
Community-acquired 
 
ANZICS = Australian and New Zealand Intensive Care Society, APD = Adult Patient Database, ARISE = 
Australasian Resuscitation in Sepsis Evaluation, ICU = intensive care unit, NFR = not for resuscitation. 
 
 
Lastly, the Australasian Resuscitation in Sepsis Evaluation (ARISE) study [23] was a large, 
international multicentre RCT comparing EGDT and standard care in ED patients with septic shock 
as defined in the original Rivers study [12]. This study, together with similar studies in the United 
States [22] and England [24] found no mortality advantage from EGDT over standard care. 
Mortality at 28 days was 15.9% for the 798 participants in the standard care arm of ARISE, with 
614 (76.9%) admitted from ED to the ICU. While the ARISE study also supplies detailed data on 
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(mostly) Australian patients admitted with community-acquired septic shock, patients not thought 
eligible for unrestrained resuscitation or unable to be consented and randomised within two hours 
of meeting inclusion were not enrolled. Other study exclusions were pregnancy and contra-
indications to central venous catheter insertion. 
 
4.2.3 – Conclusions 
In terms of participant numbers and study profile, Australian data on characteristics and outcome 
for patients with septic shock is heavily weighted by RCT and ICU data. Limitations of previous 
studies have been outlined above. Accurate data on characteristics and outcomes for all ED 
patients meeting criteria for septic shock are necessary for communication of prognosis to 
patients and families, resource planning, design of future studies and to inform further evolution 
of definitions of septic shock.   
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4.3.1 – Abstract 
 
Objective:  
Most published data on emergency department (ED) patients with septic shock have been 
generated from studies examining the effect of early protocolized resuscitation in selected 
cohorts. Consequently, these data do not generally represent patients falling outside trial inclusion 
criteria or judged unsuitable for aggressive treatment. Our aim was to determine the 
characteristics, treatment and outcomes for all ED patients fulfilling the criteria for septic shock. 
  
Methods:  
Septic shock patients were identified from a prospective database of consecutive ED patients 
admitted with infection. Descriptive data were compared with those from previous studies and 
associations between ED processes of care and mortality were determined.  
 
Results:  
A total of 399 septic shock patients were identified, with a 30-day mortality of 19.5%. The median 
ED length of stay was 9.2 h. Rates of vasopressor use (22.6%) and ICU admission (37.3%) were low. 
Subgroups fulfilling the lactate criteria alone, hypotension criteria alone and both criteria 
represented distinct shock phenotypes with increasing severity of illness and mortality. Mortality 
for patients with limitations to treatment determined in the ED was 65.6 and 6.1% for those 
without limitations. Greater volumes of intravenous fluid and early vasopressor therapy for 
appropriate patients were associated with survival.  
 
Conclusion:  
Median length of stay over 9 hours may have enhanced identification of patients with limitations 
to treatment and fluid responders, reducing invasive therapies and ICU admissions. Distinct shock 
phenotypes were apparent, with implications for revision of septic shock definitions and future 
trial design. Liberal fluids and early vasopressor use in appropriate patients were associated with 
survival. 
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4.3.2 – Introduction 
 
The management of septic shock in the emergency department (ED) has evolved considerably 
since the 2001 publication of a pivotal randomized controlled trial (RCT) of early goal-directed 
therapy (EGDT)[1]. Multiple nonrandomized, mostly before-and-after trials applying EGDT and 
reporting improved outcomes [2] were reported over the next 13 years. To date, data 
accumulated on treatment and outcomes from septic shock in the ED have several limitations.  
First, study populations are often convenience cohorts, not representative of all patients that 
meet standard criteria for septic shock. RCTs exclude patients outside strict inclusion criteria and 
most have only enrolled patients deemed suitable for unrestrained resuscitation. Many 
observational studies reporting outcomes after protocolized care did not apply the protocol to all 
eligible patients and excluded patients for whom aggressive resuscitation was deemed 
inappropriate [2]. Detailed observational data from broad groups of patients satisfying the 
standard definition for septic shock are important to benchmark the processes of care (PrOC) and 
outcomes for all patients, including those outside the confines of RCTs and observational studies 
enrolling convenience cohorts. 
 
Second, most studies have evaluated some form of protocolized resuscitation, be it ‘classic’ EGDT 
as originally described [1] with central venous oximetry (ScvO2) monitoring, or otherwise. Three 
recently published large multicentre RCTs [3-5] have found that ‘standard’ care is as efficacious as 
protocolized EGDT, and these findings invite further examination of the components of standard-
care for patients with septic shock not indulged with the resources and attention associated with 
controlled trials. 
 
This study was undertaken to clarify the characteristics, components of standard care and 
outcomes for consecutive patients satisfying the definition of septic shock in our ED. We 
hypothesized that our methods would capture a group of patients much broader than those 
represented by patients enrolled in recent RCTs and other observational studies, and the 
unselected nature of the study cohort would provide valuable insight into the true nature and 
characteristics of ED patients admitted with septic shock as defined in the EGDT era. 
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4.3.3 – Methods 
 
Study Design 
This observational study analysed a subgroup from a large prospective cohort of consecutive ED 
patients admitted with presumed infection. The study was approved by the local hospital ethics 
committee and the need for participant consent was waived. 
 
Setting and participants  
The study was conducted in the ED of a tertiary metropolitan hospital in Brisbane, Australia, with 
annual census 70 000 adult presentations. This paper reports on a planned primary analysis using 
data from a large prospective cohort [6]. Inclusion criteria for that cohort were admission from the 
ED with clinically suspected or proven infection. Patients younger than 17 years or arriving by 
interhospital transfer were not enrolled. Data were collected over a total 162-week period 
(October 2007 – December 2008 and June 2009 – May 2011). Study duration was arbitrary and 
based on available resources for data collection. Funding was provided by the Queensland 
Emergency Medicine Research Foundation.  
 
Study protocol  
Detailed methods have been published previously [6], but are outlined here. On a daily basis, 
patients admitted from or deceased within the ED were identified. Patients with admission 
diagnosis indicating possible infection were listed. The charts of these patients were then 
examined and patients were enrolled if, on the basis of recorded ED and inpatient team 
assessments, infection was considered to be the most likely reason for hospitalisation.  
 
Data were then abstracted from the chart concerning demographics, comorbidities, physiological 
observations and treatment in the ED, presumed source of infection and disposition location 
(admitted to ICU, wards, or died in ED). Patients were classified as ‘do not resuscitate’ (DNR) if, 
during the course of ED management, it was judged that any limitations to treatment were 
appropriate. This occurred within 24 h of each presentation and without knowledge of subsequent 
events. These data were later supplemented with the results of haematology, biochemistry and 
microbiological investigations. A national deaths registry was searched to identify patients 
deceased within one year of enrolment and the dates of death were recorded in those cases.  
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This study analysed the subgroup of patients with septic shock. Consistent with established 
consensus guidelines at the time of study commencement [7], and consistent with inclusion 
criteria used in contemporary large trials of protocolized resuscitation [1,3-5], septic shock was 
defined as systemic inflammatory response syndrome (at least two of: heart rate > 90 min− 1, 
respiratory rate > 20 min−1, leucocyte count > 12 000 or <4000 μL–1 and temperature < 36 or > 
38°C) and either: 
(1) Systolic blood pressure less than 90 mmHg despite fluid challenge of at least 1000 ml, 
or any vasopressor requirement in ED (hypotension criterion), or  
(2) Lactate 4 mmol/l or greater in the ED (lactate criterion). 
  
The most abnormal physiological measurements in the ED were used for the purposes of 
determining systemic inflammatory response syndrome. No formal departmental protocol was 
used for the treatment of patients presenting with septic shock. In particular, treatment was not 
based on intermittent or continuous measurement of superior vena caval oxygen saturation. 
However, in the final year of data collection, the ED contributed towards a multicentre RCT [4] 
comparing EGDT with standard care. Ten patients were randomized to EGDT over this period, with 
one patient consequently receiving blood and dobutamine therapy.  
 
Measurements  
Patients were classified according to shock type (lactate, hypotension or both criteria) and 
resuscitation status (for all resuscitation measures vs. DNR). Appropriate antibiotic treatment was 
defined as administration of antibiotics with in-vitro activity against isolated microorganisms or 
compliance with local empiric guidelines in culture-negative cases. Total intravenous fluid 
administered in the 6 h from presentation was recorded, and other aspects of early sepsis care 
(lactate measurement, blood cultures, central venous access, vasoactive drug therapy and 
mechanical ventilation) were recorded only in the ED. Severity of illness was quantified using the 
New Simplified Acute Physiology Score [8] (SAPS II) and the Acute Physiology and Chronic Health 
Status Evaluation [9] (APACHE II) score to enable adjustments in logistic regression analyses and 
comparison with other study cohorts, respectively. The primary outcome measure was 30-day 
mortality, obtained using data from the national death registry 1 year after study completion. 
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Data analysis  
Descriptive data were presented by vital status, shock type and resuscitation status. For vital 
status and resuscitation status, P values were reported from Mann–Whitney U or t tests for 
continuous data and χ2 or Fisher’s exact test for categorical data. Treatment in ED was presented 
by patient disposition and resuscitation status. Standard descriptive statistics were used for all 
variables, except time to appropriate antibiotics. The median time to antibiotic was calculated 
using the Kaplan–Meier survival function, allowing for case censoring where patients left the ED 
before appropriate antibiotics were administered.  
 
Multivariable logistic regression analyses were used to examine whether compliance with selected 
ED PrOC was associated with mortality. Emergency department PrOC assessed were lactate 
measurement, blood cultures before antibiotic administration, time to appropriate antibiotics, 
total intravenous fluid administered, central venous line placement in ED and vasopressor 
commencement in the ED. Time to appropriate antibiotic was dichotomized sequentially at 1, 2 
and 6 h to explore meaningful targets. Total fluid administered was dichotomized sequentially at 
2, 3 or 4 litres in the first 6 h to inform early fluid treatment. The regression including vasopressor 
use only included patients fulfilling the hypotension criterion and admitted from ED to ICU. In all 
regression analyses, adjustment for severity of illness was made using SAPS II rather than APACHE 
II as the former score was shown to be a more accurate mortality predictor in the study cohort 
[10]. The regression analyses were also carried out on the non-DNR patients alone. In 
supplementary analyses prompted by the recent publication of proposed new definitions for 
septic shock [11], outcomes were determined for non-DNR patients with various combinations of 
hypotension and different lactate cut-offs.  
 
4.3.4 – Results 
 
During the study period, there were 9719 admissions with presumed infection. Of these, 399 
fulfilled the criteria for septic shock, corresponding to 10.2 cases per month. Derivation of the 
study cohort is represented graphically in Fig. 4.1.  
 
One patient had missing haematocrit data and three patients had missing potassium data. These 
missing data were considered normal for the computation of illness severity scores. Sensitivity 
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analyses using multiple imputation of missing data yielded similar estimates to those reported, 
and so were excluded from the paper.  
 
Figure 4. 1: Derivation of the (septic shock) study cohort. 
 
 
Selected characteristics of the study cohort are presented in Table 4.3. The median APACHE II 
score was 19, and early limitations to treatment (DNR) were deemed appropriate for 90 patients 
(22.3%). The median ED length of stay was 9.2 h and 149 (37.3%) patients were admitted from the 
ED to the ICU, 11 of these through the operating theatre. A further 19 study patients (4.7%) were 
later transferred to ICU from the hospital wards. Seventy-eight patients (19.5%) were deceased at 
30 days, and of those deceased, 59 (75.6%) had limitations to treatment determined in the ED 
(DNR). Table 4.4 compares characteristics of the study cohort with standard care arms of recent 
RCTs enrolling similar patients [3-5]. 
 
Table 4.5 shows cohort characteristics and outcomes according to shock type and DNR status. 
Physiological derangement, percentage of blood cultures positive, ICU admission rate and 
mortality varied according to shock type. The median age of the 90 DNR patients was 81.5 years, 
ED = Emergency Department,  
SIRS = systemic inflammatory 
response syndrome. 
98 
 
and of these, 57 (63.3%) were nursing home residents and 59 (65.6%) were deceased at 30 days. 
In the remaining 309 patients with no limitations to treatment, mortality was 6.1%.  
 
Table 4. 3: Selected cohort characteristics by vital status at 30 days 
 
Characteristics 
Total cohort Alive at 30 days 
Deceased at     
30 days 
p = 
n   399 321 78  
Age (median, IQR) 63 (47-78) 59 (43-73) 76 (66-84) <0.01 
Male 230 (57.6) 189 (58.9) 41 (52.6) 0.31 
Do not resuscitate  90 (22.6) 31 (9.7) 59 (75.6) <0.01 
Nursing home resident  69 (17.3) 34 (10.6) 35 (44.9) <0.01 
APACHE II (median, IQR) 19 (13-25) 17 (12-22) 26.5 (22-31) <0.01 
SOFA (median, IQR) 6 (3-8) 5 (3-7) 8 (6-10) <0.01 
Charlson Score (median, IQR) 3 (1-4) 2 (1-4) 4 (3-6) <0.01 
Lactate (median, IQR), n=380 4.6 (3.2-6.0) 4.6 (3.2-5.8) 4.6 (3.3-7.2) 0.21 
Lactate (mean, SD), n=380 5.0 (3.2) 4.8 (3.0) 5.9 (4.0) 0.02 
Bacteraemia  136 (34.1) 107 (33.3) 29 (37.2) 0.52 
Presumed Source     
Respiratory tract  147 (36.8) 112 (34.9) 35 (44.9) 0.10 
Urinary tract  73 (18.3) 51 (15.9) 22 (28.2) 0.01 
Abdominal / Pelvic  51 (12.8) 46 (14.3) 5 (6.4) 0.06 
Soft Tissue  33 (8.3) 31 (9.7) 2 (2.6) 0.04 
Disposition     
LOS ED in hours (median, IQR) 9.2 (6.4-13.3) 9.2 (6.7-13.5) 9.2 (5.3-12.0) 0.12 
ICU admission  149 (37.3) 131 (40.8) 18 (23.1) <0.01 
Ward admission  240 (60.2) 190 (59.2) 50 (64.1) 0.43 
Died in ED  10 (2.5) 0 (0) 10 (12.8) <0.00 
Figures in parentheses are column percentages except as indicated for inter-quartile ranges (IQR). APACHE 
II = acute physiology and chronic health evaluation score, SOFA = sequential organ function assessment, SD 
= standard deviation, ICU = intensive care unit, ED = emergency department, LOS = length of stay.  
 
 
Processes of ED care varied according to disposition and DNR status (Table 4.6). Interventions 
were more frequent in the group admitted to ICU. For the entire cohort, a mean of 2.3 litres of 
intravenous fluid was administered in the first 6 h after presentation. Central venous access was 
obtained in 100 patients (25.1%) and vasopressor therapy (noradrenaline in all cases, 
supplemented with vasopressin in two) was commenced in the ED in 90 cases (22.6%). Three 
patients were treated with dobutamine. Invasive treatments were uncommon in the group with 
limitations to treatment, but these patients received appropriate antibiotics significantly sooner 
(125 vs. 154 min, p = 0.02). 
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Table 4. 4: Comparison of study patients and standard-care cohorts in recent randomised 
controlled trials of early goal-directed therapy for septic shock. 
 
Characteristic RBWH ProCESS3 ARISE4 ProMISe5 
Country of enrolment Australia USA ANZ (94%) England 
Years 2007-2011 2008-2013 2008-2013 2011-2014 
n = 399 456 804 626 
Age (mean, SD) 60.4(19.6) 62.0(16.0) 63.1(16.5) 64.3(15.5) 
Males (%) 57.6% 57.9% 59.3% 58.6% 
Limitations to care 22.6% - - - 
Nursing home residence 17.3% 16.0% 4.9% 2.2% 
APACHE II (mean, SD) 19.5(8.5) 20.7(7.5) 15.8(6.5) 18.0(7.1) 
Charlson Comorbidity Score 3(1-4) 2.9(2.6) 1(0-2) - 
MEDS score (median, IQR) 11(6-16) - - 8(6-10) 
SOFA score (median, IQR) 6(3-8) - - 4(3-6) 
Lactate (mean, SD) 5.0(3.2) 4.9(3.1) 4.2(2.8) 5.1(3.5) 
Source      
Bacteraemia (%) 34.1 28.7 37.6 - 
Respiratory (%) 36.8 33.1 32.8 33.1 
Urinary (%) 18.3 20.6 20.1 18.7 
Abdominal (%) 12.8 11.2 7.6 8.1 
Skin and soft tissue (%) 8.3 8.3 9.5 6.2 
Components of resuscitation     
Central venous access (%) 25.1 57.9 61.9 50.9 
Invasive ventilation (%) 10.0 21.7 22.4 19.0 
Dobutamine (%) 0.8 0.9 2.6 3.8 
Red cell transfusion (%) 5.8 7.5 7.0 3.8 
Vasopressor (%) 22.6 44.1 57.8 46.6 
Intensive care unit admission (%) 37.3 86.2 76.9 74.6 
Shock types     
Satisfied shock criterion (%) 54.1 53.3 69.8 55.6 
Satisfied lactate criterion (%) 65.9 60.7 46.5 63.7 
Satisfied both criteria (%) 20.0 14.0 16.3 19.3 
Outcomes     
Approximate LOS in ED (hours) 9.2 - 4.7 3.8 
Hospital mortality (%) 18.1 18.9 15.7 24.6 
90-day mortality (%) 23.3 33.7 18.8 29.2 
RBWH = Royal Brisbane and Women’s Hospital (study cohort), ProCESS3 = Protocol-based care for early 
septic shock, ARISE4 = Australasian resuscitation in sepsis evaluation, ProMISe5 = Protocolised management 
in sepsis, ANZ = Australia and New Zealand, SD = standard deviation, IQR = inter-quartile range, APACHE = 
Acute Physiology and Chronic Health Evaluation, MEDS = morality in emergency department sepsis score, 
SOFA = sequential organ function assessment, LOS = length of stay, ED = emergency department. 
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Table 4. 5: Selected cohort characteristics, outcomes by shock subtype and resuscitation status. 
 
Characteristics Lactate only 
shock 
Hypotension 
only shock 
Both shock   
criteria 
All shock 
less DNR 
DNR p= 
n (total 399) 183 136 80 309 90  
Age  
(Median, IQR) 
63  
(47-77) 
62.5  
(48.5-76) 
64.5 
(45-79.5) 
58  
(43-70) 
81.5 
(68-86) 
<0.01 
SAPS II Score 
(Median IQR) 
30  
(20-40) 
39  
(28-48.5) 
47 
(33.5-54.5) 
32  
(23-43) 
45.5  
(39-53) 
<0.01 
Charlson score  
(Median, IQR) 
3 (1-4) 3 (2-5) 2 (1-4) 2 (1-4) 4 (3-7) <0.01 
Nursing home 
status  
30 (16.4) 21 (15.4) 18 (22.5) 12 (3.9) 57 (63.3) <0.01 
Blood cultures 
positive 
51 (27.9) 44 (32.4) 41 (51.3) 112 (36.3) 24 (26.7)  0.09 
ICU admission 
 
37 (20.2) 60 (44.1) 52 (65.0) 144 (46.6) 5 (5.6) <0.01 
Mortality  
(30 days) 
27 (14.8) 29 (21.3) 22 (27.5) 19 (6.2) 59 (65.6) <0.01 
Figures in parentheses are percentages unless as indicated as inter-quartile range (IQR).  DNR = Do not 
resuscitate (limitations to treatment), SAPS II = new simplified acute physiology score, ICU = intensive care 
unit. P values relate to comparison between the last two columns. 
 
 
Multivariable regression with adjustment for disease severity was used to examine the effect of 
compliance with ED PrOC on mortality (Table 4.7). Infusion of larger volumes of fluid appeared to 
be beneficial in the entire cohort. In the subgroup with hypotension and subsequent admission to 
ICU, commencement of vasopressors in the ED was associated with a reduced risk of mortality. 
The regression analysis was repeated using data from non-DNR patients only (Table 4.8, ex 
Supplemental Table 1). However, the small number of deaths in this group resulted in wide 
confidence intervals and no significant findings. Table 4.9 (ex Supplemental Table 2) reports 
outcomes for the non-DNR patients with various combinations of hypotension and different 
lactate cut-offs. Proposed new definitions use a lactate cut-off of 2, rather than 4 mmol/l, in 
defining septic shock. We found similar mortality for each cut-off in non- DNR patients with 
hypotension (11.5 and 10.3%, respectively). Non-DNR patients with either hyperlactataemia or 
hypotension alone had low mortality (2.3–3.3%).  
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4.3.5 – Discussion 
 
In this cohort of consecutive, unselected ED patients fulfilling the standard criteria for septic 
shock, 399 patients at 10.2 patients per month were identified over the study period. The median 
length of stay in the ED was 9.2 h, and rates of vasopressor use (22.6%) and ICU admission (37.3%) 
were low. Subgroups fulfilling lactate criteria alone, hypotension criteria alone and both criteria 
represented distinct shock phenotypes with increasing severity of illness and mortality. In ED 
patients with hypotension subsequently admitted to ICU, commencement of vasopressor therapy 
in the ED was associated with survival. Overall mortality at 30 days was 19.5%, but the bulk of this 
mortality occurred in non-ICU patients with early limitations to care.  
 
 
Table 4. 6: Emergency department processes of care, by disposition and resuscitation status. 
 
Emergency Department 
Processes of Care 
total 
cohort 
ICU wards Died in            
ED 
DNR Cohort 
less DNR 
p 
                                       n = 399 149 240 10 90 309  
Lactate measured in 
patients with hypotension† 
197  
(91.2) 
111 
(99.1) 
79  
(81.4) 
7  
(100) 
48 
(82.8) 
149  
(94.3) 
<0.01 
Total fluid 1st 6hrs - litres 
 [mean, (SD)] 
2.30  
(1.72) 
3.38 
(1.72) 
1.63 
(1.34) 
2.35 
(1.70) 
2.06 
(1.34) 
2.37 
(1.81) 
0.12 
Vasopressors 90 (22.6) 81 (54.4) 6 (2.5) 3 (30) 6 (6.7) 84 (27.2) <0.01 
Central venous access         100 (25.1) 89 (59.7) 8 (3.3) 3 (30) 6 (6.7) 94 (30.4) <0.01 
Mechanical ventilation      40 (10.0) 37 (24.8) 1 (0.4) 2 (20) 2 (2.2) 38 (12.3) <0.01 
Blood cultures drawn 
before antibiotics  
349  
(87.5) 
142 
(95.3) 
198  
(82.5) 
9  
(90) 
77  
(85.6) 
272  
(88.0) 
0.53 
Time to adequate 
antibiotics‡ [median, (IQR)] 
145  
(80-259) 
115 
(59-204) 
179 
(100-288) 
172 
(117-182) 
125 
(63-212) 
154  
(85-287) 
0.02 
Red cell transfusion  23 (5.8) 15 (10.1) 7 (2.9) 1 (10) 5 (5.6) 18 (5.8) 0.92 
ICU = intensive care unit, ED = emergency department, NFR = not for resuscitation (limitations to care), IQR 
= interquartile range, SD = standard deviation. Figures in parentheses are percentages unless otherwise 
indicated. Interventions occurred in the ED and may have been discontinued on admission. Denominators - 
†216 (total hypotensive patients), ‡385 (13 patients were shown to have viral gastro-intestinal or 
respiratory illnesses so ineligible for “adequate” antibiotics, and one received pre-hospital antibiotics), 
otherwise 399. P values refer to comparisons between final two columns.  
 
 
A range of severity was apparent across subgroups satisfying the lactate criterion only, the 
hypotension criterion only and both criteria combined (Table 4.5). Physiological derangement 
(SAPS II), bacteraemia, requirement for ICU and mortality also increased across these groups. 
Elevated lactate (>4 mmol/l) and persistent hypotension were presented as alternative and 
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equivalent indicators of sepsis severity in the original Rivers et al. study [1]. Reinforcing this 
concept, subsequent researchers have found these two criteria to be associated with similar 
mortality [12,13]. However, more recent studies [14,15] have found mortality in ED patients with 
sepsis increased across subgroups meeting lactate, hypotension and combined criteria, consistent 
with the present research. Use of lactate screening has increased [16], conceivably leading to 
contemporary identification of a broader, heterogeneous group of ‘occult shock’ patients, some of 
which have a low risk of mortality [17]. 
 
 
Table 4. 7: Logistic regression - effect of compliance with emergency department processes of 
care on survival 
 
 Compliant odds ratio for survival                               
(referent non-compliant) 
ED process of care Compliant (n, %) unadjusted adjusted SAPS II 
Lactate measured† 197 (91.2) 1.56 (0.56-4.34) 1.97 (0.62-6.23) 
Time to AB (adequate) <1 hrs‡ 70 (18.1) 0.64 (0.35-1.19) 1.16 (0.57-2.36) 
Time to AB (adequate) <2 hrs‡ 151 (39.1) 0.74 (0.44-1.24) 1.54 (0.83-2.88) 
Time to AB (adequate) <6 hrs‡ 273 (70.7) 0.72 (0.40-1.30) 1.46 (0.74-2.88) 
Fluid >2 litres in 1st 6 hours 237 (59.4) 1.09 (0.66-1.80) 2.01 (1.11-3.67) 
Fluid >3 litres in 1st 6 hours 139 (34.8) 1.16 (0.69-1.98) 2.47 (1.29-4.72) 
Fluid >4 litres in 1st 6 hours 88 (22.1) 1.37 (0.73-2.58) 3.52 (1.59-7.79) 
NA in ED for hypotension to ICU§ 81 (72.3) 2.33 (0.78-6.94)  3.59 (1.07-12.0) 
ED = emergency department, SAPS II = new simplified acute physiology score, AB = antibiotics, NA = 
noradrenaline, ICU = intensive care unit.   Denominators: †216 (total hypotensive patients), ‡386 (13 
patients were shown to have viral gastro-intestinal or respiratory illnesses, therefore ineligible for 
“adequate” antibiotics), §112 (patients with hypotension admitted to ICU), otherwise = 399. 
 
 
Similarly, our study methods have likely identified a broad group of patients meeting only the 
hypotension criteria, some of whom have a low risk of mortality. In practice, it is not uncommon 
to encounter septic ED patients with hypotension despite an initial litre of intravenous fluid, but 
for blood pressure to subsequently normalize with further fluid. The median ED LOS of over 9 h in 
this study may have allowed clinicians time to establish fluid responsiveness in more cases, 
avoiding vasopressors and ICU admissions. The inclusion of hypotensive patients eventually fluid 
responsive and a heterogeneous lactate group may have contributed to the substantially lower 
rates of vasopressor and ICU therapy found in this study compared with recent RCTs (Table 4.4).  
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It has been proposed recently [11] that septic shock be redefined as infection with refractory 
hypotension requiring vasopressors and elevated lactate. We found mortality for patients with 
both hypotension and elevated lactate to be higher than for patients fulfilling either criterion 
alone. However, the requirement for vasopressor therapy to satisfy the definition of septic shock 
could be problematic in the ED, where (as our results make clear) not all patients with infection 
and refractory hypotension are treated with vasopressors and admitted to ICU. The proposed new 
definitions use a lactate cut-off of 2, rather than 4 mmol/l in defining septic shock. Supporting this 
approach, we found similar mortality for each cut-off in non-DNR patients with hypotension (Table 
4.9, ex Supplemental Table 2). Non-DNR patients with either hyperlactataemia or hypotension 
alone had low mortality (2.3–3.3%), supporting the proposal that these patients not be considered 
to have septic shock.  
 
An important patient group of septic shock patients not included in studies of protocolized 
resuscitation is that for whom aggressive treatment is not appropriate. Limitations to treatment 
were established in the ED for more than one-fifth (22.6%) of our study cohort. Subsequent 30-day 
mortality was high (65.6%), compared with that for the group with no limitations to treatment 
(6.2%). Peake et al [18]. reported that patients with previous DNR orders made up 15.7% of 324 
ED patients with septic shock, with an in-hospital mortality of 47.1%. Retrospective analyses of 
large databases have found the prevalence of early DNR orders in patients admitted with sepsis 
and septic shock to be 21% [19] and 19.6% [20], respectively. 
  
These results indicate that a large component of the mortality burden associated with septic shock 
resides within a significant but understudied group of patients with early limitations to treatment. 
Research that includes these patients and focuses on relevant non-invasive aspects of care such as 
early identification, type and amount of intravenous fluid and antimicrobial therapy is required.  
 
In this study, 75.6% of patients deceased at 30 days had limitations to treatment determined in 
the ED. Interestingly, 74.3% of the non-survivors in the standard therapy arm of the ARISE [4] trial 
also had limitations to therapy at the time of death. Although the similarity of these figures is 
coincidental, it is apparent that limitations to therapy are deemed appropriate for most 
nonsurvivors of septic shock at the time of their death (at least in Australia). Another potential 
advantage of the median ED LOS more than 9 h in the study may have been an increased 
opportunity to gather information from patients, carers and medical records, as well as initial 
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treatment response, enabling informed decisions to limit therapy in some cases. In this way, 
unnecessary invasive therapies and ICU admissions may have been avoided.  
 
Mortality for patients admitted to ICU was 12% compared with 21% for patients admitted to the 
wards. This difference is likely due to identification in the ED of patients with limitations to 
treatment and subsequent admission of this high-mortality group largely to the wards. The extent 
to which this effect might contribute towards the observed reduction in ICU mortality for patients 
with severe sepsis in recent years [21,11] is unknown.  
 
In regression analyses (Tables 4.7, 4.8), earlier administration of antibiotics was not associated 
with survival. These findings are consistent with several recent studies [23-25],  and may be 
related to time zero (ED triage) being a relatively arbitrary point in each patient’s disease process, 
as well as lower overall mortality for patients with community-acquired septic shock. For patients 
with hypotension and suitable for ICU admission, commencement of vasopressors in the ED was 
associated with survival. Other investigators have also recently shown early fluid [26] and 
vasopressor therapy [27] associated with improved outcomes. Data such as these are required to 
inform clinicians regarding fluid and vasopressor use in the post-EGDT era.  
 
Limitations  
Our methodology has some limitations. Initial case identification relied on the ED admission 
diagnosis indicating or suggesting infection. Some patients with infection may not have been 
recruited if the ED admission diagnosis did not indicate the possibility of infection. Some patients 
may have been included, but ultimately deemed to have a non-infectious cause for hospitalization. 
This number would have been minimized by data abstraction from the chart occurring up to 24 h 
after presentation, by which time the clinical impressions of the ED team and admitting inpatient 
team were informed by test results and initial clinical course. Discharge summaries and inpatient 
notes later showed that a non-infection diagnosis was ultimately judged responsible for admission 
in only 11 (2.7%) of 399 cases in this study, a figure similar to that reported in the ProCESS trial [3]. 
We recognize limitations associated with considerable heterogeneity in the group of patients 
designated ‘DNR’. We did not collect sufficient data to differentiate individual patient 
circumstances within the wide range of limits to treatment between ‘comfort care’ only and 
admission to ICU with ceilings to vasopressor doses. Another limitation is that the methods used 
were entirely observational. As such, available clinical and laboratory data were limited to those 
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generated during the course of each patient’s management. This is a single-centre study, and as 
such, our findings may not be generalizable to other patient groups. Study strengths include 
methods enabling the recruitment of a broad and inclusive prospective cohort, collection of 
detailed clinical and laboratory data, and use of a national death registry to obtain mortality 
endpoints.  
 
Conclusion  
Real-world, observational data can provide important insights into the complex clinical entity of 
septic shock. Median ED length of stay was 9 h, potentially enabling identification of patients with 
limitations to treatment and fluid responders, and reducing use of invasive therapies and ICU 
admissions. Recognition of distinct clinical shock phenotypes (hyperlactataemia, hypotension and 
both criteria) has implications for evolving definitions. In patients with persistent hypotension 
subsequently admitted to ICU, commencement of vasopressors in the ED was associated with 
survival.  
 
Acknowledgements  
The authors gratefully acknowledge valued contributions from Juliet McKenzie, Nicole Larcombe, 
Bronwyn Thomas, Kimberly Ryan, Suhasini Singh and Jadwiga Chabrowska. This study was funded 
by Queensland Emergency Medicine Research Foundation. There are no conflicts of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
 
Table 4. 8 (Supplementary Table 1): Adjusted odds ratio for survival for non-DNR patients 
compliant with selected emergency department processes of care 
 
ED process of care Compliant (n, %) Adjusted OR survival 
Lactate measured† 149 (94.3) * 
Time to AB (adequate) <1 hrs‡ 50 (16.5) 0.68 (0.23-2.06) 
Time to AB (adequate) <2 hrs‡ 191 (63.0) 0.94 (0.33-2.69) 
Time to AB (adequate) <6 hrs‡ 207 (68.3) 1.48 (0.46-4.71) 
Fluid >2 litres in 1st 6 hours 188 (60.8) 1.16 (0.37-3.69) 
Fluid >3 litres in 1st 6 hours 116 (37.5) 0.76 (0.27-2.14) 
Fluid >4 litres in 1st 6 hours 77 (24.9) 0.92 (0.32-2.69) 
NA in ED for hypotension to ICU§ 80 (74.8)  2.46 (0.60-10.0) 
 
ED = emergency department, OR = odds ratio, adjusted for SAPS II (new simplified acute physiology score), 
AB = antibiotics, NA = noradrenaline, ICU = intensive care unit.   Denominators: †158, ‡303, §107, 
otherwise = 309. *no deaths in the nine patients without lactate measurement 
 
 
Table 4. 9 (Supplementary Table 4-2): Outcomes for non-DNR patients with various lactate and 
hypotension combinations, by disposition 
  Lactate and hypotension combinations 
Disposition 
Lactate ≥4,              
no hypotension 
Hypotension 
and lactate <4 
Hypotension 
and lactate <2 
Hypotension and 
lactate ≥2 
Hypotension, ≥2 
litres, lactate ≥2 
Hypotension 
and lactate ≥4 
Ward 
3/114 
2.6% 
(0.5-7.5%) 
1/42 
2.4% 
(0.1-12.6%) 
0/24 
0% 
(0-14.2%) 
1/26 
3.8% 
(0.1-19.6%) 
1/18 
5.6% 
(0.1-27.3%) 
0/8 
0% 
(0-36.9%) 
ICU 
2/37 
5.4% 
(0.7-18.2%) 
6/57 
10.5% 
(4.0-21.5%) 
1/20 
5% 
(0.1-24.9%) 
11/87 
12.6% 
(6.5-21.5%) 
10/78 
12.8% 
(6.3-22.3%) 
6/50 
12.0% 
(4.5-24.3%) 
Entire 
cohort 
5/151 
3.3% 
(1.1-7.6%) 
8/100 
8% 
(3.5-15.2%) 
1/44 
2.3% 
(0.1-12.0%) 
13/114 
11.4% 
(6.2-18.7%) 
11/96 
11.5% 
(5.9-19.6%) 
6/58 
10.3% 
(3.9-21.2%) 
 
ICU = intensive care unit, ≥2 litres = received 2 or more litres of intravenous fluid in the 1st 6 hours  
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Section 4.4 – Summary 
 
The primary aim of the paper comprising the previous section was to collect and analyse data from 
a consecutive and inclusive cohort of ED patients that met standard criteria for septic shock, and in 
so doing facilitate new perspectives on their characteristics, treatment and outcomes. Beyond 
discussion contained within the published paper, issues ultimately relating to classification and 
prognosis are outlined further below.  
  
4.4.1 – Sepsis-3 definition of septic shock 
Shankar-Hari and colleagues published a 2015 paper in Critical Care detailing perceived 
inadequacies with the definition of septic shock in use at the time [1]. Those criticisms were 
instrumental in the formulation of the revised definition proposed in the subsequent Sepsis-3 
definitions paper [2]. No emergency medicine specialists were involved in either publication, 
despite the majority of patients hospitalised with sepsis and septic shock being initially diagnosed 
and treated in emergency departments [3]. The Sepsis-3 authors have proposed that septic shock 
be now defined as:  
“Hypotension requiring vasopressors to maintain mean arterial pressure (MAP) ≥65 mmHg and 
lactate >2mmol/L in the absence of hypovolaemia.” [1] 
Several aspects of this definition will be briefly discussed in the light of published data from this 
thesis. 
 
SIRS no longer required 
Within the sepsis-3 framework, SIRS plays no role in the definition of septic shock. It has been 
established in chapter 3 that for patients with shock (as defined in chapter 3 as hypotension 
[systolic blood pressure <90 mmHg] unresponsive to 1000mL fluid challenge or any vasopressor 
requirement) outcomes were not significantly influenced by SIRS; 30-day mortality for the 194 
patients with shock and SIRS was 23.7% and for the 24 patients without SIRS 25.0% (difference -
1.3% [95%CI -19.6 to 17%], adjusted OR 0.9 [95%CI 0.3-3.0]). These findings provide evidence from 
the ED setting to support the proposal that SIRS no longer be a requirement for septic shock. This 
is one of the few sepsis-3 changes clearly supported by the ED data gathered for this thesis. 
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Requirement for vasopressors for MAP ≥65 mmHg  
The use of mean arterial pressure (MAP) rather than systolic blood pressure (SBP) to denote a 
blood pressure threshold reflects the critical care centric approach of the sepsis-3 authors. 
Notwithstanding the limited evidence for any specific blood pressure targets, non-invasive systolic 
blood pressure would clearly be a more suitable target for clinicians in non-ICU environments such 
as the ED and wards, where the majority of septic shock cases arise. 
 
More concerningly, the stipulated requirement for vasopressor use assumes that all patients with 
septic shock will be treated with vasopressors. Unfortunately this infers that patients with 
infection complicated by profound and refractory hypotension deemed not suitable for admission 
to ICU on the basis of age, dependence or comorbidity will not have septic shock. The paradox 
here is that data collected from RBWH have demonstrated that patients with septic shock (as 
defined in the preceding paper, section 4.3) admitted to the wards have higher 30-day mortality 
(21%) than those admitted to ICU (12%). Fluids and antibiotics form the basis of treatment for 
patients with severe sepsis not judged appropriate for ICU admission, therefore research and 
quality indicators involving these therapies must involve this high-mortality subgroup. 
  
Lastly, ‘requirement for vasopressors’ assumes that circumstances that determine which patients 
are judged suitable for ICU and vasopressor therapy are uniform across countries and health care 
systems. There are data which dispute this. In a US study, Teno and colleagues [4] found rates of 
mechanical ventilation for hospitalised nursing home residents with dementia increased over time 
in association with steadily increasing numbers of available ICU beds. The number of ICU beds per 
capita population in each country also varies substantially, with the US having seven times the 
number available in the United Kingdom [5]. 
  
Examination of the cohorts enrolled in the three recent RCTs of EGDT [6-8] provide further indirect 
evidence that judgements of eligibility for invasive therapies vary in different locations and health 
care systems. An exclusion criterion for each of these co-ordinated trials was established 
limitations to therapy, suggesting all enrolled patients were judged suitable for unrestrained 
resuscitation. The (US) ProCESS cohort included 16% nursing home residents (NHR), similar to the 
17.3% figure seen with the inclusive RBWH cohort. However the (mostly Australian/New Zealand) 
ARISE cohort included only 4.9% NHR, and the ProMISe cohort (England) just 2.2% NHR. The 
seven-fold difference in NHR representation between English and US cohorts suggests systemic 
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differences in approach toward applicability of NHR for unrestrained resuscitation between these 
locations. 
    
Expected mortality for septic shock 
The stated intention of the sepsis-3 authors was to arrive at a definition for shock that identifies a 
group of patients at “significantly higher risk of mortality than for sepsis”. Calculations using their 
(mainly US-based) dataset found mortality above 40% for the criteria above [2]. However the 
requirement for vasopressor to fulfil the sepsis-3 criteria for septic shock again assumes that the 
patients at greatest risk of mortality will be admitted to ICU. The RBWH data suggest that is not 
necessarily the case. Using the previous (sepsis-2) definition for shock (hypotension unresponsive 
to 1000mL fluid or lactate ≥ 4mmol/L), 30-day mortality approximates 20% - significantly higher 
than the mortality seen for sepsis-3 “sepsis” (infection and organ dysfunction, at 11.4%-12.5% 
depending on how organ dysfunction is defined, chapter 3). On the basis of these figures the 
rationale for the change in definition for shock remains unclear. 
 
4.4.2 - Time to antibiotics 
The prognostic impact of increasing time delay to appropriate antibiotics was explored in the 
published paper forming the basis of Chapter 4 (section 4.3), recognising this metric is included in 
current treatment guidelines [9]. No relationship was demonstrated between time to appropriate 
antibiotics and outcome (Table 4-7). It must be acknowledged that association rather causation 
has been revealed with these observational data. However the same limitation undermines all 
clinical data and analyses on this topic including the 2006 Kumar et al paper most cited in support 
of time to antibiotic targets [10]. Further limitations of the Kumar paper include data from 
patients admitted to US and Canadian ICUs over the years 1989-2004 with overall (in-hospital) 
mortality 56.2% - characteristics demonstrably dissimilar to contemporary patients from 
Australian emergency departments (although positive culture rates were very similar: 34.2% 
[Kumar et al.] compared to 34.1% [RBWH cohort]). 
  
4.4.3 - Volume of resuscitation fluid 
Table 4-7 also displayed a significant association between increasing volume of fluid administered 
to septic shock patients in the six hours from presentation and greater odds of survival at 30 days. 
This stands against the findings of several observational studies that have found higher positive 
fluid balance in patients with sepsis to be associated with mortality [11]. However positive fluid 
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balance is very conceivably associated with more severe disease with greater microvascular fluid 
leak, and fluid balance is not synonymous with fluid input. Moreover the bulk of the data 
informing fluid associations were acquired in the ICU setting where patients are generally 
considered suitable for vasopressors and ventilation, and potentially without data from an earlier, 
critical phase of care in the ED or wards. 
 
Other data on fluid administration support early volume loading. Average volumes of fluid 
administered from triage to six hours after enrolment in ‘usual care’ arms of the three recent 
EGDT studies [6-8] were 4.4L, 4.3L and 4.0L respectively, and resulting mortality was low by 
historical standards. Additionally, a large retrospective study enrolling 2,849 ICU patients with 
septic shock from the US, Canada and Saudi Arabia found treatment with >3.4L of fluid in the six 
hours from hypotension onset was associated with survival [12]. 
 
Ultimately associations from non-randomised studies will not provide definitive evidence 
regarding optimal fluid therapy volumes in septic shock, and can at best be hypothesis-generating. 
Although findings from the FEAST study [13](bolus fluids were more harmful than maintenance 
fluids in African children with sepsis) are of arguable applicability to the resuscitation of adult 
patients with septic shock in the first world, the surprising results will facilitate the conduct of 
required controlled trials of low versus high volume resuscitation. 
 
4.4.4 – “Not for resuscitation” 
The propensity and preparedness for patients, their families and healthcare staff in emergency 
departments to consider whether unrestrained resuscitation (with potential ICU admission) is 
appropriate and in the interests of the critically ill patient likely varies between countries, health 
care systems and cultures. 
   
This author is unaware of data that directly support this assertion. However suggestive data exist, 
using nursing home residence as a surrogate marker for age, dependence and comorbidity. Ginde 
and colleagues [14] conducted a large retrospective study using ED diagnosis ICD-9 codes to 
identify patients presenting to US emergency departments with ‘severe sepsis’, with overall in-
hospital mortality 21%. Nursing home residents in that US study had a 48% mortality rate, with 
39% admitted to ICU. In the RBWH cohort (19.5% overall mortality), nursing home residence 
conferred a 51% mortality rate, but only 3% of NHR (2 of 69) were admitted to ICU. It may be that 
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in government-funded health care systems such as those in Australia, New Zealand and the United 
Kingdom, a pragmatic perception prevails that for most elderly, dependent patients with 
substantial comorbidity, ICU admission is neither beneficial nor cost effective. This statement may 
potentially be disputed on the basis of how one defines ‘benefit’. 
 
An assessment of the benefit of greater ‘treatment intensity’ (a composite measure including ICU 
admission, invasive ventilation, and dialysis) for older (>65) patients at higher risk of mortality 
admitted to 169 US hospitals was conducted by Barnato et al [15]. These investigators calculated a 
small mortality benefit at 30 days post admission associated with higher treatment intensity, but 
this effect was attenuated at 180 days. No assessment of quality of life in survivors was possible. 
An evolving awareness of the increased morbidity and dependence associated with surviving a 
severe sepsis admission [16] together with the value of independence and quality of life to elderly 
patients [17] should increasingly inform dialogue between clinicians, patients and their families, 
and consequent disposition decisions. Essential ingredients in these conversations are accurate 
severity assessments, and estimations of ‘benefit’ as perceived by patients and families.  
 
Sepsis patients determined – either in the ED or prior to hospital presentation - unsuitable for 
invasive therapies on the basis of dependence, co-morbidity and poor quality of life will not 
feature reliably in datasets of ICU patients or cohorts enrolled in RCTs which routinely exclude 
such patients. It is only in detailed and inclusive observational ED cohorts such as that enrolled in 
the present work and other related research [18-20] that the magnitude, characteristics and 
outcomes for these ‘NFR’ patients are revealed. Given that most are treated with antibiotics and 
fluids, opportunities should not be missed to measure quality of care and further examine the 
effects of these interventions in a high mortality group through these observational data [21]. 
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Chapter 5: Validation of Established Severity of Illness 
Scores in Sepsis 
 
Section 5.1 – Synopsis 
 
Sections five and six of this thesis turn from ‘sepsis syndromes’ classifications to examination of 
established severity of illness scores, many of which are derived mathematically as outlined in 
section 1.2. This chapter focusses on a range of severity scores that have established utility in the 
classification of critical illness or infections. Selected scores will be introduced and relevant 
validation literature systematically reviewed in section 5.2, with particular note made of the varied 
characteristics and mortality of patients cohorts enrolled in previous validation studies. The 
published paper comprising section 5.3 reports on one of the largest external validations of the 
selected scores, and explores the implications of changing cohort characteristics and overall 
mortality – essentially assessing spectrum validity/transportability. Findings and implications 
within the wider thesis objectives are summarised in section 5.4. 
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Section 5.2 – Literature Review 
 
5.2.1 - Risk Stratification Scores – what are they for? 
The awareness of discrete patient or disease characteristics associated with better or worse 
outcome is inherent in the informed clinical assessment of patients presenting with all illnesses, 
including infection. The evidence-based distillation of these characteristics, using large databases 
of patients with the disease of interest forms the basis of risk stratification score derivation.  
Clinical prediction (or risk stratification) scores may be used at the bedside to aid diagnostic or 
therapeutic decision-making in patients with infection. Identifying patients at low risk may avoid 
costly diagnostic workup or hospital admission, or facilitate the use of narrow-spectrum 
antimicrobials. Awareness of high risk of mortality may facilitate timely active care including 
broad-spectrum antimicrobials and invasive therapies. Estimation of clinical risk allows more 
precise communication between clinicians, and between clinicians and patients and their families. 
Assessment of prognosis is especially important for discussions about the appropriateness of 
limitations to care. Risk stratification scores also have important research applications, enabling 
comparisons between cohorts of patients within and between institutions and studies, and 
allowing adjustment for disease severity in regression analyses.  
  
5.2.2 - Validation of prognostic scores 
The performance of a prognostic score across a range of settings beyond that in which it was 
initially derived is termed generalisability, or transportability [1]. The process of assessing a score’s 
performance in other settings is often referred to as external validation. Discrimination and 
calibration are two important characteristics of a prognostic score’s performance often measured 
in validation studies. Discrimination refers to the score’s ability to differentiate between patients 
or patient groups at higher or lower risk of the outcome of interest. Discrimination is usually 
quantified using the area under the receiver operating characteristic curve (AUROC). Calibration 
refers to agreement between outcome probabilities predicted by the score and those observed in 
the new study group under investigation. 
 
Characteristics of five clinical risk stratification tools will be reviewed in this chapter: the mortality 
in emergency department sepsis (MEDS) score [2], the sepsis-related (or sequential) organ failure 
(SOFA) assessment [3], the severe sepsis score (SSS) [4], the acute physiology and chronic health 
evaluation score (APACHE II) [5], and the simplified acute physiology score (SAPS II) [6]. These 
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scores were chosen either because they were initially derived from and intended for use in 
patients with infection (MEDS, SOFA, Severe Sepsis Score), or are widely used in populations with 
critical illness (APACHE II, SAPS II). A literature review was undertaken to identify papers in which 
the objective was to assess the operating characteristics of any of these scores in ED patients with 
infection. Medline and EMBASE databases were searched using combinations of the terms 
‘Emergency’ AND ‘adult’ AND ‘mortality’ AND (‘infection’ OR ‘sepsis’ OR ‘septic’ OR ‘SIRS’) AND 
each of the scores of interest in turn. Relevant full-text articles in English and additional relevant 
articles referenced by those were reviewed. Findings are summarised in the tables and text below.  
 
5.2.3 - The Mortality in Emergency Department Sepsis (MEDS) score 
This score was derived from a single-centre cohort of 2070 adult ED patients who were judged to 
have possible infection, as indicated by the ordering of blood cultures [2]. Patients were enrolled 
in this derivation study during 2000-2001, and the overall cohort hospital mortality rate (truncated 
at 28 days) was 5.4%. Multiple logistic regression was used to identify independent predictor 
variables and assign weighted values in the completed prediction rule. The score was designed to 
predict mortality risk in emergency department patients presenting with infection. The MEDS 
score was published in 2003 and for more than a decade remained the only prognostic scoring 
system specifically designed for ED patients with infection. 
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Table 5. 1: MEDS validation studies 
1st Author Country Year Patient population n = Mortality AUROC Calibration Notes 
Shapiro 2 USA 2003 ED patients at risk of infection determined 
by BC collection 
2070 5.3% 0.82 yes Derivation of the MEDS score 
Chen 7 Taiwan 2006 Non-surgical ICU patients from ED with 
severe sepsis 
276 32.6% 0.75 no  
Shapiro 8 USA 2007 Examined one year outcomes for same 
cohort as Shapiro above 
3102 21.5%  yes  One year mortality 
Howell 9 USA 2007 ED patients enrolled if “at risk for 
infection” 
 
2132 3.9% 0.85 no ED CURB65 [32] = 0.79 
Sankoff10 USA 2008 ED patients admitted with SIRS (73% with 
presumed infection) – from 4 centres. 
385 9% 0.88 yes ED Lactate = 0.78 
MEDS overestimated mortality 
Lee 11 Taiwan 2008 ED patients with sepsis (24% with severe 
sepsis or septic shock) 
525 10.5% 0.78 no MEDS AUROC for 0-5 days = 
0.89, AUROC for 6-30 days = 
0.78 
Nguyen12 USA 2008  ED patients eligible for EGDT – severe 
sepsis and septic shock 
246 35% 0.60 yes ED APACHE II = 0.73, ED SAPS II 
= 0.71. MEDS underestimated 
mortality. 
Jones 13 USA 2008 ED patients eligible for EGDT – severe 
sepsis and septic shock 
143 23% 0.61 yes MEDS underestimated mortality 
Vorwerk14 UK 2009 ED patients with sepsis, 2 centres 307 23% 0.82 no Abbreviated MEDS – no 
neutrophil band score.  
ED lactate = 0.62 
Crowe 15 USA 2010 ED patients eligible for EGDT 
 
216 32.9% 0.74 no ED CURB6532 = 0.59 
Ghanem – 
Zoubi16 
Israel 2011 Elderly general medical admissions with 
sepsis (96% from the ED) – 49% aged >80 
1072 21.9% 0.73 yes  
Hermans17 Holland 2012 Admission with sepsis (34% with severe 
sepsis or septic shock) 
 
331 11.5% 0.81 yes Lactate = 0.75, CRP = 0.68 
MEDS underestimated mortality 
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1st Author Country Year Patient population n = Mortality AUROC Calibration Notes 
Nguyen18 USA 2012 ED patients eligible for EGDT 
 
541 31.8% 0.63 yes ED APACHE II and PIRO scores 
both = 0.71. MEDS 
underestimated mortality. 
Wilhelm19 Germany 2012 ED patients admitted with sepsis and 
blood culture taken (33% with severe 
sepsis or septic shock) 
211 8.5% 0.78 no ED APACHE II = 0.80, SOFA 0.71  
Geier 20 Germany 2013 ED patients with suspected sepsis (45% 
with severe sepsis or septic shock) 
151 14.6% 0.87 no Abbreviated MEDS – no 
neutrophil band score 
Cildir 21 Turkey 2013 ED patients with sepsis (72% with severe 
sepsis or septic shock) 
230 32.2% 0.77 no Abbreviated MEDS for non-
severe (mortality 12.5%) = 0.83 
and severe sepsis (39.8%) = 0.71 
Zhao 22 China 2013 ED patients with sepsis (36% with severe 
sepsis or septic shock) 
501 26.7% 0.77 no MEDS + procalcitonin = 0.813 
Chen23 
Liu24 
Yin25    
China 2013 ED patients with sepsis (45 % with severe 
sepsis or septic shock). Patients with 
malignancy and terminal disease 
excluded. 
680 27.8% 
(in- 
hospital) 
0.72 no 3 studies, combining MEDS with 
adrenomedullin23, presepsin24, 
and soluble thrombomodulin25 
Innocenti26 Italy 2014 ED patients with severe sepsis or septic 
shock admitted to ED-HDU 
135 29% 0.66 no APACHE II = 0.72, SAPS II = 0.76, 
SOFA = 0.70 (all in ED) 
Chen 27 China 2014 ED patients with sepsis (29% with severe 
sepsis) 
295 26.4% 0.82 no APACHE II = 0.81 – neither score 
improved with HFABP 
Chen28,29 China 2014 ED patients with sepsis (severities and 
exclusions as above Chen studies) 
680 26.2% 
(28 day) 
0.74 no MEDS 0.74, APACHE II 0.74, 
SOFA 0.75, with Lactate = 0.81, 
0.81, 0.8228. PIRO 0.7429 
 Tan 30 China 2014 ED patients with severe sepsis 665 34.6% 0.81 no APACHE II 0.706, Lactate 0.727. 
MEDS + lactate = 0.865 
Hilderink31 Holland 2014 Medical admissions with sepsis (43% with 
severe sepsis or septic shock) 
600 15% 0.82 yes CURB6532 0.78, APACHE II 0.71 
MEDS underestimated mortality 
USA = United States, ED = Emergency Department, AUROC = area under receiver operating curve, ICU = intensive care unit, BC = blood culture, SIRS = 
systemic inflammatory response syndrome, EGDT = early goal-directed therapy, PIRO = predisposition, infection, response, organ failure, APACHE = acute 
physiology and chronic health evaluation, SOFA = sequential organ failure assessment, SAPS = simplified acute physiology score, HDU = high dependency 
unit, HFABP = heart-type fatty acid-binding protein. CURB65 = confusion, urea, respiratory rate, blood pressure and age ≥65. 
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Table 5. 2: APACHE II validation studies 
1st Author Country Year Patient population n = Mortality AUROC Calibration Notes 
Nguyen35 USA 2000 ED patients with critical illness – 79% with 
septic shock. 
81 30.9% 0.72 yes ED SAPS II = 0.76. ED APACHE II 
overestimated mortality. 
Nguyen12 USA 2008  ED patients eligible for EGDT – severe 
sepsis and septic shock 
246 35% 0.73 yes ED SAPS II = 0.71. ED APACHE II 
overestimated mortality. 
Sivayoham36 UK 2010 ED patients with sepsis subsequently 
admitted to ICU within 7 days 
321 30.5% 0.69  Derivation study for MISSED 
score36 
Nguyen18 USA 2012 ED patients eligible for EGDT – severe 
sepsis and septic shock 
 
541 31.8% 0.71 yes ED APACHE II and PIRO scores 
both = 0.71. APACHE II 
overestimated mortality. 
Wilhelm19 Germany 2012 ED patients admitted with sepsis and 
blood culture taken (33% with severe 
sepsis or septic shock) 
211 8.5% 0.80 no SOFA 0.71  
Chen23, 24,25 China 2013 ED patients with sepsis (45 % with severe 
sepsis or septic shock). Patients with 
malignancy and terminal disease 
excluded. 
680 27.8% 
(in- 
hospital) 
0.74 no combined with 
adrenomedullin23, presepsin24, 
and soluble thrombomodulin25 
Innocenti26 Italy 2014 ED patients with severe sepsis or septic 
shock admitted to ED-High dependence 
unit 
135 29% 0.72 no ED SAPS II = 0.76, ED SOFA = 
0.70  
Chen27 China 2014 ED patients with sepsis (29% with severe 
sepsis) 
295 26.4% 0.81 no APACHE II AUROC did not 
improve with HFABP 
Chen28,29 
(2 studies)  
China 2014 ED patients with sepsis (severities and 
exclusions as above Chen studies) 
680 26.2% 
(28 day) 
0.74 no MEDS 0.74, APACHE II 0.74, 
SOFA 0.75, with Lactate = 0.81, 
0.81, 0.8228. PIRO 0.7429 
 Tan30 China 2014 ED patients with severe sepsis 665 34.6% 0.71 no Lactate 0.727.  
 
Hilderink31 Holland 2014 Medical admissions with sepsis (43% 
with severe sepsis or septic shock) 
600 15% 0.71 yes CURB6532 0.78 APACHE II 
overestimated mortality. 
Abbreviations as above + UK = United Kingdom, MISSED = Mortality in severe sepsis in the emergency department. 
 
1
1
8 
Table 5. 3: SAPS II validation studies 
1st Author Country Year Patient population n = Mortality AUROC Calibration Notes 
Nguyen35 USA 2000 ED patients with critical illness – 79% with 
septic shock. 
81 30.9% 0.76 yes ED SAPS II overestimated 
mortality. 
Jones37 USA 2005 ED patients with shock, 62% with sepsis 91 21% 0.72 yes ED SAPS II overestimated 
mortality 
Nguyen12 USA 2008  ED patients eligible for EGDT – severe 
sepsis and septic shock 
246 35% 0.71 yes ED SAPS II overestimated 
mortality. 
Kofoed38 Denmark 2009 ED patients admitted with sepsis 
 
151 5.9% 0.89 no SOFA 0.80 
Innocenti26 Italy 2014 ED patients with severe sepsis or septic 
shock admitted to ED-High dependence 
unit 
135 29% 0.76 no ED SOFA = 0.70  
 
Table 5. 4: SOFA validation studies 
1st Author Country Year Patient population n = Mortality AUROC Calibration Notes 
Kofoed38 Denmark 2008  ED patients admitted with sepsis 151 5.9% 0.80 N/A ED SAPS II = 0.89 
 
Jones39 USA 2009 ED patients with sepsis and (hypotension 
or lactate >4) and anticipated ICU care 
248 21% 0.75 N/A  
Wilhelm19 Germany 2012 ED patients admitted with sepsis and blood 
culture taken (33% with severe sepsis or 
septic shock) 
211 8.5% 0.71 N/A  
Chen28,29  China 2014 ED patients with sepsis (45 % with severe 
sepsis or septic shock). Patients with 
malignancy and terminal disease excluded. 
680 26.2% 
(28-day) 
0.75 N/A  
Innocenti26 Italy 2014 ED patients with severe sepsis or septic 
shock admitted to ED-High dependence 
unit 
135 29% 0.70 N/A  
Ryoo40 South 
Korea 
2014 ED patients with severe sepsis and eligible 
for EGDT (Missed external validation) 
280 18.9% 0.71 N/A MISSED score = 0.64 
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Table 5.1 summarises the findings of 24 identified MEDS validation studies published between 
2006 and 2014. Discrimination with respect to mortality outcome was presented in all studies 
using area under the receiver operating curve (AUROC) statistic, and calibration was reported as 
indicated in only 8 cases (33%). MEDS discrimination was highly variable, with AUROC values 
ranging from 0.60 to 0.88. A major contributor to this broad range of values is likely to be 
differences in cohort size and severity of illness between studies. The MEDS score was derived in a 
cohort with low overall mortality (5.3%) but encompassing patients with a range of mortality risk. 
Validation studies using cohorts with similar low overall mortality and broad range of mortality risk 
such as Howell et al [9] and Sankoff et al [10] have reported the highest AUROC values. Conversely, 
studies enrolling only patients with higher risk of mortality (severe sepsis and septic shock) have 
reported lower AUROC values [12,13,26]. The potential adverse impact of narrowing the spectrum 
of disease severity during external validation (spectrum generalisability) has been recognised [33]. 
The variety of countries and health care systems, as well as the range of time periods 
encompassed by the MEDS validation studies also are likely to contribute to the observed 
variation in reported discrimination and calibration performance (geographical and temporal 
generalisability). 
 
Several studies compared discrimination performance of MEDS to other scores of interest that 
were calculated in the ED (APACHE II, SAPS II, and SOFA) with inconsistent results. APACHE II 
displayed superior discrimination compared to MEDS in cohorts comprising patients with severe 
sepsis or septic shock [12,18,26]. One study [26] found SAPS II superior to MEDS, and two studies 
found SOFA and MEDS to have similar discrimination [26,28]. More recent studies demonstrated 
enhanced discrimination through combining MEDS with other biomarkers such as lactate [28,30], 
procalcitonin [22], adrenomedullin [23], soluble thrombomodulin [25], presepsin [24], and heart-
type fatty acid-binding protein [27]. 
 
Methodological generalisability refers to the reproducibility of the methods used to measure 
variables and calculate scores when applied in varied settings [33]. In this context, the MEDS score 
has been criticised for potential variation in the availability, interpretation and measurement of 
some predictor variables [34]. There is subjective bias inherent in the variable “terminal illness”, 
and neutrophil bands are not measured in some centres. Another MEDS variable with substantial 
variation in importance between health care environments is “resident in nursing home”. It is 
likely that nursing home residence is a powerful surrogate marker of dependence and therefore 
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associated with age and comorbidity. In the MEDS derivation study [2] conducted in Boston, the 
incidence of nursing home residence was 14%. The reported incidence of nursing home residence 
in the MEDS validation studies varied widely from 1.8% [22] to 59% [15]. Several validation studies 
excluded patients with terminal illness, metastatic cancer, or limitations to care, with clear 
implications for performance of a score that includes closely related variables. Of the studies in 
which calibration was performed, most reported the MEDS score consistently underestimated 
mortality [12,13,17,18,31]. This was likely due to the higher cohort mortality in those studies, 
compared to the MEDS derivation group. 
 
In summary, performance of the MEDS score was best in study groups with a broad range of 
severity, more closely resembling the initial derivation cohort. When applied to groups of patients 
with higher severity of illness, MEDS discrimination was poorer and the score consistently 
underestimated observed mortality. 
 
5.2.4 - APACHE II and SAPS II in ED patients with infection 
The APACHE II score was developed in 1985 using a large database of North American ICU 
patients. The components include 12 physiology variables, diagnostic category and information on 
co-morbid status. The most abnormal physiological values in the initial 24 hours of ICU admission 
are used. The final score ranges from zero to 71, which can be used to estimate hospital mortality. 
The New Simplified Acute Physiology Score (SAPS II) was derived from a large cohort of 13,152 
patients admitted to mixed, medical and surgical ICUs from ten European and two North American 
countries over 1991-1992. Logistic regression analysis was used to create a score consisting 17 
variables with maximum score 163, which can be used to calculate an estimate of expected 
hospital mortality. As with APACHE II, the most abnormal value for each variable over the initial 24 
hours in ICU is used. 
 
Tables 5.2 and 5.3 summarise the characteristics and results of published studies that have 
assessed the performance of APACHE II and SAPS II scores in ED patients with infection. The wide 
range in setting and cohort mortality evident across the many APACHE II and SAPS II validation 
studies makes general conclusions difficult. However, cohorts with lower overall mortality are 
seen to generate higher AUROC scores. For example, Kofoed and colleagues [38] examined 151 
Danish ED patients with cohort mortality 5.9%, and found SAPS II to have superior discrimination 
with AUROC 0.89. Regarding calibration, APACHE II and SAPS II measured in the ED were 
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consistently found to overestimate mortality. These scores were originally derived using data in 
the ICU, and preceding scores in the ED have been shown to be higher [35]. Another reason for 
poor calibration may be the time interval since development, during which sepsis outcomes have 
improved.  
    
5.2.5 - The SOFA score in ED patients with infection 
In contrast to the APACHE II and SAPS II scoring systems, the SOFA score was created by consensus 
conference in 1994 and revised in 1996. The purpose of the score was to quantitatively describe 
the extent of sepsis-related dysfunction in each of six organ systems. Unlike APACHE II and SAPS II 
scores, the SOFA score is not used to calculate an estimate of expected mortality. The SOFA score 
is now more often referred to as the sequential organ failure score, and applied to patients with a 
broad range of conditions as well as sepsis. Although there has been increasing interest in changes 
in the SOFA score at different time points during hospital stay [41], there are few studies 
examining the utility or performance of the score in ED patients with infection. Table 5.4 
summarises relevant papers identified. 
 
5.2.6 - The Severe Sepsis Score in ED patients with infection 
The severe sepsis score (SSS) was recently derived using data from 23,428 patients enrolled over 
four years in an international database of patients with severe sepsis or septic shock [4]. Thirty-six 
weighted variables combined to produce the final score, which could have values from zero to 
130. The model was well calibrated with discrimination AUROC values 0.70-0.80. However, age 
and co-morbidity data were unavailable for any subjects, potentially limiting the predictive power 
of the model. The paper describing the derivation of the SSS was published in 2014, and to this 
time it has not been externally validated. 
 
5.2.7 – Quality Assessment 
A framework combining the essential elements of the QUADAS-2 [42] and QUIPS [43] tools has 
been used hereafter to make an overall assessment of the quality, heterogeneity and potential for 
bias in the 32 identified studies. Results are summarised in four domains. 
1. Study sample represents the population of interest. Investigators chose to assess the 
scores of interest in a wide range of emergency patients, ranging from ‘all ED patients at 
risk of infection’ (mortality 3.9%) [9] to patients with septic shock eligible for a severe 
sepsis intervention pathway (highest reported mortality 35% [12]). Two studies were 
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confined to patients admitted to ICU [35,37] and one enrolled patients admitted to an ED 
high dependence unit [26]. The cohorts of patients admitted to ICU/HDU and treated on 
severe sepsis pathways mandating invasive therapies inherently excluded patients not 
thought to be suitable for unrestrained treatment. These cohorts were consequently less 
likely to include patients from nursing homes or with terminal illnesses, reducing the utility 
of the MEDS score. 
2. Index test consistently applied. Missing data were addressed by only 12 of 32 papers, and 
most of those investigators assumed missing data to be within normal ranges.  
Inconsistencies between studies were evident regarding two MEDS variables: the definition 
of ‘terminal illness’, and availability of neutrophil band forms. 
3. Endpoints measured accurately and consistently. In-hospital mortality (at 28 days or 
otherwise) was the most frequently recorded outcome measure. Beyond that, telephone 
call to ascertain vital status at 28 days was employed by five investigators [19,23,26,28,31], 
and only two studies used definitive external databases for mortality outcomes [8,16].  
4. Appropriate statistical analysis. All studies (bar one [8]) provided statistical analysis in 
which overall discrimination was quantified using area under the receiver operating curve 
(AUROC). None of the study scores had established clinical utility at pre-specified thresh-
holds, so diagnostic accuracy indices such as sensitivity and specificity were not reported. 
Calibration data were provided by fewer than half (15 of 34, 44%) of the reviewed studies. 
 
5.2.8 – Conclusions 
The operating characteristics of five prognostic scoring systems used in populations of ED patients 
with infection have been reviewed. Validation studies have been conducted with cohorts of 
varying mortality and severity of illness across settings world-wide. In general, discrimination was 
reduced in patient groups with higher overall mortality for all scores. However, other factors such 
as setting, health care system, period of study, eligibility for invasive therapies and local 
interpretation of score components varied significantly between studies making comparisons and 
generalisations difficult. The SSS remained to be externally validated, and none of the scores had 
been validated in Australian emergency department patients with infection of any severity. 
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5.3.1 – Abstract 
 
Objectives: The objectives of this study were to 1) validate a number of severity of illness scores in 
a large cohort of emergency department patients admitted with presumed infection and 2) 
compare the performance of scores in patient subgroups with increasing mortality: infection 
without systemic inflammatory response syndrome, sepsis, severe sepsis, and septic shock.  
Design: Prospective, observational study.  
Setting: Adult emergency department in a metropolitan tertiary, university-affiliated hospital.  
Patients: Emergency department patients admitted with presumed infection.  
Interventions: None.  
Methods: Consecutive emergency department patients admitted with presumed infection were 
identified over 162 weeks in two periods between 2007 and 2011. Clinical and laboratory data 
sufficient to calculate Mortality in Emergency Department Sepsis score, Acute Physiology and 
Chronic Health Evaluation II, Simplified Acute Physiology Score II, Sequential Organ Failure 
Assessment, and the Severe Sepsis Score were entered into a database. Model discrimination was 
quantified using area under the receiver operating curve. Calibration was assessed using visual 
plots, Hosmer-Lemeshow statistics, and linear regressions of observed and predicted values.  
Measurements and Main Results: A total of 8,871 patients were enrolled with 30-day mortality of 
3.7%. Area under the receiver operating curve values for the entire cohort were: Mortality in 
Emergency Department Sepsis score of 0.92, Simplified Acute Physiology Score II and Acute 
Physiology and Chronic Health Evaluation II scores of 0.90, Sequential Organ Failure Assessment 
score of 0.86, and Severe Sepsis Score of 0.82. Discrimination decreased in subgroups with greater 
mortality for each score. All scores overestimated mortality, but closest concordance between 
predicted and observed mortality was seen with Mortality in Emergency Department Sepsis score.  
Conclusions: The decrease in area under the receiver operating curve seen in subgroups with 
increasing mortality may explain some variation in results seen in previous validation studies. 
Scores developed in intensive care settings overestimated mortality in the emergency 
department. Our results underscore the importance of employing predictive models developed in 
similar patient populations. The Mortality in Emergency Department Sepsis score outperformed 
more complex predictive models and would be the most appropriate scoring system for use in 
similar emergency department populations with a wide spectrum of mortality risk. 
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5.3.2 – Introduction 
 
Emergency Department (ED) patients with infection present with a wide spectrum of disease and 
consequent mortality risk. Illness severity scores may be useful in predicting an individual’s 
requirement for resources, disposition and outcome, and for comparing groups of patients and 
adjusting for illness severity in research settings. A range of scores has been used to estimate 
illness severity in ED patients with infection. Some of these scores were intended for use in 
patients with infection, such as the Mortality in Emergency Department Sepsis (MEDS) [1] score, 
the Sequential Organ Failure Assessment (SOFA) [2] score, and the recently developed Severe 
Sepsis Score (SSS) [3]. Other scores were developed for use in critical care populations with a range 
of illnesses, such as the Acute Physiology and Chronic Health Evaluation (APACHE II) [4] and the 
New Simplified Acute Physiology Score (SAPS II) [5]. Although these critical care scores were 
derived more than a decade ago, they remain the most frequently cited measurements of severity 
of illness in contemporary sepsis research [6-10]. 
 
A number of studies have assessed the performance of severity scores in ED patients with 
infection, with the most commonly assessed scores being MEDS, APACHE II, SOFA and SAPS II [11]. 
However, there are wide variations in health-care setting, cohort size and characteristics, and 
objectives among the existing validation literature. Only one small study has attempted to assess 
the relative performance of scores across subgroups of sepsis severity [12], and the SSS has not 
been externally validated. The objectives of this study were: 1) to assess the performance of 
several severity of illness scores in a large and inclusive cohort of ED patients admitted with 
presumed infection, and 2) to compare the performance of scores in subgroups of patients with 
increasing mortality and varied clinical characteristics. 
 
5.3.3 – Materials and Methods 
 
Setting and participants 
This study is one of a series of investigations from a prospective observational database of ED 
patients admitted with presumed infection. The setting was an adult metropolitan university-
affiliated hospital in Australia with annual ED census over 72,000. Inclusion criterion was 
admission from the ED with presumed infection. Patients less than 17 years of age or arriving by 
inter-hospital transfer were excluded. Data were collected over two periods, October 2007-
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December 2008 (unfunded pilot period), and June 2009-May 2011 (funded period), totaling 162 
weeks. 
 
Study Protocol 
Database methodology has been previously described in detail [13] but is reported briefly here. 
The list of all ED patients admitted over the previous 24 hours was reviewed daily and those with 
ED diagnosis indicating proven, suspected or possible infection as a cause of admission were 
identified. Patients were enrolled if their hospital records indicated both the ED and admitting 
inpatient teams judged infection to be the cause for hospitalization. Data were then abstracted 
from the chart including patient demographics, co-morbidities, physiological status and treatment 
in the ED, presumed source of infection, and disposition from the ED. Results of biochemistry, 
hematology and microbiology tests were subsequently obtained from central hospital databases. 
The national deaths registry was consulted annually, and date of death was entered if applicable. 
All data were de-identified, and systems established to ensure data quality and security [13]. 
Approval for the study was granted by the hospital’s human research ethics committee and the 
requirement for patient consent was waived due to the entirely observational nature of the 
project. 
 
Measurements 
Patients were classified according to the following subgroups: infection without SIRS, sepsis, 
severe sepsis and septic shock. In accordance with contemporary consensus guidelines14, SIRS was 
defined as at least two of the following: heart rate greater than 90 min-1, respiratory rate greater 
than 20 min-1, leukocyte count greater than 12,000 μL–1 or less than 4,000 μL–1, and temperature 
less than 36 or greater than 38 degrees Celsius. Sepsis was defined as infection with SIRS, and 
severe sepsis as sepsis with organ dysfunction. A modified SOFA score [13] was used to grade 
organ dysfunction, with a score of two or more in any organ system indicating dysfunction. 
Baseline (pre-existing) organ dysfunction was judged present if abnormal clinical or laboratory 
data on discharge from the most recent previous admission corresponded to a SOFA score greater 
than zero. Baseline organ function was assumed normal in the absence of previous data. For 
patients with baseline organ dysfunction, an increase in SOFA score of at least one on presentation 
was required to satisfy study criteria for acute organ dysfunction. Septic shock was defined as 
sepsis with either 1) persistent hypotension (systolic blood pressure < 90 mm Hg) despite a fluid 
bolus of at least 1,000 mL or 2) measured ED lactate greater than 4 mmol/L. 
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Severity of illness scores (MEDS, SOFA, SSS, APACHE II, and SAPS II) were calculated for each 
patient. The general variables contributing to each of these scores have been summarized in Table 
5.9 (ex Supplemental Table 1). Regarding the MEDS score (Table 5.5), the variable “terminal 
illness” was defined for study purposes as underlying co-morbidity with at least 50% chance of 
mortality within 30 days of admission, metastatic solid tumor, or hematological malignancy with 
limitations to care.  
 
 
Table 5. 5: The Mortality in Emergency Department Sepsis (MEDS) score - components, weightings 
and mortality 
Variable Points 
Rapidly terminal comorbid illness 6 
Age >65 years 3 
Tachypnoea or hypoxia 3 
Septic shock 3 
Platelets <150,000/mm3 3 
Neutrophil bands >5% 3 
Nursing home resident 2 
Altered mental state 2 
Lower respiratory tract infection 2 
Points range 
Predicted 28-day mortality 
(%) 
0 to 4 0.9 
5 to 7 2 
8 to 12 7.8 
13 to 15 20.2 
>15 50 
                                     
Furthermore, the hospital laboratory did not routinely report neutrophil band forms so that 
variable was not included in the score. For all scores, the most abnormal measurement of each 
parameter recorded in the ED was used for score calculation, and missing values were presumed 
normal. Mortality at thirty days after presentation was the primary outcome measure. In cases of 
re-admissions within 90 days, one single admission episode was selected at random for inclusion 
in this study. 
 
Statistical Analysis 
Analyses were performed using Stata version 12 (StataCorp, 2011, College Station, TX). Baseline 
characteristics of the study sample were reported by vital status at 30 days. Pearson  and Mann-
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Whitney U tests were used to compare categorical and continuous variables respectively for 
survivors and non-survivors. Performance of each of the severity of illness scores was assessed in 
the entire study cohort, the sepsis subgroups, and the patients admitted from ED to ICU. 
Discrimination was assessed using receiver operating characteristic (ROC) curve analysis. The area 
under the curve for each ROC curve (AUROC) was computed using a non-parametric method and 
AUROC pairs were compared using the algorithm suggested by DeLong, DeLong, and Clarke-
Pearson [15]. Statistical significance was set at p value less than 0.01 when comparing AUROCs to 
reduce the inflated type I error rate that can occur with a large number of statistical comparisons. 
The Hosmer-Lemeshow (H-L) statistic was used to assess model calibration. Predicted mortalities 
for the APACHE II, SAPS II and SSS scores were calculated using the equation: 
exp(Logit)/1+exp(Logit). Logits were taken from the logistic equations outlined in the development 
of the scoring systems (Table 5.10, ex Supplemental Table 2). Predicted mortality for the MEDS 
score was based on the initial MEDS derivation study (Table 5.5). 
 
For APACHE II, SAPS II and SSS scores, predicted and observed mortalities were compared across 
seven categories of risk; 0 to less than 10%, 10 to less than 20%, 20 to less than 30%, 30 to less 
than 40%, 40 to less than 50%, 50 to less than 60% and greater than or equal to 60%. Collapsing 
across the highest risk categories ensured that the H-L statistic was not influenced by small cell 
sizes. For MEDS, the H-L statistic was computed by comparing predicted and observed mortality 
across the five pre-defined categories. It was appreciated that the H-L test is sensitive to sample 
size such that for large sample sizes, even small deviations between observed and expected values 
can result in a significant test [16]. Therefore, other measures of calibration were used to 
supplement this test. The first was a calibration graph of observed versus expected mortality. If 
the model calibrates well, the plot of expected versus actual mortality will not substantially 
deviate from the 45-degree line of perfect fit. Second, linear regressions of observed and 
predicted values were conducted.17 A well calibrated model should have a slope not significantly 
different from unity and an intercept not statistically different from zero. For the APACHE II, SAPS 
II and SSS scores, the regression included observed versus predicted mortality for each value of 
the score. For the MEDS score, categorized expected and observed values were used (Table 5.5). 
Regressions were also conducted for the APACHE II, SAPS II and SSS scores by the seven categories 
of risk and the results were substantially the same as those reported by individual scores. The 
individual score results were used as they have narrower confidence intervals and were thus a 
more conservative test.   
129 
 
 
5.3.4 – Results 
 
Data were collected for 9,717 admissions over the 162-week study period. After discounting 846 
cases of readmission within 90 days, the final study cohort comprised 8,871 presentations (Fig. 
5.1). Physical observations were recorded for all patients, and some laboratory data were missing 
for 0.7%. Three hundred and twenty-seven patients (3.7%) were deceased at 30 days.  
 
Selected characteristics of the study cohort are presented in Table 5.6. Of the entire cohort, 4,695 
patients (52.9%) had infection but not SIRS, leaving 4,176 (47.1%) with sepsis of all severities. 
Mortality at 30 days for the entire cohort and the subgroups, sepsis (all severities), severe sepsis 
(including shock), and septic shock, was 3.7%, 6.1%, 12.8%, and 19.6%, respectively. Discrimination 
(based on AUROC point estimates) was optimal with the MEDS score and declined for SAPS II, 
APACHE II, total SOFA, and SSS in sequence (Table 5.7 and Fig. 5.2) in all primary subgroups. 
Supplemental Table 5.11 (ex Supplemental Table 3) provides p values comparing each pair of 
scores by sepsis subcategory. Superiority of the MEDS AUROC was statistically significant for all 
comparisons except that with SAPS II.  
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Figure 5. 1: Derivation of the study cohort (SIRS = systemic inflammatory response syndrome)  
                                          
 
Calibration plots comparing observed and expected mortality for the entire cohort are presented 
in Figure 5.3. Visual inspection reveals that all scores overestimated mortality, with MEDS 
providing the closest concordance. Across cohort subgroups, most of the scores had a significant 
H-L chi-square (Table 5.8), indicating the lack of model fit. The MEDS score provided estimated 
probabilities closest to those seen in the data. For this score, the largest contribution to the H-L 
chi-square value came from the observed mortality being slightly lower than expected in the very 
large group of patients with an MEDS score between 0 and 4. This category alone resulted in the 
significant chi-square value. For MEDS, the intercept of the regression model of observed and 
predicted values did not differ from zero and the slope did not differ from one (Table 5.12, ex 
Supplemental Table 4) for all subgroups, indicating good model calibration. Using this method, the 
only other combination with good calibration was the SAPS II score in the entire cohort. 
 
In additional analyses (Table 5.13, ex Supplemental Table 5), scores were assessed in patients with 
bacteremia (n = 618) and patients without limitations to care (n = 8,544). Discrimination in these 
subgroups was good for all scores except the SSS, and evidence for calibration was seen for MEDS 
in the bacteremia group only. 
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Table 5. 6: Selected cohort characteristics stratified by mortality at 30 days. 
Characteristic All patients 
(n=8871) 
Alive 
(n=8544) 
Dead 
(n=327) 
p value 
Demographics     
Males, n (%) 4553 (51.3) 4369 (51.1) 184 (56.3) 0.07 
Median Age (IQR) 49 (30-69) 47 (29-67) 79 (69-86) <0.01 
NHR (n, %) 575 (6.5) 434 (5.1) 141 (43.1) <0.01 
Median Charlson Score (IQR) 1 (0-3) 1 (0-3) 4 (2-6) <0.01 
Not for resuscitation, n (%) 327 (3.7) 148 (1.7) 179 (54.7) <0.01 
Admitted to ICU 227 (2.6) 206 (2.4) 21 (6.4) <0.01 
Infection source, n (%)     
Respiratory 2101 (23.7) 1961 (23.0) 140 (42.8) <0.01 
Urinary tract 1397 (15.7) 1330 (15.6) 67 (20.5) 0.02 
Abdominal/pelvic 1323 (14.9) 1293 (15.1) 30 (9.2) <0.01 
Soft tissue  2797 (31.5) 2270 (32.4) 27 (8.3) <0.01 
Other 1253 (14.1) 1190 (13.9) 63 (19.3) <0.01 
SIRS criteria, n (%)     
Heart Rate>90 4504 (50.8) 4274 (50.0) 231 (70.6) <0.01 
Respiratory Rate >20 2009 (22.6) 1797 (21.0) 212 (64.8) <0.01 
Temperature >38 or <36.0 2797 (31.5) 2654 (31.1) 143 (43.7) <0.01 
White Cell Count <4 or >12 3933 (44.3) 3726 (43.6) 207 (63.3) <0.01 
Organ dysfunctions, n (%)     
Cardiovascular 218 (2.5) 166 (1.9) 52 (15.9) <0.01 
Respiratory 779 (8.8) 540 (7.6) 129 (39.4) <0.01 
Renal 413 (4.7) 328 (3.8) 85 (26.0) <0.01 
Haematological 291 (3.3) 265 (3.1) 26 (8.0) <0.01 
Hepatic 457 (5.2) 432 (5.1) 25 (7.6) 0.04 
Neurological 120 (1.4) 83 (1.0) 37 (11.3) <0.01 
Sepsis subgroups, n (%)     
Sepsis (incl. severe and shock) 4176 (47.1) 3923 (45.9) 253 (77.4) <0.01 
Severe sepsis (incl. shock) 1325 (14.9) 1155 (13.5) 170 (52.0) <0.01 
Septic shock 357 (4.0) 285 (3.3) 72 (22.0) <0.01 
Median Severity Scores (IQR)     
MEDS 3 (0-7) 3 (0-6) 14 (10-16) <0.01 
APACHE II 6 (2-11) 5 (2-10) 17 (13-23) <0.01 
SAPS II 17 (10-26) 16 (9-25) 39 (31-46) <0.01 
SOFA  1 (0-2) 1 (0-2) 5 (3-7) <0.01 
Severe Sepsis Score 13 (9-21) 13 (9-20) 31 (20-49) <0.01 
IQR = inter-quartile range, NHR = nursing home resident, SIRS = systemic inflammatory response criteria, 
ICU = Intensive Care Unit, SOFA = sequential organ failure assessment, APACHE = Acute Physiology and 
Chronic Health Evaluation, SAPS = New Simplified Acute Physiology Score, MEDS=Mortality in Emergency 
Department Sepsis. 
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5.3.5 – Discussion 
 
In this study, the MEDS score generally displayed superior operating characteristics in terms of 
both discrimination and calibration across a range of sepsis severity subgroups. In terms of 
discrimination, the advantage of MEDS score over other scores was statistically significant for all 
comparisons except that with SAPS II. The critical care scores SAPS II and APACHE II discriminated 
well but substantially overestimated mortality. The recently derived SSS displayed the poorest 
discrimination and also overestimated mortality. 
 
Figure 5. 2: Receiver operating curves 
 
A: Entire cohort, B: Sepsis, C: Severe Sepsis, D: Septic Shock, E: Patients admitted from emergency to the 
Intensive Care Unit. MEDS = Mortality in Emergency Department Sepsis Score, APACHE = Acute Physiology 
and Chronic Health Evaluation, SAPS II = New Simplified Acute Physiology Score, SOFA = Sequential Organ 
Failure Assessment, SSS = Severe Sepsis Score. 
 
 
The MEDS score provided good-to-excellent discrimination across all sepsis subgroups, with 
AUROC values of 0.83 to 0.92. MEDS also described the closest relationship between predicted 
and observed mortality. These results are likely due to the similarities between our cohort 
(mortality 3.7%) and that in the MEDS derivation study (1), which recruited 2,070 patients 
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presumed to have infection identified by a blood culture request (mortality 5.3%). It has been 
established that variations in patient mix and cohort mortality can significantly impact the 
performance of predictive models [18,19]. Demonstrating this principle, prior MEDS validation 
articles have enrolled patients from at least 10 countries, with mortality ranging from 3.9% (20) to 
35% (21) and consequent AUROC estimates between 0.60 [21] and 0.88 [22]. MEDS validation 
studies with cohorts of greater severity of illness have found the score to underestimate mortality 
[23-15]. Performance of the MEDS score was optimized by the inclusion of a broad range of 
participants, including elderly nursing home residents and patients with substantial comorbidity. 
Nursing home residence is an established marker of comorbidity, dependence, and consequent 
mortality risk [26]. The MEDS variable “nursing home resident” harnesses this predictive power, 
but that effect will likely be reduced in cohorts that exclude elderly patients with limitations to 
care. Similarly, the most heavily weighted MEDS variable “terminal illness” is likely to be a 
powerful predictor in broad and inclusive patient groups but much less useful in cohorts that 
exclude those patients. For example, a series of studies from China [27-31] explored the 
performance of several scores and biomarkers in a cohort of 680 ED patients with sepsis, but 
those with malignancy and terminal disease were excluded. MEDS discrimination in those studies 
was modest, with AUROC values of 0.72–0.74.  
 
 
Table 5. 7: Area under receiver operating characteristic curves (95% confidence intervals) for 
scores, by sepsis subgroups. 
 
Score Entire cohort 
(n=8871) 
Sepsis (incl. 
severe and 
shock) 
(n=4176) 
Severe 
sepsis (incl. 
shock) 
(n=1325) 
Septic shock 
(n=357) 
ICU 
(n=227) 
 MEDS 0.92 
(0.90-0.93) 
0.90 
(0.88-0.92) 
0.86 
(0.83-0.89) 
0.87 
(0.84-0.92) 
0.84 
(0.76-0.92) 
APACHE II 0.90 
(0.88-0.91) 
0.86 
(0.84-0.88) 
0.79 
(0.76-0.83) 
0.79 
(0.74-0.84) 
0.77 
(0.67-0.87) 
SAPS II 0.90 
(0.89-0.92) 
0.88 
(0.86-0.90) 
0.82 
(0.78-0.85) 
0.82 
(0.78-0.87) 
0.80 
(0.71-0.88) 
SOFA 0.86 
(0.84-0.88) 
0.83 
(0.80-0.86) 
0.78 
(0.75-0.82) 
0.74 
(0.68-0.79) 
0.74 
(0.65-0.84) 
SSS 0.82 
(0.79-0.84) 
0.78 
(0.75-0.80) 
0.69 
(0.65-0.74) 
0.63 
(0.56-0.70) 
0.64 
(0.51-0.77) 
APACHE II = Acute Physiology and Chronic Health Evaluation, SAPS II = New Simplified Acute Physiology 
Score, SOFA = Sequential Organ Failure Assessment, MEDS = Mortality in Emergency Department Sepsis, 
SSS = Severe Sepsis Score, ICU=Intensive Care Unit 
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Despite their age, the critical care scores APACHE II and SAPS II generally discriminated well. In the 
subgroup of patients admitted to ICU and the subgroup without limitations to care (in which there 
were likely fewer nursing home residents or patients with significant comorbidity), these scores 
discriminated as well as, or better than the MEDS score. Previous studies examining these scores 
in patients eligible for advanced resuscitation [25] or admission to a high dependency unit [32] 
have reported APACHE II and SAPS II discrimination superior to MEDS. 
 
Consistent with our findings, APACHE II and SAPS II scores calculated in the ED have previously 
been found to overestimate mortality [23,25]. Nguyen et al [33] demonstrated significant 
reductions in APACHE II and SAPS II scores between ED and ICU patients admitted with critical 
illness. These scores were developed to estimate mortality risk in the first 24 hours of ICU 
admission, so higher preceding scores using ED data are likely to overestimate mortality. The 
steady reduction in mortality in patients with sepsis over the last decade [34] may also cause 
previously developed models to overestimate mortality. 
 
Figure 5. 3: Calibration plots for the overall cohort, by score. 
 
A: Mortality in Emergency Department Sepsis Score (MEDS), B: Acute Physiology and Chronic Health 
Evaluation (APACHE II), C: New Simplified Acute Physiology Score (SAPS II), D: Severe Sepsis Score (SSS). 
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Discrimination with SOFA score was moderate and consistent with previous studies reporting 
AUROC between 0.70 [32] and 0.80 [35]. In this study, the discrimination of SSS was poor in the 
subgroups with severe sepsis and septic shock (AUROC values of 0.69 and 0.62, respectively). 
Performance of these models was likely hampered by the lack of variables accounting for age and 
comorbidity. Neither score would be optimal for use in a broad and inclusive patient cohort with 
low overall mortality. 
 
There are limitations to the study methods. Potential subjects were identified using the diagnosis 
recorded in an ED admission database. Although the list of diagnoses used to screen for patients 
was broad, it is possible that this process failed to identify some ED patients admitted with 
infection. Conversely, it is possible that some subjects thought to have infection were ultimately 
diagnosed with a non-infectious cause for admission. We aimed to minimize these occurrences by 
only enrolling cases in which the provisional diagnosis of both the ED and inpatient teams were 
concordant and consistent with infection. A secondary analysis assessing the performance of 
scores in the 618 patients with bacteremia (Table 5.13, ex Supplemental Table 5) revealed similar 
results. No interventions were initiated by the study investigators, and so clinical and laboratory 
data collected were limited to those generated during the course of each patient’s routine 
management. This may have impacted on the resulting severity scores, as frequency of data 
acquisition has been shown to affect scores that use the highest (or lowest) value over a set time 
period [36]. The legacy scores, APACHE II and SAPS II, were evaluated because they remain the 
most frequently cited measures of illness severity in this field [6-10]. It is possible that updated 
versions of these scores may have performed differently. The study was conducted at a single 
center, potentially impacting on the generalizability of results. Strengths of this study include the 
analysis of a large, prospective cohort with wide spectrum of disease severity, facilitating analysis 
of model performance in patient subgroups. The use of death registry data ensured the accuracy 
of mortality endpoints. 
 
Our results emphasize the importance of using severity scores appropriate to the cohort under 
consideration. For ED patients with sepsis of all severities, the MEDS score provides an accurate 
estimate of prognosis and has the added advantage of relative simplicity. In cohorts that exclude 
patients with substantial limitations to care, comorbidity, or terminal illness, the MEDS score may 
be less effective than critical care scores, such as SAPS II or APACHE II. The poor calibration seen 
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with the critical care scores makes them a suboptimal choice for comparing cohorts of ED patients 
with sepsis between studies. 
 
Table 5. 8: Hosmer-Lemeshow statistics for scores by sepsis subcategory. 
Score Total Cohort 
(n=8871) 
Sepsis 
(n=4176) 
Severe Sepsis 
(n=1325) 
Septic shock 
(n=357) 
ICU 
(n=227) 
MEDS 36.26,  
p<0.01 
12.57,  
p=0.01 
2.87, 
p=0.41 
5.07, 
p=0.17 
2.13, 
p=0.55 
APACHE II 518.12,  
p<0.01 
291.85 
p<0.01 
136.19, 
p<0.01 
67.11,  
p<0.01 
118.38, 
p<0.01 
SAPS II 146.93,  
p<0.01 
357.73, 
p<0.01 
19.54,  
p=0.01 
16.27,  
p=0.01 
51.54, 
p<0.01 
SSS 494.33, 
p<0.001 
206.48 
p<0.01 
63.03,  
p<0.01 
40.99,  
p<0.01 
73.29,  
p<0.01 
ICU=Intensive Care Unit, MEDS = Mortality in Emergency Department Sepsis Score, SAPS II = New Acute 
Physiology Score, APACHE II = Acute Physiology and Chronic Health Assessment, SSS = Severe Sepsis Score. 
Bolded values are those where the Hosmer-Lemeshow statistic indicated good model fit.  
 
Conclusions 
Performance of a severity of illness score is dependent on the characteristics of the cohort under 
consideration. The MEDS score displayed superior operating characteristics in ED patients with 
infection. 
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Table 5. 9 (Supplementary Table 1): General parameters used in the calculation of scores 
        SCORES     
  
 
MEDS SAPS II APACHE II SOFA SSS 
Parameters             
Age   X X X 
 
  
Chronic disease   
 
X X 
 
  
Nursing home   X 
   
  
Terminal illness   X 
   
  
Type of admission   
 
X X 
 
X 
Geographic region   
    
X 
GCS   X X X X X 
Temperature     X X   X 
Blood pressure   X X X X X 
Heart rate   
 
X X 
 
  
Vasopressor use   
   
X X 
Fluids   
    
X 
Lactate   
    
X 
FiO2/PaO2/Aa gradient     X X X X 
pH       X     
Bicarbonate     X       
Respiratory rate   X   X   X 
Mechanical ventilation           X 
Specific source   X       X 
Hyperglycaemia   
    
X 
Sodium   
 
X X 
 
  
Potassium   
 
X X 
 
  
White cell count   X X X 
 
X 
Haematocrit   
  
X 
 
  
Platelets   X 
  
X X 
Bilirubin   
 
X 
 
X X 
Creatinine       X X X 
Urea     X       
Acute renal failure       X     
Urine output     X   X X 
              
MEDS = Mortality in Emergency Department Sepsis, SAPS II = New Simplified Acute Physiology Score, 
APACHE II = Acute Physiology and Chronic Health Evaluation, SOFA = Sequential Organ Failure Assessment, 
SSS = Severe Sepsis Score. X indicates one or more related variables contribute to the score. A SOFA score 
of two or more was used to indicate organ failure in the SSS. 
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Table 5. 10 (Supplementary Table 2): Logits used in the prediction of mortality 
Score Logit 
APACHE II -3.517 + 0.146*APACHE II 
SAPS II score -7.631 + 0.0737*SAPS II + 0.9971*Ln (SAPS II) 
SSS -2.88334 + SSS*0.0366 
APACHE = Acute Physiology and Chronic Health Evaluation, SAPS II = New Simplified Acute Physiology 
Score, SSS = Severe Sepsis Score 
 
 
 
Table 5. 11 (Supplementary Table 3): Comparison of area under receiver operating characteristic 
curve for the five scores by sepsis category 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEDS = Mortality in Emergency Department Sepsis Score, SAPS II = New Acute Physiology Score, APACHE II 
= Acute Physiology and Chronic Health Assessment, SOFA = Sequential Organ Failure Assessment, SSS = 
Severe Sepsis Score. Bolded values are those where ROC curves are not significantly different.    
 
 
 
 
 
 
Comparison Total Cohort 
(n=8871) 
Sepsis 
(n=4176) 
Severe 
Sepsis 
(n=1325) 
Septic shock 
(n=357) 
ICU (n=227) 
MEDS v 
APACHE 
0.92 v 0.90 
p<0.01 
0.90 v 0.86 
p<0.01 
0.86 v 0.79 
p<0.01 
0.87 v 0.79 
p=0.01 
0.84 v 0.77 
p=0.29 
MEDS v SAPS II 0.92 v 0.90 
p=0.09 
0.90 v 0.88 
p=0.02 
0.86 v 0.82 
p=0.01 
0.87 v 0.82 
p=0.05 
0.84 v 0.80 
p=0.42 
MEDS v SOFA 0.92 v 0.86 
p<0.01 
0.90 v 0.83 
p<0.01 
0.86 v 0.78 
p<0.01 
0.87 v 0.74 
p<0.01 
0.84 v 0.74 
p=0.11 
MEDS v SSS 0.92 v 0.82 
p<0.01 
0.90 v 0.78 
p<0.01 
0.86 v 0.69 
p<0.01 
0.87 v 0.63 
p<0.01 
0.84 v 0.64 
p<0.01 
APACHE v SAPS  0.90 v 0.90 
p=0.16 
0.86 v 0.88 
p=0.04 
0.79 v 0.82 
p=0.05 
0.79 v0.82 
p=0.05 
0.77 v 0.80 
p=0.48 
APACHE v 
SOFA 
0.90 v 0.86 
p<0.01 
0.86 v 0.83 
p<0.01 
0.79 v 0.78 
p=0.52 
0.79 v 0.74 
p=0.04 
0.77 v 0.74, 
p=0.48 
APACHE v SSS 0.90 v 0.82 
p<0.01 
0.86 v 0.78 
p<0.01 
0.79 v 0.69 
p<0.01 
0.79 v 0.63 
p<0.01 
0.77 v 0.64 
p=0.01 
SAPS II v SOFA 0.90 v 0.86 
p<0.01 
0.88 v 0.83 
p<0.01 
0.82 v 0.78 
p=0.05 
0.82 v 0.74 
p<0.01 
0.80 v 0.74 
p=0.28 
SAPS II v SSS 0.90 v 0.82 
p<0.01 
0.88 v 0.78 
p<0.01 
0.82 v 0.69 
p<0.01 
0.82 v 0.63 
p<0.01 
0.80 v 0.64, 
p<0.01 
SOFA v SSS 0.86 v 0.82 
p<0.01 
0.83 v 0.78 
p<0.01 
0.78 v 0.69 
p<0.01 
0.74 v 0.63 
p<0.01 
0.74 v 0.64 
p=0.02 
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Table 5. 12 (Supplementary Table 4): Intercepts and coefficients from regression of expected and 
observed mortality. 
 
MEDS = Mortality in Emergency Department Sepsis Score, SAPS II = New Acute Physiology Score, APACHE II 
= Acute Physiology and Chronic Health Assessment, SSS = Severe Sepsis Score. Bolded values are those 
where the slope does not include unity. Note that there is evidence for model calibration if the 95% 
confidence interval for the intercept incudes 0 and the 95% confidence interval for the slope includes unity. 
 
 
Table 5. 13 (Supplementary Table 5): Area under receiver operating curves (95% confidence 
intervals) for scores, in patients with bacteremia and patients without limitations to care. 
 
Score Bacteremia 
(n=618) 
Patients without limitations 
to care 
(n=8544) 
MEDS 0.83 (0.77-0.88) 0.86 (0.84-0.89) 
APACHE II 0.79 (0.74-0.84) 0.85 (0.84-0.89) 
SAPS II 0.85 (0.81-0.89) 0.87 (0.85-0.90) 
SOFA 0.80 (0.74-0.85) 0.82 (0.79-0.86) 
SSS 0.72 (0.66-0.79) 0.76 (0.72-0.80) 
MEDS = Mortality in Emergency Department Sepsis, APACHE II = Acute Physiology and Chronic Health 
Evaluation, SAPS II = New Simplified Acute Physiology Score, SOFA = Sequential Organ Failure Assessment, 
SSS = Severe Sepsis Score  
 
 
 
 
 
Score Total Cohort 
(n=8871) 
Sepsis 
(n=4176) 
Severe Sepsis 
(n=1325) 
Septic shock 
(n=357) 
ICU 
(n=227) 
MEDS Intercept 0.00 
(-2.91 to 0.91) 
-1.02 
(-2.90 to 0.87) 
-0.84 
(-2.86 to 1.19) 
-1.57 
(-8.21 to 5.08) 
0.88 
(-3.13 to 4.89) 
MEDS Slope 0.96 
(0.88 to 1.03) 
0.99 
(0.92 to 1.07) 
1.10 
(1.02 to 1.19) 
1.13 
(0.86 to 1.41) 
0.73 
(0.57 to 0.90) 
APACHE Intercept -0.03 
(-0.12 to 0.06) 
-0.03 
(-0.12 to 0.07) 
-0.02 
(-0.12 to 0.07) 
-0.03 
(-0.14 to 0.08) 
0.00 
(-0.08 to 0.09) 
APACHE Slope 0.66 
(0.49 to 0.83) 
0.64 
(0.47 to 0.81) 
0.63 
(0.46 to 0.80) 
0.59 
(0.39 to 0.78) 
0.20 
(0.04 to 0.37) 
SAPS II Intercept -0.019 
(-0.09 to 0.05) 
-0.01 
(-0.09 to 0.06) 
0.00 
(-0.08 to 0.08) 
0.01 
(-0.09 to 0.10) 
0.00 
(-0.08 to 0.09) 
SAPS II Slope 0.85 
(0.70 to 1.00) 
0.83 
(0.67 to 0.98) 
0.81 
(0.64 to 0.97) 
0.74 
(0.55 to 0.94) 
0.38 
(0.18 to 0.57) 
SSS Intercept 0.00 
(-0.08 to 0.08) 
0.00 
(-0.08 to 0.09) 
0.03 
(-0.08 to 0.13) 
0.00 
(-0.13 to 0.13) 
0.01 
(-0.10 to 0.12) 
SSS Slope 0.58 
(0.36 to 0.80) 
0.55 
(0.33 to 0.77) 
0.50 
(0.24 to 0.76) 
0.54 
(0.23 to 0.85) 
0.30 
(0.02 to 0.57) 
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Section 5.4 – Context and conclusions 
 
The literature review demonstrated that interpretation of the validation literature for each of the 
scores studied was complicated by considerable heterogeneity in study cohorts, leading to range 
of results (for example AUROC for MEDS ranged between 0.60 and 0.88, for SOFA 0.70 – 0.80, 
APACHE II 0.69 – 0.80,  and SAPS II 0.71 – 0.89). MEDS had the broadest range, and performed 
particularly poorly (with the lowest AUROCs seen for any scores) in cohorts of patients at high risk 
of mortality and eligible for invasive therapies [1, 2]. Eligibility for invasive therapy in those studies 
would likely have reduced the frequency of patients with life-threatening co-morbidity and nursing 
home residents (NHR), therefore reducing the impact of the associated MEDS variables. 
Discrimination can be expected to suffer most in a new cohort when patients with the very highest 
risk of mortality (NFR, NHR) and the lowest mortality risk (non-severe sepsis) are removed [3].  
 
The paper in preceding section (5.3) was designed to validate commonly used scores, several for 
the first time in an Australian cohort, but also to demonstrate the change in predictive scores’ 
prognostic accuracy when the characteristics of the study cohort are varied in a controlled fashion. 
In this way, an assessment of spectrum transportability can be made. Clinicians are generally 
cognisant of the need to be aware of the consequences of limited spectrum transportability in the 
context of diagnostic tests (effectively changing the pre-test probability) [4] but may also benefit 
from an awareness of similar issues with prognostic tools. 
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Chapter 6: Clinical Prediction in Community-Acquired 
Pneumonia 
 
Section 6.1 – Synopsis 
 
Pneumonia is defined as an acute infection of the lung parenchyma [1], and the associated clinical 
syndrome has been described in literature from antiquity [2]. Community-acquired pneumonia 
(CAP) is defined as pneumonia occurring in the absence of hospitalisation or hospital attendance 
[3]. Pneumonias occurring in nursing home residents and after aspiration have historically been 
regarded as clinically and aetiologically distinct from CAP [4,5]. Community-acquired pneumonia is 
one of the commonest infection-related diagnoses for ED patients admitted to hospital [6,7]. 
 
A variety of severity scores have been either derived or proposed after expert review for risk 
stratification of patients with CAP [8]. Unlike the severity scores designed for use in broad groups 
of patients with infection reviewed and investigated in Chapter 5, CAP severity scores have been 
incorporated into patient care at the bedside, to assist in real-time clinical decision-making.  
The most common clinical use for CAP severity scores is assistance with determination of the most 
appropriate site for ongoing treatment beyond the ED. Identification of patients with mild disease 
that could be safely and appropriately treated in the community is vital for reduction of costs [9] 
as well as avoidance of morbidity and mortality associated with hospitalisation [10]. On the other 
end of the severity spectrum, the early identification of patients with severe pneumonia enables 
consideration of admission to intensive care (ICU) or high dependency units. Delayed admission to 
ICU has been associated with excess morbidity and mortality [11]. 
 
Several national guidelines have consequently endorsed the use of CAP severity scores for 
determination of site of ongoing care. Examples include the Infectious Disease Society of America 
/ American Thoracic Society guidelines (IDSA/ATS 2007) endorsed in the USA [12], the British 
Thoracic Society guidelines [13], and the Australian Therapeutic guidelines (recommending PSI 
then SMARTCOP) [14]. Several other national authorities have endorsed various scores [8]. 
 
In section 6.2, performance of common CAP severity scores will be systematically reviewed, 
through critique of published validation studies and previous systematic reviews. Reviewed 
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validation studies will be assessed using domains corresponding to those in the QUADAS-2 [15] 
and the QUIPS [16] tools outlined in Chapter 1. Areas of heterogeneity and deficiency in research 
to date will be identified. 
 
Section 6.3 comprises the published, peer-reviewed original research paper “Utility of community-
acquired pneumonia severity scores in guiding disposition from the emergency department: 
intensive care or short stay unit?” [17]. The paper analyses data for patients in the thesis database 
that have lower respiratory tract recorded as the source of infection, together with chest x-ray 
reports consistent with pneumonia and without characteristics associated with hospital-acquired, 
nursing home acquired, or aspiration pneumonia. This study extends previous research in two 
ways: 1) careful minimisation of selection, spectrum and partial verification biases with data from 
the thesis database, and 2) assessing performance of severity scores at lowest risk thresholds to 
identify patients suitable for brief admission to a short stay unit. 
 
Section 6.4 provides brief contextualisation and conclusions that can be drawn from the review 
and original research comprising the preceding two sections. 
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Section 6.2 – Systematic Review: Community-Acquired Pneumonia Severity Scores  
 
6.2.1 – Severity scores in this review 
An array of community-acquired pneumonia (CAP) severity scoring systems exist in the current 
literature. The six scores outlined below have been chosen for review and further investigation in 
this chapter based on either frequency of use or relevance to the Australian clinical context. 
 
Pneumonia Severity Index (1997) 
The Pneumonia Severity Index (PSI) [1] was the first CAP severity score derived and remains one of 
the most widely used today. Twenty variables were identified through logistic regression and used 
to compute an integer score which assigns patients to one of five severity classes (I-V), based on 
the risk of 30-day mortality (Table 6.1). Consideration of outpatient treatment is suggested for 
patients in classes I and II, based on observed low mortality risk (0.1-0.6%), and consideration for 
intensive care admission suggested for patients with PSI classes IV/V. Criticism of this score has 
centred around heavy weightings for age and co-morbidity, and overall score complexity [2]. 
 
CURB65 (2003) 
The CURB65 score evolved over several refinements of the ‘British Thoracic Society (BTS) rule’ [3]. 
The score comprises only five variables: acute confusion, urea >7mmol/L, respiratory rate ≥30 
breaths/minute, low blood pressure (systolic <90 mmHg, diastolic ≤60 mmHg), and age ≥65 years. 
Each variable carries the same weight and the total score predicts 30-day mortality. The suggested 
criteria for severe CAP is a score of ≥3 (3-5). The CURB65 variables were identified through logistic 
regression, through which albumin (<30g/L) was shown to be a more powerful predictor of 
mortality than age ≥65. The age variable was added to CURB rather than albumin because it was 
judged more freely available. Criticisms of this score have included poor prediction of ICU 
admission [4], and underestimation of disease severity in younger patients [5]. 
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Table 6. 1: Pneumonia Severity Index (PSI) classes and estimated mortality 
Characteristic Points PSI class with expected 30-day mortality 
Age    
Males Age in years  
Females Age - 10  
Nursing home resident 10  
Co-existing illness   
Neoplastic disease 30  
Liver disease 20  
Congestive heart disease 10  
Cerebrovascular disease 10           
Renal disease 10          PSI class I: age ≤50  
Physical examination findings           No co-existing illness or exam findings 
Altered mental status 20          Expected mortality 0.1% 
Respiratory rate ≥30 breaths/minute 20  
Systolic blood pressure <90 mmHg 20  
Temperature <35 or ≥40°C 15  
Pulse rate ≥125/minute 10  
Laboratory and radiographic findings            PSI class II: (≤70 points)          mortality 0.6%  
Arterial pH <7.35 30           PSI class III: (71 - 90 points)                     0.9% 
Urea >11.0 mmol/L 20           PSI class IV: (91 - 130 points)                   9.3% 
Sodium <130 mmol/L 20           PSI class V: (>130 points)                          27% 
Glucose ≥14.0 mmol/L 10  
Haematocrit <30% 10  
Arterial pO2 <60 mmHg 10  
Pleural effusion  10  
Adapted from reference [1]. Estimated mortality data is from the PORT validation cohort (n=2,287)  
 
 
Table 6. 2: The CURXO score 
Minor Criteria Major Criteria 
C Confusion   
U Urea >30 g/dL P pH <7.30 
R Respiratory rate >30 breaths / min. S Systolic blood pressure <90 mmHg 
X CXR – multilobar or bilateral consolidation   
O PaO2 <54 mmHg or PaO2/FiO2 <250   
80 Age ≥80 years   
Severe CAP = ≥1 major or ≥2 minor criteria 
Adapted from reference (6). CXR = chest x-ray, PaO2 = arterial partial pressure of oxygen, FiO2 = fraction of inspired 
oxygen, CAP = community acquired pneumonia. 
 
 
CURXO (2006) 
This score [6] has been referred to as CURXO, CURXO-80, SCAP, and the ‘Espana rule’ by various 
investigators and reviewers. Derived from ED patients admitted with CAP to a single Spanish 
hospital, the CURXO score was one of the first to use a composite endpoint incorporating in-
hospital death, mechanical ventilation or shock. Eight predictor variables were identified through 
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logistic regression and weighted as either major or minor criteria (see Table 6.2). Severe CAP 
(‘SCAP’) was defined by at least one major or two minor criteria. 
 
IDSA/ATS (2007) 
Guidelines for the classification and management of CAP were jointly published by the Infectious 
Disease Society of America (IDSA) and the American Thoracic Society (ATS) in 2007 [7]. Criteria for 
identification of patients with severe CAP potentially requiring intensive care admission were 
determined through an expert consensus process. Severe CAP was defined as at least one of two 
major (mechanical ventilation and shock requiring vasopressors) or ≥3 of nine minor criteria. The 
guidelines also recommended use of PSI or CURB65 to identify patients with CAP that may 
potentially be treated in the outpatient environment.  
 
Table 6. 3: IDSA/ATS 2007 criteria for severe community acquired pneumonia 
Minor Criteria Major Criteria 
 Confusion/disorientation   
 Uraemia (BUN ≥20 mg/dL)  Invasive mechanical ventilation 
 Respiratory rate ≥30 breaths/minute  Septic shock requiring vasopressors 
 PaO2/FiO2 ≤250   
 Multilobar infiltrates on chest x-ray   
 Leucopoenia (WCC <4000 cells/mm3)   
 Thrombocytopaenia (platelets < 105 cells/mm3)   
 Hypothermia (core temperature <36°C)   
 Hypotension requiring aggressive fluids   
Severe CAP = ≥1 major or ≥3 minor criteria 
Adapted from reference [7]. BUN = blood urea nitrogen, PaO2 = arterial partial pressure of oxygen, FiO2 = fraction of 
inspired oxygen, WCC = white cell count, CAP = community acquired pneumonia. 
 
 
SMARTCOP (2008) 
Data from a large prospective observational study that recruited patients with CAP from six 
Australian centres were used to derive this score [8]. Logistic regression was used to determine 
clinical variables associated with receipt of invasive respiratory or ventilatory support. In this, 
SMARTCOP differed from the scores summarised above, which aimed to predict either mortality 
(PSI and CURB65), intensive care admission (IDSA/ATS 2007), or a combination of these (CURXO). 
Eight SMARTCOP variables contribute to the final score, two of which have age-adjusted cut-offs. 
The resulting complexity has drawn criticism despite acknowledgement of greater accuracy [9].   
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Table 6. 4: The SMARTCOP score 
Variable Points Interpretation 
S Systolic BP <90 mmHg 2   
M Multilobar CXR involvement 1   
A Albumin <35 g/L 1   
R Respiratory rate (age-adjusted cut-offs) 1 0-2 points Low risk of IRVS 
      Age ≤50: RR ≥25 breaths/minute       3-4 points Moderate risk (1 in 8) of IRVS 
      Age >50: RR ≥30 breaths/minute  5-6 points High risk (1 in 3) of IRVS 
T Tachycardia ≥125 beats/minute 1 ≥7 points Very high risk (2 in 3) of IRVS 
C Confusion (new onset) 1   
O Oxygen low (age adjusted cut-offs) 2   
      Age ≤50: PaO2<70mmHg or SpO2 ≤93%    
      Age >50: PaO2<60mmHg or SpO2 ≤90%    
P Arterial pH <7.35 1   
Adapted from reference [8]. BP = blood pressure, CXR = chest x-ray, RR = respiratory rate, PaO2 = arterial partial 
pressure of oxygen, SpO2 = pulse oximetry, IRVS = invasive respiratory or vasopressor support. 
 
 
CORB (2006) 
The CORB score [10] was derived in a single-centre Australian cohort, partly in response to 
complexity of previous scores. Logistic regression was again used to identify weighted 
independent predictors for the composite outcome of in-hospital mortality or requirement for 
invasive ventilation or inotropic support. The final score has four components (confusion, oxygen 
saturation ≤90%, respiratory rate ≥30 breaths/minute, and systolic blood pressure <90 mmHg), 
with severe CAP suspected if two or more criteria are present in the ED.  
 
Community acquired pneumonia scores that were not reviewed 
Numerous CAP severity scores were not reviewed in this study. Some scores, such as previous 
iterations or variations of the British Thoracic Society (BTS) rule (CURB, CRB, CRB65) or the 
American Thoracic Society (ATS) rules, have been superseded by scores summarised above 
(CURB65 and IDSA/ATS 2007 guidelines respectively). Other proposed CAP severity scores, while 
described in current literature, have not yet gained a clinical foot-hold through widespread 
external validation. Examples include SOAR [11], A-DROP [12], PARB [13], CURSI/CURASI [14], and 
CARSI/CARASI [15]. 
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6.2.2 – Systematic Review  
Given the broad range of CAP severity scores outlined above, the bedside clinician may feel more 
confused than supported regarding key decisions such as optimal site-of-care for each patient. The 
purpose of this review was to critically appraise the peer-reviewed literature regarding diagnostic 
accuracy of the six study scores, and to determine conclusions from and clinical deficits in that 
body of work. The review was structured according to the MOOSE (guidelines for meta-analysis 
and systematic reviews of observational studies) [16] framework.  
 
Study question 
In Adult ED patients admitted with community acquired pneumonia, 
1. What is the diagnostic accuracy of the designated study CAP severity scores (PSI, CURB65, 
CORB, CURXO, SMARTCOP and the IDSA/ATS 2007 minor criteria) used with standard 
thresholds for severe CAP in prediction of [mortality/ICU admission/need for invasive 
respiratory or vasopressor support (IRVS)]? 
2. What is the diagnostic accuracy of the study CAP severity scores at lowest threshold for 
prediction of hospital length of stay ≤48 hours, thus potentially suitable for short-stay unit 
admission? 
 
Search strategy 
Databases (EMBASE, PUBMED) were searched using the following terms: (community-acquired 
pneumonia) AND [predict* OR (severity score*) OR prognosis OR mortality], as well as (‘PSI’ or 
‘pneumonia severity index’ or ‘Fine score’ or ‘PORT score’), (‘CURB65’ or ‘CURB-65’), (‘IDSA/ATS’), 
(‘CORB’), (‘SMARTCOP’ or ‘SMART-COP’), and (‘CURXO’ or ‘CURXO-80’ or ‘SCAP’). No time intervals 
were specified, but only results in English were eligible for assessment. Target papers were 
observational studies enrolling ED patients with CAP, and assessing the nominated scores at 
standard thresholds. For inclusion, assessment of diagnostic accuracy for prediction of any of the 
specified outcomes was required in terms of sensitivity/specificity and/or area under receiver 
operating characteristic curve (AUROC). Reference lists from included studies and previous 
systematic reviews were also searched for potentially suitable papers. Studies in abstract form 
were included if sufficient data to meet review inclusion criteria were available. 
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Figure 6. 1: Search strategy with identification of review papers 
 
                  
AUROC = area under receiver operating curve, ICU = intensive care unit, IRVS = invasive respiratory or 
vasopressor support. 
 
 
Results 
Fifty-two original studies from over 20 countries met search criteria for this review, including four 
papers presented in abstract form only. Four previous systematic reviews with similar objectives 
and search criteria were also reviewed, and component studies were included if suitable. Figure 6-
1 presents the search parameters, study inclusion criteria and results graphically. 
 
Tables 6.5 (PSI), 6.6 (CURB65), 6.7 (SMARTCOP), 6.8 (CURXO), 6.9 (IDSA/ATS 2007) and 6.10 
(CORB) summarise the cohort characteristics and results of the reviewed studies for each score. 
The PSI and CURB65 scores were assessed most frequently (in 36 and 39 papers respectively). 
Fourteen papers assessed SMARTCOP, eight and seven assessed CURXO and the IDSA/ATS 2007 
minor criteria respectively, and no studies were identified in which the CORB score was externally 
validated.  
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Table 6. 5: Studies assessing the PSI score 
Year First Author Country 
(UN code) 
Site 
No. 
Prospective/ 
Retrospective 
n 
(ages) 
Consecutive 
(Y/N) 
Outpatients 
(%) 
NFR 
(E/I) 
NHR 
(E/I) 
Mort. 
(%) 
Endpoint Endpoint 
prevalence 
Sens 
(%) 
Spec 
(%) 
AUROC 
1997 Fine (derivation)1 USA 78 Retro 14199 Y 0 I I 10.2 Mortality 10.2 - - - 
1999 Flanders17 USA 22 Retro 1024  0 I I 4.8 Mortality 4.8 - - 0.85 
2004 Ewig18 ESP 1 P 696 Y 0 E I 6.8 Mortality 
ICU 
6.8 
16.7 
- 
- 
- 
- 
 
0.61 
2004 Querol-Ribelles19 ESP 1 P 243 - - - - 6.2 Mortality 6.2 - - 0.92 
2004 Van der Eerden20 NED 1 P 260 - 0 I I 10.0 Mortality 10.0 33 94 - 
2005 Aujesky21 USA 32 P 3181 - 34.0 I I 4.6 Mortality 4.6 79 70 0.81 
2006 Buising22 AUS 1 P 392 Y 13.5 I I 9.4 Mortality 
ICU 
Mortality/ICU 
9.4 
6.6 
14.0 
97 
84 
91 
48 
45 
49 
0.82 
0.69 
0.71 
2006 Capelastegui23 ESP 1 P 1776 Y 38.1 I I 6.7 Mortality 6.7 - - 0.89 
2006 Espana24 ESP 1 P 1057 Y 38.1 E I 9.1 Mortality / IRVS 11.5 95 68 0.81 
2006 Spindler25 SWE 1 P 114 Y 0 I I 11.4 Mortality 11.4 100 60 0.85 
2007 Man26 HKG 1 P 1016 Y 0 I I 8.6 Mortality 8.6 84 50 0.74 
2007 Renaud27 FRA 
ESP 
16 
14 
P 
P 
925 
853 
N 
N 
17.7 
33.6 
I 
I 
I 
I 
10.6 
6.3 
Mortality 
Mortality 
10.6 
6.3 
93 
94 
53 
57 
0.85 
0.89 
2008 Ananda-Rajah28 AUS 1 R 408 N 0 I I 15.4 Mortality 
ICU 
15.4 
10.5 
94 
86 
32 
30 
0.72 
0.58 
2008 Chalmers29 GBR 1 P 335 (<50) Y 0 E I 1.5 IRVS 9.9 55 83 0.80 
2008 Scheutz30 CHE 1 P 373 Y 4.6 I I 11.0 Mortality 11.0 - - 0.72 
2009 Yandiola31 ESP 3 P 671 Y 0 I E 3.7 ICU 8.5 70 57 0.63 
2009 Phua32 SGP 1 P 1242 
1017 
N 0 I 
E  
I 14.7 Mortality 
ICU 
14.7 96 
72 
58 
65 
0.86 
0.75 
2010 Espana33 ESP 3 P 712 Y 0 I I 6.7 Mortality 30d 6.7 88 55 0.79 
2010 Shah34 IND 1 P 150 N 0 I I 10.7 Mortality 
ICU 
10.7 
23.3 
100 
100 
39 
45 
- 
- 
2010 Chen35 TWN 1 P 987 
348 (<64) 
438 (<85) 
201 (≥85) 
Y 33.2 I I 6.9 
5.2 
7.1 
9.5 
Mortality 6.9 
5.2 
7.1 
9.5 
96 
89 
100 
100 
51 
81 
38 
20 
0.83 
0.87 
0.85 
0.69 
  
 
1
5
0 
 
Year First Author Country 
(UN code) 
Site 
No. 
Prospective/ 
Retrospective 
n 
(ages) 
Consecutive 
(Y/N) 
Outpatients 
(%) 
NFR 
(E/I) 
NHR 
(E/I) 
Mort. 
(%) 
Endpoint Endpoint 
prevalence 
Sens 
(%) 
Spec 
(%) 
AUROC 
2010 Dusemund36 CHE 6 P 925 N 7.5 I I 5.4 Mortality 
ICU 
5.4 
- 
- 
- 
- 
- 
0.82 
0.68 
2011 Ochoa-Gondar37 ESP - Retro 590 (≥65) N 13.1 I I 13.6 Mortality 13.6 86 41 0.73 
2011 Chalmers38 GBR - P 1062 Y - E I 4.5 Mortality 
ICU 
4.5 
7.6 
88 
78 
62 
63 
0.81 
0.74 
2011 Fukuyama39 JPN 1 P 505 Y 0 I E 6.5 Mortality / IRVS 
ICU 
Mortality 
11.9 
6.2 
6.5 
96 
94 
93 
35 
32 
31 
- 
- 
- 
2012 Robbins-Browne40 AUS 1 P/R 367 N 22.0 E I 3.0 IRVS 10.1 65 84 0.76 
2012 Labarere41 CHE 6 Retro 850 N 8.6 I E 4.7 ICU (3 days) 7.5 74 50 0.66 
2012 Luque42 ESP 1 P 152 Y 0 I I 11.8 Mortality 11.8 94 27 0.71 
2012 Yang43 CHN 1 Retro 675 N 0 I I 10.5 Mortality 10.5 - - 0.94 
2013 Kohno44 JPN 135 P 482 N 0 I E 12.3 Mortality 12.3 - - 0.63 
2013 Ribeiro45 PRT 1 R 142 N 0 - - 1.4 Mortality 
ICU 
1.4 
15.5 
100 
55 
66 
69 
0.96 
0.62 
2013 Varshochi46 IRN 2 P 134 N 0 I I 26.1 Mortality 26.1 80 67 0.77 
2015 Fernandes47 ESP 1 P 55 N 0 I I 10.9 Mortality 10.5 100 69 0.88 
2015 Alici48 TUR 1 P 84 N 0 I E 7.1 IRVS 
Mortality 
16.7 
7.1 
93 
100 
86 
78 
0.92 
0.89 
2015 Naderi49 IRN 1 P 120 N 0 I I 23.6 Mortality 23.6 80 75 0.80 
2016 Liu50 CHN 
ITA 
1 
1 
Retro 
P 
1640 
704 
Y 0 I I 8.5% 
- 
Mortality 
Mortality 
8.5 
- 
- 
- 
- 
- 
0.80 
0.75 
2016 Zhang51 SGP 1 P 1902 Y 0 I I 15.7 Mortality 15.7 95 50 0.82 
2017 Shehata52 EGY 1 P 250 Y 0 I I 11.2 Mortality 
ICU 
11.2 
29.6 
61 
21 
83 
97 
0.74 
0.58 
Country codes are United Nations standard reference. Dashes indicate data unavailable. NFR = not for resuscitation, NHR = nursing home resident, E = excluded, I = 
included, Sens = sensitivity, Spec = specificity, AUROC = area under receiver operating curve, ICU = intensive care unit, IRVS = invasive respiratory or vasoactive support. 
Spindler25 cohort = invasive pneumococcal disease, Ribeiro45 = Strep pneumoniae only. Chalmers 200829 patients aged <50 only, Xiao 2013 patients were all aged ≥65. 
Kohno44 – all patients had respiratory failure on entry. 
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Table 6. 6: Studies assessing the CURB65 score 
Year First Author Country 
(UN code) 
Site 
No. 
Prospective/ 
Retrospective 
Patient# 
(ages) 
Consecutive 
(Y/N) 
Outpatients 
(%) 
NFR 
(E/I) 
NHR 
(E/I) 
Mort. 
(%) 
Endpoint Endpoint 
prevalence 
Sens 
(%) 
Spec 
(%) 
AUROC 
2003 Lim (derivation)3 UK/NZ and 
NED 
4 Prospective 718 N 0 I E 9.6 Mortality 9.6 68 75 - 
2005 Aujesky21 USA 32 P 3181 N 34.0 I I 4.6 Mortality  4.6 45 87 0.77 
2006 Buising22 AUS 1 P 392 Y 13.5 I 
 
I 
 
9.4 Mortality 
ICU 
Mortality/ICU 
9.4 
6.6 
14.0 
81 
58 
71 
68 
65 
69 
0.82 
0.66 
0.76 
2006 Capelastegui23 ESP 1 P 1776 Y 38.1 I I 6.7 Mortality 6.7 - - 0.87 
2006 Espana24 ESP 1 P 1057 Y 38.1 E I 9.1 Mortality / IRVS 11.5 68 87 0.78 
2006 Myint11 GBR 1 P 189 N 0 I I 14.8 Mortality (6 wk) 14.4 82 64 - 
2006 Barlow53 GBR 2 Retrospective 419 N 0 I I 18.9 Mortality 18.9 71 69 0.78 
2006 Spindler25 SWE 1 P 114 Y 0 I I 11.4 Mortality 11.4 62 86 0.84 
2007 Man26 HKG 1 P 1016 Y 0 I I 8.6 Mortality 8.6 59 77 0.73 
2008 Ananda-Rajah28 AUS 1 Retro 408 N 0 I I 15.4 Mortality 
ICU 
15.4 
10.5 
62 
61 
66 
65 
0.69 
0.63 
2008 Chalmers29 GBR 1 P 335(<50) Y 0 E I 1.5 IRVS 9.9 55 90 0.81 
2008 Scheutz30 CHE 1 P 373 Y 4.6 I I 11.0 Mortality 11.0 - - 0.69 
2008 Shindo54 JPN 1 Retro 329 N  I I 9.4 Mortality 9.4 - -  0.84 
2008 Zuberi55 PAK 1 P 137 N 0 I E 13.1 Mortality 13.1 78 82 0.86 
2009 Yandiola31 ESP 3 P 671 Y 0 I E 3.7 ICU 8.5 75 46 0.61 
2009 Brown56 USA 1 Retro 2413 N 36 E E 3.7 IRVS in ICU 12.3 - - 0.76 
2009 Phua32 SGP 1 P 1242 
1017 
N 0 I 
E  
I 14.7 Mortality 
ICU 
14.7 61 
26 
83 
88 
0.82 
0.68 
2009  Parsonage57 GBR 2 P 428 
132 
296 
358 
Y  I I 
 
 
E 
18.5 
 
Mortality 
(age <65) 
(age ≥65) 
(NHR excluded) 
18.5 
5.0 
24.7 
- 
71 
33 
74 
- 
70 
98 
54 
- 
0.78 
0.93 
0.70 
0.80 
2010 Shah34 IND 1 P 150 N 0 I I 10.7 Mortality 
ICU 
10.7 
23.3 
88 
91 
89 
84 
- 
- 
2010 Chen35 TWN 1 P 987 
348 (<64) 
438 (<85) 
201 (≥85) 
Y  I I 6.9 
5.2 
7.1 
9.5 
Mortality 6.9 
5.2 
7.1 
9.5 
82 
22 
65 
47 
49 
99 
75 
66 
0.73 
0.80 
0.73 
0.60 
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Year First Author Country 
(UN code) 
Site 
No. 
Prospective/ 
Retrospective 
Patient# 
(ages) 
Consecutive 
(Y/N) 
Outpatients 
(%) 
NFR 
(E/I) 
NHR 
(E/I) 
Mort. 
(%) 
Endpoint Endpoint 
prevalence 
Sens 
(%) 
Spec 
(%) 
AUROC 
2010 Espana33 ESP 3 P 712 Y 0 I I 6.7 Mortality 30d 6.7 52 82 0.73 
2010 Dusemund36 CHE 6 P 925 N 7.5 I I 5.4 Mortality 
ICU 
5.4 
- 
- 
- 
- 
- 
0.72 
0.65 
2011 Jones58 USA 1 Retro 2069 N 42 I I 4.1 Mortality 4.1 - - 0.82 
2011 Chalmers38 GBR 1 P 1062 Y - E I 4.5 Mortality 
ICU 
4.5 
7.6 
63 
60 
76 
77 
0.74 
0.74 
2011 Fukuyama39 JPN 1 P 505 Y 0 I E 6.5 Mortality / IRVS 
ICU 
Mortality 
11.9 
6.2 
6.5 
63 
77 
60 
72 
71 
69 
- 
- 
- 
2011 Ochoa-Gondar37 ESP - Retro 590 (≥65) N 13.1 I I 13.6 Mortality 13.6 33 90 0.67 
2012 Labarere41 CHE 6 Retro 850 N 8.6 I E 4.7 ICU (3 days) 7.5 30 84 0.63 
2012 Luque42 ESP 1 P 152 Y 0 I I 11.8 Mortality 11.8 72 66 0.74 
2012 Yang59 CHN 1 Retro 675 N 0 I I 10.5 Mortality 10.5 - - 0.91 
2013 Varshochi46 IRN 2 P 134 N 0 I I 26.1 Mortality 26.1 83 69 0.74 
2013 Xiao60 CHN 1 Retro 240 (≥65) Y 0 I I 35.0 Mortality 35.0 81 70 0.81 
2015 Fernandes47 ESP 1 P 2013 N 0 I I 10.9 Mortality 10.5 67 84 0.88 
2015 Alici48 TUR 1 P 84 N 0 I E 7.1 IRVS 
Mortality 
16.7 
7.1 
64 
83 
90 
86 
0.89 
0.89 
2015 Li61 HKG 1 
2 
Retro 
P 
1230 
1409 
N 
Y 
0 
0 
E 
E 
I 
I 
1.3 
3.8 
Mortality 
Mortality 
1.3 
3.8 
- 
- 
- 
- 
0.92 
0.91 
2015 Naderi49 IRN 1 P 120 N 0 I I 23.6 Mortality 23.6 60 71 0.71 
2016 Liu50 CHN 
ITA 
1 
1 
Retro 
P 
1640 
704 
Y 0 I I 8.5% 
- 
Mortality 
Mortality 
8.5 
- 
- 
- 
- 
- 
0.76 
0.66 
2016 Sharp62 USA 14 Retro 21,183 N 37.5 I E 4.8 Mortality 4.8 41 89 0.76 
2016 Mohanty63 IND 2 P 128 N 0 I E 13.3 Mortality 
ICU/IRVS 
SCAP (both) 
13.3 
25.0 
28.1 
59 
69 
67 
66 
71 
74 
0.78 
0.87 
0.87 
2016 Zhang51 SGP 1 P 1902 Y 0 I I 15.7 Mortality 15.7 33 87 0.71 
2017 Shehata52 EGY 1 P 250 Y 0 I I 11.2 Mortality 
ICU 
11.2 
29.6 
54 
30 
80 
81 
0.71 
0.55 
Country codes are United Nations standard reference. Dashes indicate data unavailable. NFR = not for resuscitation, NHR = nursing home resident, E = excluded, I = 
included, Sens = sensitivity, Spec = specificity, AUROC = area under receiver operating curve, ICU = intensive care unit, IRVS = invasive respiratory or vasoactive support. 
Shindo54 enrolled ‘pneumonia in patients carrying out activities of daily living’ – 24% were NHR. Age limits for patients in Chalmers29, Ochoa-Gondar37, Xiao60 
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Table 6. 7: Studies assessing the SMARTCOP score 
Year First Author Country 
(UN code) 
Site 
No. 
Prospective/ 
Retrospective 
n Consecutive 
(Y/N) 
Outpatients 
(%) 
NFR 
(E/I) 
NHR 
(E/I) 
Mort. 
(%) 
Endpoint Endpoint 
prevalence 
Sens 
(%) 
Spec 
(%) 
AUROC 
2008 Charles (deriv.)8 AUS 6 P 882 N 1.5 E I 5.7 IRVS 10.3 92.3 62.3 0.87 
2008 Chalmers29 GBR 1 P 335 Y 0 E I 1.5 IRVS 9.9 85 82 0.87 
2009 Brown56 USA 1 Retro 2413 N 36 E E 3.7 IRVS in ICU 12.3 - - 0.83 
2009 Lim64 SGP 1 P 250 Y 0 E I 12.1 Mortality 
ICU 
12.1 70 
74 
76 
90 
- 
- 
2010 Davis65 AUS 1 P 184 N 0 E I 8.7 IRVS 21 71 69 0.75 
2010 Dusemund36 CHE 6 P 925 N 7.5 I I 5.4 Mortality 
ICU 
5.4 
- 
- 
- 
- 
- 
0.84 
0.83 
2011 Chalmers38 GBR 1 P 1062 Y - E I 4.5 Mortality 
ICU 
4.5 
7.6 
75 
79 
74 
79 
0.79 
0.85 
2011 Fukuyama39 JPN 1 P 505 Y 0 I E 6.5 Mortality / IRVS 
ICU 
Mortality 
11.9 
6.2 
6.5 
96 
100 
93 
50 
46 
45 
- 
- 
- 
2012 Robbins-Browne40 AUS 1 P/R 367 N 22.0 E I 3.0 IRVS 10.1 97 71 0.89 
2012 Labarere41 CHE 6 Retro 850 N 8.6 I E 4.7 ICU (in 3 days) 7.5 61 74 0.75 
2013 Ribeiro45 PRT 1 R 142 N 0 - - 1.4 Mortality 
ICU  
1.4 
15.5 
100 
82 
68 
76 
0.88 
0.85 
2015 Alici48 TUR 1 P 84 N 0 I E 7.1 IRVS 
Mortality 
16.7 
7.1 
100 
100 
54 
49 
0.94 
0.92 
2015 Naderi49 IRN 1 P 120 N 0 I I 23.6 Mortality 23.6 84 70 0.82 
2016 Liu50 CHN 
ITA 
1 
1 
Retro 
P 
1640 
704 
Y 0 I I 8.5% 
- 
Mortality 
Mortality 
8.5 
- 
- 
- 
- 
- 
0.79 
0.72 
2016 Mohanty63 IND 2 P 128 N 0 I E 13.3 Mortality 
ICU/IRVS 
SCAP (both) 
13.3 
25.0 
28.1 
100 
97 
97 
32 
35 
38 
0.85 
0.89 
0.88 
Country codes are United Nations standard reference. Dashes indicate data unavailable. NFR = not for resuscitation, NHR = nursing home resident, E = excluded, I = 
included, Sens = sensitivity, Spec = specificity, AUROC = area under receiver operating curve, ICU = intensive care unit, IRVS = invasive respiratory or vasoactive support. 
Other comments as for tables above. 
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Table 6. 8: Studies assessing the CURXO score 
Year First Author (ref) Country Site 
No. 
Prospective/ 
Retrospective 
n Consecutive 
(Y/N) 
Outpatients 
(%) 
NFR 
(E/I) 
NHR 
(E/I) 
Mort. 
(%) 
Endpoint Endpoint 
prevalence 
Sens 
(%) 
Spec 
(%) 
AUROC 
2006 Espana (deriv.)6 ESP 1 P 1057 Y 38.1 E I 9.1 Mortality / IRVS 11.5 92 74 0.83 
2009 Yandiola31 ESP 3 P 671 Y 0 I E 3.7 ICU 8.5 81 68 0.75 
2009 Brown56 USA 1 R 2413 N 36 E E 3.7 IRVS in ICU 12.3 - - 0.83 
2010 Espana33 ESP 3 P 712 Y 0 I I 6.7 Mortality 30d 6.7 77 65 0.75 
2011 Chalmers38 GBR 1 P 1062 Y - E I 4.5 Mortality 
ICU 
4.5 
7.6 
94 
94 
54 
56 
0.74 
0.75 
2011 Fukuyama39 JPN 1 P 505 Y 0 I E 6.5 Mortality / IRVS 
ICU 
Mortality 
11.9 
6.2 
6.5 
98 
94 
97 
39 
35 
35 
- 
- 
- 
2012 Labarere41 CHE 6 Retro 850 N 8.6 I E 4.7 ICU (3 days) 7.5 61 70 0.74 
2013 Ribeiro45 PRT 1 R 142 N 0 - - 1.4 Mortality 
ICU  
1.4 
15.5 
100 
91 
51 
58 
0.95 
0.85 
2016 Mohanty63 IND 2 P 128 N 0 I E 13.3 Mortality 
ICU/IRVS 
SCAP (both) 
13.3 
25.0 
28.1 
100 
94 
94 
35 
34 
38 
0.92 
0.94 
0.96 
Country codes are United Nations standard reference. Dashes indicate data unavailable. NFR = not for resuscitation, NHR = nursing home resident, E = excluded, I = 
included, Sens = sensitivity, Spec = specificity, AUROC = area under receiver operating curve, ICU = intensive care unit, IRVS = invasive respiratory or vasoactive support. 
Other comments as for tables above. 
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Table 6. 9: Studies assessing IDSA/ATS 2007 minor criteria 
Year First Author (ref) Country Site 
No. 
Prospective/ 
Retrospective 
n Consecutive 
(Y/N) 
Outpatients 
(%) 
NFR 
(E/I) 
NHR 
(E/I) 
Mort. 
(%) 
Endpoint Endpoint 
prevalence 
Sens 
(%) 
Spec 
(%) 
AUROC 
2009 Brown56 USA 1 Retro 2413 N 36 E E 3.7 IRVS in ICU 12.3 54 95 0.88 
2009 Phua32 SGP 1 P 1242 
1017 
N 0 I 
E  
I 14.7 Mortality 
ICU 
14.7 81 
58 
83 
91 
0.88 
0.85 
2009 Lim64 SGP 1 P 250 Y 0 E I 12.1 Mortality 
ICU 
12.1 63 
49 
84 
95 
- 
- 
2011 Chalmers38 GBR 1 P 1062 Y - E I 4.5 Mortality 
ICU 
4.5 
7.6 
58 
75 
80 
82 
0.78 
0.85 
2012 Labarere41 CHE 6 Retro 850 N 8.6 I E 4.7 ICU (3 days) 7.5 33 92 0.72 
2015 Li61 HKG 1 
2 
Retro 
P 
1230 
1409 
N 
Y 
0 
0 
E 
E 
I 
I 
1.3 
3.8 
Mortality 
Mortality 
1.3 
3.8 
38 
82 
96 
83 
0.81 
0.82 
2015 Naderi49 IRN 1 P 120 N 0 I I 23.6 Mortality 23.6 76 47 0.64 
2016 Mohanty63 IND 2 P 128 N 0 I E 13.3 Mortality 
ICU/IRVS 
SCAP (both) 
13.3 
25.0 
28.1 
82 
88 
86 
58 
65 
67 
0.86 
0.93 
0.93 
Country codes are United Nations standard reference. Dashes indicate data unavailable. NFR = not for resuscitation, NHR = nursing home resident, E = excluded, I = 
included, Sens = sensitivity, Spec = specificity, AUROC = area under receiver operating curve, ICU = intensive care unit, IRVS = invasive respiratory or vasoactive support. 
Patients meeting IDSA/ATS major criteria were excluded in Phua32, Chalmers38, and Labarere41, and included in Brown56, Li61, Naderi49 and Mohanty63.      
 
 
Table 6. 10: Studies assessing the CORB score 
Year First Author (ref) Country Site 
No. 
Prospective/ 
Retrospective 
n Consecutive 
(Y/N) 
Outpatients 
(%) 
NFR 
(E/I) 
NHR 
(E/I) 
Mort. 
(%) 
Endpoint Endpoint 
prevalence 
Sens 
(%) 
Spec 
(%) 
AUROC 
2007 Buising10 
(derivation) 
AUS 1 P 392 Y 13.5 I I 9.4 Mortality/ICU 
ICU 
14.0 
6.6 
72 
81 
70 
68 
0.72 
0.74 
AUS = Australia. NFR = not for resuscitation, NHR = nursing home resident, E = excluded, I = included, Sens = sensitivity, Spec = specificity, AUROC = area under receiver 
operating curve, ICU = intensive care unit, IRVS = invasive respiratory or vasoactive support.
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Assessment of quality and heterogeneity 
Several tools have been devised for use in previous systematic reviews for objective assessment of 
quality and potential for bias in diagnostic and observational studies. Some have been briefly 
discussed in chapter one of this thesis, such as the revised ‘Quality Assessment of Diagnostic 
Accuracy Studies’ (QUADAS-2) tool proposed by Whiting and colleagues [66] and the ‘Quality in 
Prognostic Studies’ (QUIPS) tool described by Hayden et al [67]. There are similarities in the 
assessment criteria prescribed within these tools. A combined framework comprising four 
domains has been adopted for the cumulative quality assessment of the validation studies 
identified for review. 
1. Study sample represents the population of interest. A multicentre, prospective study 
enrolling consecutive unselected ED patients with CAP would provide the least opportunity 
for bias in this domain. Only four of the 52 studies reviewed met these criteria 
[31,33,57,61], although an overall majority (37 studies) were of prospective design. 
Significant heterogeneity was observed in the way investigators defined CAP, and 
particularly how non-community acquired pneumonia (e.g. healthcare-associated, hospital-
associated, immunosuppression-associated) was defined and excluded. Similar comments 
apply regarding exclusion of nursing home patients and patients ‘not for resuscitation’. 
Only one study excluded both nursing home residents and patients not for resuscitation 
[56]. Substantial variation also existed regarding the percentage of outpatients included in 
study populations; most studies (65%) did not include outpatients, with the remainder 
including between 1.5% [8] and 42% [58] outpatients with CAP. Some studies included 
patients only from certain age ranges, for example <50 or ≥65 years of age [29,37,60], and 
others included CAP patients with pneumococcal infection only [25,45]. 
2. Index (severity score) tests consistently applied. Severity scores were consistently applied 
as defined, however some opportunity for bias was identified regarding missing data. Most 
studies provided some information on missing data, but statistical methods utilised to 
account for this varied. Arterial blood gas data were most often missing with a potential to 
introduce bias, as these data were likely present for only the sicker patients. There was 
some variation in the way the IDSA/ATS 2007 criteria were assessed between studies – 
most investigators assessed the minor criteria only, but patients meeting IDSA/ATS major 
criteria were excluded in some [32,38,41] and included in others [49,56,61,63].      
3. Endpoints measured accurately and consistently. Substantial heterogeneity was observed 
regarding study endpoints. Mortality outcomes varied between 28-day, 30-day, 6-week 
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and hospital mortality, and non-mortality outcomes varied between ICU admission, 
invasive therapies (IRVS), and use of invasive therapies in ICU. Variation between ICU 
admission criteria and availability of ICU beds and services in different countries represents 
another potential source of heterogeneity and bias [68]. Earlier studies examining PSI and 
CURB65 scores predominantly defined mortality endpoints, while more recent papers 
assessing performance of SMARTCOP, CURXO and the IDSA/ATS minor criteria have 
reported both mortality and ICU/IRVS endpoints. 
4. Appropriate statistical analysis. This was largely controlled in the study inclusion criteria 
used for this review; only studies which assessed the scores under review and reported 
diagnostic accuracy in terms of either sensitivity/specificity or area under the receiver 
operating curve (AUROC) were eligible for inclusion.  
 
Diagnostic accuracy results 
Several themes were evident from the results of studies included in this review. For PSI and 
CURB65, sensitivity and overall discrimination were high for mortality endpoints. These findings 
concur with those of an early (2010) review [69] in which pooled results from meta-analysis 
estimated AUROC for PSI and CURB65 to be 0.81 and 0.80 respectively. Chen et al [35] also 
demonstrated that diagnostic accuracy for both PSI and CURB65 scores was reduced in patient 
cohort subgroups with advanced age. For prediction of mortality, studies that compared 
performance of PSI and newer scores such as SMARTCOP, CURXO and ISDA/ATS 2007 minor 
criteria found old and new scores to have similar overall discrimination [32,33,38]. 
 
Identified review studies spanned 1999 to 2017, and over that time a clear general shift in study 
endpoints was apparent. Earlier studies all assessed diagnostic performance of scores with 
mortality endpoints, whereas more recent studies have not only focussed on newer scores, but 
also prioritised clinical endpoints such as ICU admission and receipt of invasive therapies (IRVS), 
with or without mortality. For prediction of ICU admission or IRVS, SMARTCOP was assessed by 12 
studies. The two largest of these recruited 2413 [56] and 1062 [38] patients, and found both 
sensitivity and specificity approximately 80% and AUROC 0.83-0.85. The seven studies that 
assessed CURXO for prediction of ICU/IRVS found sensitivity generally higher (mostly over 90%) 
but with reduced specificity (34-56%) and similar AUROC (0.82-0.85). Use of the IDSA/ATS minor 
criteria to predict ICU/IRVS was investigated in six papers, finding strong discrimination (AUROC 
0.85-0.93). 
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The predictive ability of PSI for ICU admission was assessed in 11 papers, with most reporting 
mediocre AUROC values of 0.58-0.65. A 2012 systematic review [70] also found that more recently 
derived scores such as SMARTCOP, CURXO and IDSA/ATS 2007 had superior discrimination for 
prediction of ICU admission than the older scores PSI and CURB65. It must be acknowledged that 
PSI and CURB65 were developed to predict mortality, and prediction of requirement for invasive 
support is a substantially different function [71]. The divergence between these endpoints is likely 
to be more marked in health care systems with fewer ICU resources and more pragmatic 
cost/benefit approaches to ICU admission for patients with high baseline dependence and poor 
quality of life. In the United Kingdom, for example, there are markedly fewer ICU beds per head of 
population [68], and elderly patients with multiple comorbidities are much less likely to be 
admitted to ICU compared to those in the USA [72]. In these circumstances, it would be expected 
that CAP severity scores would perform differently in prediction of ICU admission compared to 
mortality endpoints. Supporting this proposition, Chalmers and colleagues [38] reported AUROC 
for older scores (PSI and CURB65) higher than for newer scores (SMARTCOP, IDSA/ATS) for 
prediction of mortality, and vice versa for prediction of ICU admission in their 2011 study of 1062 
British patients admitted with pneumonia. Unfortunately, no identified North American studies 
examined performance severity scores in prediction of both mortality and ICU admission 
endpoints. The (known and unknown) variations in ICU bed availability and ICU admission 
practices between countries and health-care systems adds yet another layer of heterogeneity that 
confounds interpretation of the available international literature examining performance of CAP 
severity scores. 
 
No papers were identified that attempted to assess the utility of low CAP severity scores for 
prediction of brief hospital admission. 
 
Review Summary and Conclusions 
1. Despite identification of over fifty studies examining diagnostic accuracy of CAP severity 
scores, substantial heterogeneity in settings, patient identification/characteristics and 
endpoints limits conclusions beyond the broad findings summarised above. 
2. Studies enrolling prospective cohorts of consecutive emergency patients admitted with 
CAP comprise less than half of the identified papers. More studies of this type are required. 
159 
 
 
3. Several papers sought to determine diagnostic accuracy in a cohort of patients eligible to 
receive invasive therapies. However just one previous study excluded both nursing home 
patients and patients with limitations to treatment in the ED [56]. Further analysis using 
cohorts with these characteristics would help to inform practical decision-making at the 
bedside [73]. 
4. Diagnostic accuracy of low severity scores for prediction of brief hospital admission has not 
yet been investigated. The benefits of brief admission in terms of cost, morbidity and 
potentially mortality [74] make investigation of this aspect of CAP severity score usage a 
priority. 
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6.3.1 – Abstract 
 
Objective: To assess community acquired pneumonia severity scores from two perspectives: (i) 
prediction of ICU admission or mortality, and (ii) utility of low scores for prediction of discharge 
within 48 hours, potentially indicating suitability for short-stay unit admission.  
 
Methods: Patients with community acquired pneumonia were identified from a prospective 
database of emergency patients admitted with infection. Pneumonia severity index (PSI), CURB65, 
CORB, CURXO, SMARTCOP scores and the Infectious Diseases Society of America / American 
Thoracic Society (IDSA/ATS) minor criteria were calculated. Diagnostic accuracy statistics 
(sensitivity, specificity, predictive values, likelihood ratios and area under receiver operating 
characteristic curves [AUROC]) were determined for both endpoints. 
 
Results: Of 618 patients admitted with community-acquired pneumonia judged eligible for 
invasive therapies, 75 (12.1%) were admitted to ICU or deceased at 30 days, and 87 (14.1%) were 
discharged within 48 hours. All scores effectively stratified patients into categories of risk. For 
prediction of severe pneumonia, SMARTCOP, CURXO and IDSA/ATS discriminated well (AUROC 
0.84–0.87). SMARTCOP and CURXO showed optimal sensitivity (85% [95% confidence interval (CI) 
75–92%]), while specificity was highest for CORB and CURB65 (93% and 94%, respectively). Using 
lowest risk categories for prediction of discharge within 48 hours, only SMARTCOP and CURXO 
showed specificity >80%. PSI demonstrated highest positive predictive value (31% [95% CI 24–
39%]) and AUROC (0.74 [95%CI 0.69–0.79]).       
 
Conclusions: Community-acquired pneumonia severity scores had different strengths; SMARTCOP 
and CURXO were sensitive with potential to rule out severe disease, while the high specificity of 
CORB and CURB65 facilitated identification of patients at high risk of requirement for ICU. Low 
severity scores were not useful to identify patients suitable for admission to short-stay units.  
 
 
Key words: clinical decision making, emergency medicine, pneumonia, prognosis. 
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6.3.2 – Introduction 
 
Community-acquired pneumonia (CAP) is a common condition with substantial associated 
morbidity and mortality [1]. After initial diagnosis and commencement of therapy, a key 
determination in the management of emergency department (ED) patients with CAP is the 
appropriate location for ongoing care. For patients were severe CAP, delayed admission to ICU is 
associated with worse outcomes [2]. Conversely, identification of low-risk patients suitable for 
outpatient treatment is crucial; inpatient treatment is over twenty times the cost of community-
based care [3], and increasing cost and morbidity are directly associated with hospital length of 
stay [4,5]. Selected low-risk patients may be suitable for admission to an ED short-stay unit, 
facilitating early discharge. Accurate risk stratification of ED patients with CAP can optimise 
decisions regarding location of further treatment with potential reductions in morbidity, mortality, 
and costs.      
 
A range of CAP severity scores exists [6-11]. Australian guidelines [12] recommend the use of 
SMARTCOP [11] or CORB [9] for identification of patients with severe disease at greater risk of 
requirement for invasive therapies and mortality. Neither score has been externally validated in 
ED patients from non-tropical Australia. Other systems such as  CURB65 [7], CURXO (also known as 
‘S-CAP’ or ‘Espana rule’) [8] and IDSA/ATS 2007 (Infectious Disease Society of America/American 
Thoracic Society guidelines 2007) [10] are recommended for identification of high-risk patients in 
Britain, Europe and North America respectively. Performance of the latter scores in Australian 
patients has not been assessed. 
 
Admission to an emergency department short stay unit is increasingly recognised as a suitable 
alternative for patients likely to be discharged within a short time frame. Because discharge 
planning is implicit with admission to a short stay unit, length of stay (LOS) in hospital and 
associated costs can be reduced [13]. The application of severity scores to determine the 
suitability of patients with low-risk CAP for admission to short stay units remains unexplored to 
date.  
 
The goal of the present study was to evaluate and compare risk stratification performance of 
established severity scores in a prospective cohort of consecutive ED patients admitted with CAP 
and eligible for invasive therapies. There were two aims, each relevant to disposition decisions: to 
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assess (i) the utility of high scores for prediction of severe CAP (ICU admission or death), and (ii) 
the utility of low scores for prediction of admission of ≤48 hours, thus potentially identifying 
patients suitable for admission to an ED short stay unit. 
 
6.3.3 – Methods 
 
Study design and setting 
This was a pre-planned study using a prospective observational database of ED patients admitted 
with infection. The setting was a tertiary, university-affiliated adult hospital in Australia, with 
annual census over 70,000 presentations. Approval was obtained from the hospital Human 
Research Ethics Committee. 
 
Participants 
Methods used for enrolment of patients in the parent database have been described previously 
[14] and are outlined as follows. Patients were included if admitted from the ED with presumed 
infection of any kind. Patients were excluded if they were aged less than 17 years or transferred 
from another hospital. Consecutive eligible patients were identified daily. Patients were enrolled 
over two periods, October 2007 – December 2008 (unfunded pilot), and June 2009 – May 2011 
(funded data collection) totalling 162 weeks. The period of data collection was determined by 
available funding.  
 
Subjects from the parent database were included in the current analysis if they met criteria for 
CAP, defined for study purposes as (i) lower respiratory tract source plus consolidation on CXR, 
and (ii) not associated with immunosuppression or hospital admission in the previous 30 days.  
Immunosuppression was defined as current use of systemic corticosteroids or other 
immunosuppressive drugs, chemotherapy within the last six weeks, organ transplantation, HIV, 
splenectomy or IV drug use. Nursing home residents (NHR) and patients determined ‘not for 
resuscitation’ (NFR) in the ED were excluded, to identify a study cohort of CAP patients judged 
eligible for invasive therapies at the time of ED assessment. 
 
Outcomes 
Two discrete endpoints were defined. First, a composite endpoint of either ICU admission or 30-
day mortality was used to define ‘severe pneumonia’ for study purposes. At the study hospital, 
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patients with pneumonia were generally accepted for ICU admission only if invasive therapies 
were already instituted or highly likely to be required. Mortality was included in the composite 
‘severe pneumonia’ endpoint because identification in the ED of patients at risk of subsequent 
mortality during admission might enable earlier discussion of suitability for ICU admission. Second, 
discharge within 48 hours of ED presentation (without death or readmission at 30 days) was used 
to define ‘mild pneumonia’, potentially suitable for brief admission to an ED or general medical 
short stay unit. 
 
Methods and Measurements 
Within the parent database, detailed data regarding the most abnormal physiology, investigation 
results and therapeutic interventions in the ED were recorded for each patient, together with 
comorbidities and LOS in hospital and ICU where applicable. Mortality outcomes were sourced 
from a national death registry. The database was designed to comply with requirements of the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement [15]. 
The parent database included information required for the calculation of the following CAP 
severity scores: PSI [6], CURB65 [7], CURXO [8], CORB [9], ATS/IDSA 2007 guideline [10] and 
SMARTCOP [11] (components of these scores have been summarised in Supplementary Tables 1–
5, presented within this thesis as Tables 6.14 – 6.19). While data for computation of the scores 
were collected prospectively, the scores were calculated retrospectively.  
 
For each CAP severity score, diagnostic accuracy was determined for prediction of ‘severe 
pneumonia’ using standard published thresholds: PSI class IV–V, CURB65 ≥ 3, CURXO ≥10 (one 
major or two minor criteria), CORB ≥2 and SMARTCOP ≥3. For the IDSA/ATS guideline, only the 
minor criteria were assessed (threshold ≥3), as the major criteria (mechanical ventilation and 
vasopressor support) would normally present a clear indication for ICU admission. This approach 
has been adopted previously [16,17]. Diagnostic accuracy of the lowest severity class for each 
score was then assessed for prediction of discharge within 48 hours. These thresholds were PSI 
class I, CURXO score ≤4 (no major or minor criteria), no major or minor IDSA/ATS criteria and a 
score of zero points for CURB65, CORB and SMARTCOP. 
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Data analysis 
Analyses were performed using Stata version 14 (StataCorp, 2015, College Station, TX, USA). 
Baseline characteristics of the study sample were reported by the composite endpoint of 30-day 
mortality or ICU admission. Pearson χ2-test or Fisher’s exact test was used to compare categorical 
variables where expected cell sizes were >5 or ≤5, respectively. The Mann–Whitney U test was 
used to compare continuous variables. Patient outcomes (median LOS, discharge within 48 hours 
[without death or readmission at 30 days], admission to ICU and 30-day mortality) were reported 
for classes of pneumonia severity as defined by each score. The area under receiver operating 
characteristic curve (AUROC) was computed for each score using a non-parametric method,  and 
AUROC pairs were compared using the algorithm suggested by DeLong et al [18].  
 
Diagnostic accuracy statistics (sensitivity, specificity, predictive values and likelihood ratios [LR]) 
for each of the scoring systems were reported for prediction of two endpoints: (i) ICU admission or 
30-day mortality (‘severe pneumonia’), and (ii) discharge within 48 hours, without death or 
readmission within 30 days (‘mild pneumonia’). In primary analyses, missing values were assumed 
within normal ranges for computation of pneumonia severity scores; this approach was 
considered to be a valid representation of severity score use in the clinical context. The one 
exception was use of pulse oximetry (SpO2) values of <90% in place of missing arterial blood gas 
values to denote hypoxia in the CURXO and IDSA/ATS scores. Similar approximations are officially 
incorporated into the other two scores that utilise blood gas data (PSI and SMARTCOP). To 
determine whether the general assumption of normality resulted in biased estimates, a sensitivity 
analysis was conducted in which diagnostic accuracy statistics and AUROC analyses were 
recalculated using multiple imputation of missing data. Imputed values were derived using those 
components of each score with complete data, the outcome variable of interest and any of the 
following variables that were not included in the score: age, gender, SpO2 (>95%, 90–95% or 
<90%), and systolic blood pressure (≥90 or <90 mmHg). Truncated regression or ordinal logistic 
regression was conducted as appropriate for each score and 50 imputed data sets were utilised. 
 
6.3.4 – Results 
 
Over the three-year study period, 1091 patients were admitted from the ED with suspected lower 
respiratory tract infection and consolidation reported on CXR. After exclusion of 473 patients 
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(immunosuppression, recent hospitalisation, NHR and NFR), 618 patients with CAP and presumed 
eligible for invasive therapies remained for inclusion in the study cohort (Figure 6.2).  
 
The median age of the study cohort was 56 years and 54% were male. Median hospital LOS was 6 
days (inter-quartile range [IQR] 3-10 days), and 30-day mortality was 2.2% (13 deaths). Table 6.11 
lists these and other characteristics of the study cohort. A total of 75 patients (12%) met the 
combined ‘severe CAP’ endpoint, comprising 64 patients admitted to ICU and 11 patients 
deceased after NFR orders were imposed after admission to the wards (median time to death for 
these 11 patients was 15 days). A total of 87 patients (14%) met ‘mild CAP’ criteria (discharge 
within 48 hours without death or readmission at 30 days). Figure 6.2 shows both the derivation of 
the study cohort and flow of patients through the study. The proportions of patients meeting each 
study endpoint according to severity scores are detailed in Table 6.12. All scores were found to 
effectively stratify patients according to hospital LOS and risk of severe disease.  
 
Table 6.13 summarises the diagnostic accuracy statistics for prediction of ‘severe CAP’ and ‘mild 
CAP’ endpoints. Sensitivity for prediction of severe CAP was >80% for SMARTCOP and CURXO only; 
negative LRs for these scores were 0.2 and 0.3 respectively (95% confidence interval [CI] 0.1-0.4 
for both). CORB and CURB65 showed highest specificity (93% and 94% respectively), with 
corresponding positive LRs of 6.0 (95% CI 4.0-8.9) and 4.6 (95% CI 2.8-7.5) respectively. For 
prediction of discharge within 48 hours, SMARTCOP, CURXO, PSI and IDSA/ATS all showed 
acceptable specificity (>75%). However no score produced a positive LR >3 (highest was PSI class I: 
2.7 [95% CI 2.1-3.5]). 
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Figure 6. 2: Derivation of the study cohort and flow of patients through the study 
 
ICU = intensive care unit. Patients meeting the ‘severe CAP’ endpoint comprised the 64 admitted to ICU and 
a further 11 patients never admitted to ICU but deceased within 30 days. The ‘mild CAP’ endpoint was met 
by 87 patients who were discharged within 48 hours without death or re-admission in the next 30 days. 
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Table 6. 11: Characteristics of the study cohort 
 
Total   
n=618 
No ICU 
admission 
and alive at 
30 days 
n=543  
ICU 
admission   
or deceased 
within 30 
days 
n=75 
p 
Demographics and comorbidities     
Age, median (IQR) 56 (39-75) 56 (39-76) 54 (38-67) 0.23 
Male, n (%) 336 (54) 286 (53) 50 (67) 0.02 
Chronic lung disease, n (%) 199 (32) 168 (31) 31 (41) 0.07 
Heart disease, n (%) 120 (19) 103 (19) 17 (23) 0.45 
Diabetes, n (%) 80 (13) 66 (12) 14 (19) 0.12 
Malignancy, n (%) 51 (8) 44 (8) 7 (9) 0.72 
Charlson score, median (IQR) 1 (0-2) 1 (0-2) 1 (0-3) 0.09 
Severity of illness in ED     
Respiratory failure, n (%) 199 (32) 143 (26) 56 (75) <0.001 
Invasive ventilation, n (%) 11 (2) 0 (0) 11 (15) <0.001 
Shock, n (%) 21 (3) 6 (1) 15 (20) <0.001 
Lactate (mmol/L), median (IQR)† 1.6 (1.1-2.4) 1.5 (1.1-2.2) 2.1 (1.3-3.1) <0.001 
Blood culture positive, n (%) 34 (6) 19 (3) 15 (20) <0.001 
APACHE II, median (IQR) 8 (5-12) 7 (5-11) 14 (9-20) <0.001 
Outcomes 
    Hospital LOS (days), median (IQR)  6 (3-10) 5 (3-9) 13 (7-21) 0.001 
Discharged alive ≤48 hours, n (%)  87 (14) 86 (16) 1 (1) <0.001 
Admitted to ICU, n (%) 64 (10) 0 (0) 64 (85) <0.001 
Deceased at 30 days, n (%) 14 (2) 0 (0.0) 14 (19) <0.001 
Pneumonia severity scores, median (IQR)     
PSI  68 (41-96) 66 (39-90) 94 (66-125) <0.001 
CURB-65 1 (0-2) 1 (0-2) 2 (1-3) <0.001 
CORB 0 (0-1) 0 (0-1) 1 (1-2) <0.001 
CURXO (points) 6 (5-15) 5 (0-11) 22 (11-32) <0.001 
SMARTCOP  2 (1-4) 2 (1-3) 5 (3-7) <0.001 
Number of IDSA/ATS minor criteria 1 (0-2) 1 (0-2) 3 (2-4) <0.001 
 
IQR = Inter-quartile range, ICU=intensive care unit. APACHE = acute physiology and chronic health 
evaluation, LOS = length of stay, Respiratory failure and shock correspond to sequential organ function 
assessment (SOFA) ≥2. †n=382 
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Table 6. 12: Outcomes stratified by severity scores 
Severity score and class 
Totals 
Median 
length of 
stay, days 
(IQR) 
Discharged 
≤48 hours        
(n = 87) 
n (row %) 
ICU 
admission 
(n=64) 
n (row %) 
30-day 
mortality 
(n = 14) 
n (row %) 
30d 
mortality 
and/or ICU        
(n = 75) 
n (row %) 
Pneumonia Severity Index       
I 158 3 (2-6) 49 (31) 5 (3) 0 (0) 5 (3) 
II 171 5 (3-8) 27 (16) 18 (11) 1 (1) 19 (11) 
III 113 7 (4-11) 5 (4) 10 (9) 0 (0) 10 (9) 
IV 129 9 (5-21) 3 (2) 19 (15) 5 (4) 23 (18) 
V 47 8 (5-15) 3 (6) 12 (26) 8 (17) 18 (38) 
CURB-65 score groups       
0 points 240 4 (2-7) 66 (28) 11 (5) 1 (0) 12 (5) 
1 (0-1 points) 434 5 (3-9) 79 (18) 31 (7) 3 (1) 33 (8) 
2 (2 points) 130 7 (5-14) 8 (6) 16 (12) 6 (5) 21 (16) 
3 (3-5 points) 54 11 (6-22) 0 (0) 17 (31) 5 (9) 21 (39) 
CORB score groups       
0 points 405 5 (3-9) 77 (19) 14 (3) 4 (1) 18 (4) 
1 (0-1 points) 545 6 (3-10) 86 (16) 33 (6) 10 (2) 42 (8) 
2 (2 points) 49 7 (5-17) 1 (2) 17 (35) 0 (0) 17 (35) 
3 (3, 4 points) 24 10 (6-15) 0 (0) 14 (58) 4 (17) 16 (67) 
CURXO       
No major or minor 139 4 (2-7) 40 (29) 0 (0) 0 (0) 0 (0) 
SCAP (≥1 major or ≥2 minor) 297 7 (5-14) 18 (6) 54 (18) 13 (4) 64 (22) 
IDSA/ATS 2007       
NO major or minor 166 4  (2-7) 44 (27) 1 (1) 0 (0) 1 (1) 
≥3 minor 110 9 (6-18) 3 (3) 40 (36) 7 (6) 45 (41) 
≥4 minor 
44 
10.5 (6.5-
23) 
0 (0) 23 (52) 5 (11) 26 (59) 
SCAP (≥1 major or ≥3 minor) 113 9 (6-17) 3 (3) 42 (37) 7 (6) 47 (42) 
SMARTCOP       
0 points 93 4 (2-7) 24 (26) 0 (0) 0 (0) 0 (0) 
low risk for IRVS (0-2 points) 372 5 (3-9) 70 (19) 6 (2) 5 (1 ) 11 (3) 
moderate (3-4 points) 141 6 (3-9) 13 (9) 9 (6) 4 (3) 13 (9) 
high (5-6 points) 78 7.5 (5-18) 4 (5) 28 (36) 2 (3) 29 (37) 
very high (≥7 points) 27 10 (6-24) 0 (0) 21 (78) 3 (11) 22 (81) 
 
IQR = inter-quartile range, ICU=intensive care unit, SCAP = severe community-acquired pneumonia, IRVS = 
invasive respiratory or vasopressor support 
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Table 6. 13: Predictive performance of scores 
A) Prediction of ICU admission or 30-day mortality 
 
Model (scores) 
n = 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
PSI (classes IV-V) 176 
55% 
(43-66%) 
75% 
(71-79%) 
23%  
(17-30%) 
92% 
(89-95%) 
2.2 
(1.7-2.8) 
0.6 
(0.5-0.8) 
CURB-65 (3-5) 54 
28% 
(18-49%) 
94% 
(92-96%) 
39% 
(26-53%) 
90% 
(88-93%) 
4.6 
(2.8-7.5) 
0.8 
(0.7-0.9) 
CORB (2-4) 73 
44% 
(33-56%) 
93% 
(90-95%) 
45% 
(34-57%) 
92% 
(90-94%) 
6.0 
(4.0-8.9) 
0.6 
(0.5-0.7) 
CURXO (≥10)  
(≥1 major or ≥2 minor) 
297 
85% 
(75-92%) 
57% 
(53-61%) 
22% 
(17-27%) 
97% 
(94-98%) 
2.0 
(1.7-2.3) 
0.3 
(0.1-0.4) 
IDSA/ATS  
(≥3 minor) 
110 
60% 
(48-71%) 
88% 
(85-91%) 
41% 
(32-51%) 
94% 
(92-96%) 
5.0 
(3.7-6.7) 
0.5 
(0.3-0.6) 
SMARTCOP (≥3) 246 
85% 
(75-92%) 
66% 
(62-70%) 
26% 
(21-32%) 
97% 
(95-99%) 
2.6 
(2.2-3.0) 
0.2 
(0.1-0.4) 
 
B) Prediction of discharge within 48 hours without death or readmission at 30 days 
 
Model (scores) 
n = 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
LR+ 
(95% CI) 
LR- 
(95% CI) 
PSI (class I) 158 
56% 
(45-67%) 
79% 
(76-83%) 
31% 
(24-39%) 
92% 
(89-94%) 
2.7 
(2.1-3.5) 
0.5 
(0.4-0.7) 
CURB-65 (0) 240 
76% 
(66-84%) 
67% 
(63-71%) 
28% 
(22-34%) 
94% 
(92-97%) 
2.3 
(2.0-2.7) 
0.4 
(0.2-0.5) 
CORB (0) 405 
89% 
(80-94%) 
38% 
(34-43%) 
19% 
(15-23%) 
95% 
(92-98%) 
1.4 
(1.3-1.6) 
0.3 
(0.2-0.5) 
CURXO (≤4) 
(no major or minor) 
139 
46% 
(35-57%) 
81% 
(78-85%) 
29% 
(21-37%) 
90% 
(87-93%) 
2.5 
(1.9-3.3) 
0.6 
(0.5-0.8) 
IDSA/ATS  
(no major or minor) 
166 
51% 
(40-61%) 
77% 
(73-81%) 
27% 
(20-34%) 
90% 
(87-93%) 
2.2 
(1.7-2.9) 
0.6 
(0.5-0.8) 
SMARTCOP (0) 93 
28% 
(19-38%) 
87% 
(84-90%) 
26% 
(17-36%) 
88% 
(85-91%) 
2.1 
(1.4-3.2) 
0.8 
(0.7-1.0) 
 
ICU=Intensive Care Unit, PPV = positive predictive value, NPV = negative predictive value, LR+ = positive 
likelihood ratio, LR- = negative likelihood ratio, CI = confidence interval. 
 
Figure 6.3 displays overall discrimination using AUROC for each score for predicting ‘severe CAP’ 
(panel A) and ‘mild CAP’ (panel B). For prediction of severe CAP, discrimination was highest for 
SMARTCOP, CURXO and IDSA/ATS (AUROC 0.84-0.87), with no significant difference between 
values for these scores (all AUROC comparisons are shown in Supplementary Tables 6 and 7, 
labelled 6.19 and 6.20 in this thesis). Discrimination for prediction of discharge within 48 hours 
was poor, with AUROC ranging from 0.64 to 0.74.  
 
 
 
 
171 
 
 
Figure 6. 3: Receiver operating characteristic (ROC) curves 
 
Panel A: prediction of ‘severe community acquired pneumonia’ (intensive care admission or death), panel 
B: prediction of discharge within 48 hours (and remaining alive at 30 days). AUROC = area under receiver 
operating characteristic curve, CI = confidence interval. Large symbols indicate established (A) or proposed 
(B) operating points. 
 
Data were missing in <1% of patients for all score variables except pH and arterial blood gas values 
(missing in 49.0% and 64.5% of cases, respectively). Pulse oximetry (SpO2) values were recorded 
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for all patients. Results after multiple imputation were similar to those reported for the primary 
analyses and are provided in Supplementary Tables 8 and 9 (thesis Tables 6.21 and 6.22). 
 
6.3.5 – Discussion 
 
Early identification of patients with severe CAP is essential to prompt discussion regarding ICU 
admission or potential mortality with patients and family. For identification of ‘severe CAP’, 
SMARTCOP, CURXO and IDSA/ATS showed good overall discrimination (AUROC 0.84–0.87). 
SMARTCOP and CURXO had good sensitivity (85%) and negative LR (0.2 and 0.3, respectively), 
while specificity and positive LR were highest for CORB and CURB-65. For prediction of discharge 
within 48 hours, diagnostic performance of CAP severity scores was poor. 
 
Interpretation of the considerable literature examining CAP severity scores is confounded by 
heterogeneity in settings, inclusion and exclusion criteria and outcomes between validation 
studies [19, 20]. Previous Australian studies have assessed several scores. Buising and colleagues 
evaluated PSI and CURB-65,21 and later derived CORB9 in a single-centre cohort of 392 ED 
patients with CAP. For prediction of combined death and/or ICU admission, predictive values and 
AUROC for PSI and CURB-65 (0.71 and 0.76, respectively) well approximated those reported in the 
present study. Acknowledging PSI and CURB-65 were derived to predict mortality, Charles et al. 
[11] derived the SMARTCOP score to predict requirement for invasive therapies (invasive 
respiratory or vasopressor support [IRVS]) using a multicentre Australian cohort of ED patients 
with CAP determined suitable for active treatment. In that study, a SMARTCOP score of ≥3 
correctly identified 92% of patients ultimately receiving IRVS, and misclassified 37.7% of patients 
not requiring IRVS, with AUROC 0.87. The present study examined a cohort of patients presumed 
in the ED to be suitable for invasive therapies (NHR and NFR patients were excluded), but defined 
a composite end-point of ICU admission or death to include patients deceased on the ward 
without ICU admission. In that context, SMARTCOP sensitivity and AUROC were similar (85% and 
0.87, respectively; Table 6.13, Fig. 6.3). A study performed in Darwin Hospital [22] found 
SMARTCOP effective to rule out severe disease (sensitivity 97%, NPV 99.6%, AUROC 0.89) and 
CORB ≥2 potentially useful to rule in severe disease, with specificity 92%. Our findings in a 
temperate Australian setting are similar (SMARTCOP with negative LR 0.2 and CORB with highest 
positive LR 6.0). Desirable operating characteristics of a CAP severity score will vary according to 
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context and nature of the clinical decision supported. A sensitive score (such as SMARTCOP) may 
be useful in the ED to identify a larger group of patients at higher likelihood of requiring ICU, 
either for early senior attention in the ED or referral to an ICU outreach service for review on the 
ward. In this regard, our analysis shows that the SMARTCOP score is superior to most and 
equivalent to the best performing similar scores used elsewhere. It confirms that in Australia, 
SMARTCOP remains effective as a screening tool for patients that may require ICU, and patients 
that should be assessed for suitability to go to ICU in the event of deterioration later in their 
admission. More specific scores such as CURB-65 and CORB provide greater certainty that ICU 
level support will be required and could be utilised during referral for admission to that service. 
 
The present study is the first to assess the performance of CURXO and the IDSA/ATS minor criteria 
in Australia. CURXO sensitivity and AUROC (85%, 0.84) were very similar to those in the Spanish 
CURXO derivation study (92%, 0.83), likely due to the similarity between cohorts and end-points 
(ICU admission or mortality) [8]. Several previous investigators have assessed the IDSA/ATS minor 
criteria, but results have varied widely depending on inclusion or otherwise of patients meeting 
major criteria (effectively IRVS) and definition of severe CAP [23, 24]. In the present study 
IDSA/ATS minor criteria showed good overall discrimination (AUROC 0.84) and specificity, with 
useful positive LR (5.0). 
 
The present study was the first to explore the utility of low CAP severity scores for identifying 
patients discharged within 48 hours of admission, as a surrogate for suitability for admission to an 
ED short-stay unit. In contrast to prediction of severe CAP, specificity (together with positive 
predictive value and positive LR) may be desirable characteristics of a score used to determine 
which ED patients with CAP are suitable for short-stay admission to avoid inefficiencies associated 
with secondary referrals. Only 25–30% of patients in the lowest risk categories of most scores 
were discharged within 48 hours, with optimal performance with PSI class I (positive predictive 
value 31%) (Table 6.13). Median hospital LOS for low-risk patients ranged between 3 and 5 days, 
with similar figures reported in other studies [25, 26]. Characteristics such as hypoxia, failure of 
outpatient therapy, homelessness and social disadvantage have been found to be associated with 
admission of ‘low-risk’ CAP patients [27, 28] and our data suggests that these features generally 
may not resolve within 48 hours for most patients. Previous investigators have developed general 
short-stay admission decision tools [29] and examined characteristics associated with failure of 
short-stay admission for ED patients with infection [30]. Both avenues of enquiry have identified 
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advanced age, comorbidity and dependence as factors associated with inappropriate short-stay 
unit admission. The PSI score is heavily weighted towards these factors, explaining the better 
diagnostic characteristics seen with PSI class I. Despite this, no score provided sufficient diagnostic 
accuracy for use in prediction of CAP patients suitable for admission to an ED short-stay unit. 
 
Several limitations must be acknowledged. This is an observational study; data collected were 
therefore limited to those recorded in the process of standard patient care. However, missing data 
were reported and minimal for all fields except pH and arterial blood gas values, which were 
unavailable in similar proportions in other CAP validation studies [9,16,23]. The study was 
conducted at a single Australian metropolitan tertiary hospital, and hence, results and conclusions 
may not be generalisable. Study strengths include the recruitment of a large prospective cohort of 
consecutive patients admitted with CAP, with firm mortality end-points from a national database. 
A range of contemporary CAP severity scores were assessed, including the first Australian 
validation of CURXO and IDSA/ATS scores. To our knowledge, the utility of low CAP severity scores 
to predict ED short-stay unit admission has not been previously investigated. 
 
6.3.6 – Conclusions 
 
CAP severity scores had different strengths; CURXO and SMARTCOP were sensitive scores with 
potential to rule out severe disease, while the high specificity of CORB and CURB-65 facilitated 
identification of patients at high risk of invasive therapies or mortality. Low severity scores were 
not useful to identify patients suitable for admission to short-stay units. Decisions regarding 
suitability of patients with low-risk CAP for short-stay admission should incorporate individual 
reasons for hospitalisation in each case. 
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Table 6. 14 (Supplementary Table 6.1): The pneumonia severity index 
Characteristic Points PSI class with expected 30-day mortality 
Age    
Males Age in years  
Females Age - 10  
Nursing home resident 10  
Co-existing illness   
Neoplastic disease 30  
Liver disease 20  
Congestive heart disease 10  
Cerebrovascular disease 10           
Renal disease 10          PSI class I: age ≤50  
Physical examination findings           No co-existing illness or exam findings 
Altered mental status 20          Expected mortality 0.1% 
Respiratory rate ≥30 breaths/minute 20  
Systolic blood pressure <90 mmHg 20  
Temperature <35 or ≥40°C 15  
Pulse rate ≥125/minute 10  
Laboratory and radiographic findings            PSI class II: (≤70 points)          mortality 0.6%  
Arterial pH <7.35 30           PSI class III: (71 - 90 points)                     0.9% 
Urea >11.0 mmol/L 20           PSI class IV: (91 - 130 points)                   9.3% 
Sodium <130 mmol/L 20           PSI class V: (>130 points)                          27% 
Glucose ≥14.0 mmol/L 10  
Haematocrit <30% 10  
Arterial pO2 <60 mmHg 10  
Pleural effusion  10  
PSI = pneumonia severity index. Adapted from reference [6]. Estimated mortality data is from the PORT 
validation cohort (n=2,287)  
 
 
Table 6. 15 (Supplementary Table 6.2): Components of the CURB-65 and CORB scores 
C Confusion, acute 
U Urea > 7.0 mmol/L 
R Respiratory rate ≥ 30 breaths / minute 
B Blood pressure low (systolic <90 mmHg, diastolic ≤60 mmHg) 
65 Age ≥ 65 years 
  
C Confusion, acute 
O Oxygenation – SpO2 ≤ 90% 
R Respiratory rate ≥ 30 breaths / minute 
B Blood pressure low (systolic blood pressure < 90 mmHg) 
Each variable carries the same weight and the total score predicts 30-day mortality. The suggested CURB-65 
criteria for severe CAP is a score of ≥3 (3-5), and for CORB ≥2 (2-4). 
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Table 6. 16 (Supplementary Table 6.3): The CURXO score 
Minor Criteria Major Criteria 
C Confusion   
U Urea >30 g/dL P pH <7.30 
R Respiratory rate >30 breaths / min. S Systolic blood pressure <90 mmHg 
X CXR – multilobar or bilateral consolidation   
O PaO2 <54 mmHg or PaO2/FiO2 <250   
80 Age ≥80 years   
Severe CAP = ≥1 major or ≥2 minor criteria 
Adapted from reference [8]. CXR = chest x-ray, PaO2 = arterial partial pressure of oxygen, FiO2 = fraction of 
inspired oxygen, CAP = community acquired pneumonia. 
 
Table 6. 17 (Sup Table 6.4): The IDSA/ATS 2007 criteria for severe community-acquired pneumonia 
 
Minor Criteria Major Criteria 
 Confusion/disorientation   
 Uraemia (BUN ≥20 mg/dL)  Invasive mechanical ventilation 
 Respiratory rate ≥30 breaths/minute  Septic shock requiring vasopressors 
 PaO2/FiO2 ≤250   
 Multilobar infiltrates on chest x-ray   
 Leucopoenia (WCC <4000 cells/mm3)   
 Thrombocytopaenia (platelets < 105 cells/mm3)   
 Hypothermia (core temperature <36°C)   
 Hypotension requiring aggressive fluids   
Severe CAP = ≥1 major or ≥3 minor criteria 
Adapted from reference [10]. BUN = blood urea nitrogen, PaO2 = arterial partial pressure of oxygen, FiO2 = 
fraction of inspired oxygen, WCC = white cell count, CAP = community acquired pneumonia. 
 
 
Table 6. 18 (Supplementary Table 6.5): The SMARTCOP score 
Variable Points Interpretation 
S Systolic BP <90 mmHg 2   
M Multilobar CXR involvement 1   
A Albumin <35 g/L 1   
R Respiratory rate (age-adjusted cut-offs) 1 0-2 points Low risk of IRVS 
      Age ≤50: RR ≥25 breaths/minute       3-4 points Moderate risk (1 in 8) of IRVS 
      Age >50: RR ≥30 breaths/minute  5-6 points High risk (1 in 3) of IRVS 
T Tachycardia ≥125 beats/minute 1 ≥7 points Very high risk (2 in 3) of IRVS 
C Confusion (new onset) 1   
O Oxygen low (age adjusted cut-offs) 2   
      Age ≤50: PaO2<70mmHg or SpO2 ≤93%    
      Age >50: PaO2<60mmHg or SpO2 ≤90%    
P Arterial pH <7.35 1   
Adapted from reference [11]. BP = blood pressure, CXR = chest x-ray, RR = respiratory rate, PaO2 = arterial 
partial pressure of oxygen, SpO2 = pulse oximetry, IRVS = invasive respiratory or vasopressor support. 
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Table 6. 19 (Supplementary Table 6.6): Area under receiver operating curve comparisons for 
severity scores in prediction of intensive care admission or mortality. 
 PSI Class 
0.70 
(0.64-0.76) 
CURB65 
0.70 
(0.64-0.77) 
CORB 
0.78 
(0.72-0.83) 
CURXO 
0.84 
(0.80-0.89) 
SMARTCOP 
0.87 
(0.82-0.91) 
IDSA/ATS 
0.84 
(0.79-0.88) 
PSI       
CURB65 p = 0.82      
CORB p = 0.02 p = 0.003     
CURXO p <0.001 p <0.001  p <0.001    
SMARTCOP p <0.001  p <0.001   p <0.001 p = 0.31   
ISDA/ATS  p <0.001  p <0.001  p=0.01 p = 0.77 p = 0.26  
Column headings show area under receiver operating curve for each score with 95% confidence intervals. 
IDSA/ATS minor criteria were assessed. 
 
 
Table 6. 20 (Supplementary Table 6.7): Area under receiver operating curve comparisons for 
severity scores in prediction of discharge with 48 hours  
 
 PSI Class 
0.74 
(0.69-0.79) 
CURB65 
0.73 
(0.68-0.78) 
CORB 
0.64 
(0.60-0.68) 
CURXO 
0.71 
(0.66-0.77) 
SMARTCOP 
0.66 
(0.60-0.72) 
IDSA/ATS 
0.71 
(0.66-0.76) 
PSI       
CURB65 p = 0.38      
CORB p <0.001 p <0.001     
CURXO p = 0.18 p = 0.39 p <0.001    
SMARTCOP p = 0.01 p = 0.04 p = 0.46 p = 0.06   
ISDA/ATS  p = 0.26 p = 0.30 p = 0.002 p = 0.65 p = 0.06  
Column headings show area under receiver operating curve for each score with 95% confidence intervals. 
IDSA/ATS minor criteria were assessed. 
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Table 6. 21 (Supplementary Table 6.8): Predictive performance of scores with imputed data 
A) Prediction of 30-day mortality or ICU admission 
 Missing data presumed normal Imputed data 
Model (scores) % in 
class 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
% in 
class 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PSI (classes IV-V) 28% 
55% 
(43-66%) 
75% 
(71-79%) 
32% 
52% 
(40-63%) 
71% 
(67-75%) 
CURB-65 (3-5) 9% 
28% 
(18-40) 
94% 
(92-96%) 
9% 
28% 
(18-38%) 
94% 
(92-96%) 
CORB (2-4) 12% 
44% 
(32.5-56%) 
93% 
(90-95%) 
N/A N/A N/A 
CURXO (≥10)  
(≥1 major / ≥2 minor) 
48% 
85% 
(75-92%) 
57% 
(53-61%) 
55% 
86% 
(77-95%) 
49% 
(41-56%) 
IDSA/ATS  
(≥3 minor) 
18% 
60% 
(48-71%) 
88% 
(85-91%) 
22% 
63% 
(52-75%) 
84% 
(80-88%) 
SMARTCOP (≥3) 40% 
85% 
(75-92%) 
66.5 
(62-70%) 
49% 
89% 
(81-96%) 
56% 
(50-62%) 
B) Prediction of discharge within 48 hours and alive at 30 days 
 Missing data presumed normal Imputed data 
Model (scores) % in 
class 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
% in 
class 
Sensitivity (%) Specificity (%) 
PSI (class I) 26% 
56% 
(45-67%) 
79% 
(76-83%) 
26% 
56% 
(46-67) 
79% 
(76-83) 
CURB-65 (0) 39% 
76% 
(66-84%) 
67% 
(63-71%) 
39% 
76% 
(67-85%) 
67% 
(63-71%) 
CORB (0) 65.5% 
88.5 
(80-94%) 
38% 
(34-42.5) 
N/A N/A N/A 
CURXO-80 (≤4) 
(no major or minor)  
22.5% 
46% 
(35-57%) 
81% 
(78-85%) 
17% 
33% 
(17.5-49%) 
86% 
(81-91%) 
IDSA/ATS  
(no major or minor) 
27% 
51% 
(49-61.5) 
77% 
(73-80.5) 
23% 
43% 
(25-61%) 
80% 
(74-87%) 
SMARTCOP (0) 15.0% 
28% 
(18.5-38%) 
87% 
(84-90%) 
12% 
19% 
(7-32%) 
89% 
(85-93%) 
ICU = intensive care unit. N/A = not applicable – there were no missing CORB score values. In table results, 
figures in parentheses are 95% confidence intervals. 
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Table 6. 22 (Sup Table 6.9): Area under receiver operating curve results for imputed data 
 PSI Class CURB65 CORB CURXO SMARTCOP IDSA/ATS 
Mortality or ICU admission: 
     
Missing data 
presumed normal 
0.70 
(0.64-0.76) 
0.70 
(0.64-0.77) 
0.78 
(0.72-0.83) 
0.84 
(0.80-0.89) 
0.87 
(0.82-0.91) 
0.84 
(0.79-0.88) 
Missing data 
imputed 
0.66 
(0.60-0.73) 
0.70 
(0.64-0.77) N/A 
0.81 
(0.75-0.87) 
0.85 
(0.80-0.90) 
0.82 
(0.77-0.87) 
Discharge within 48 hours:      
Missing data 
presumed normal 
0.74 
(0.69-0.79) 
0.73 
(0.68-0.78) 
0.64 
(0.60-0.68) 
0.71 
(0.66-0.77) 
0.66 
(0.60-0.72) 
0.71 
(0.66-0.76) 
Missing data 
imputed 
0.75 
(0.70-0.80) 
0.73 
(0.68-0.78) 
N/A 
0.73 
(0.67-0.78) 
0.65 
(0.59-0.71) 
0.70 
(0.65-0.76) 
ICU = intensive care unit, N/A = not applicable – there were no missing CORB score data. Figures in 
parentheses are 95% confidence intervals. IDSA/ATS minor criteria only. 
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Section 6.4 – Chapter Summary and Thesis Contextualisation 
 
Risk stratification scores for patients with community-acquired pneumonia (CAP) represent an 
example of practical severity score use in assisting disposition location decisions in the ED and/or 
mortality risk. In section 6.2, characteristics and results of previous CAP validation literature were 
consolidated. That review found substantial variation in study cohort characteristics (convenience 
versus consecutive samples, study definitions of CAP, inclusion or otherwise of patients from 
nursing homes or with established limitations to therapy) as well as endpoints (mortality, invasive 
therapies, intensive care unit admission). Availability of ICU beds and associated ICU admission 
practices in individual health care systems were identified as key factors potentially influencing 
interplay between study endpoints and severity score performance. Local health care system 
characteristics may have influenced individual investigators’ decisions regarding cohort and 
endpoint selection in each study included in the review.  
 
The published paper comprising section 6.3 (“Utility of community-acquired pneumonia severity 
scores in guiding disposition from the emergency department: Intensive care or short-stay unit?”) 
examined utility of CAP severity scores at the Royal Brisbane and Women’s Hospital (RBWH), a 
large tertiary adult hospital in temperate Australia [1]. At that centre, admission to ICU was 
generally an reserved for patients demonstrated to need invasive organ support (most commonly 
mechanical ventilation or vasopressor support). Patients with significant dependence and 
established limitations to therapy were generally judged not likely to benefit from ICU admission. 
Advantages of ward-based care for this subgroup of patients with high predicted mortality may 
include greater awareness and interaction with family, as well as preservation of dignity and focus 
on symptom control and amelioration rather than an ‘all-or-nothing’ approach to cure [2]. 
Resources and culture of health care providers and patients may influence these decisions [3], and 
to the extent to which ICU admission practices in the context of ED patients with severe 
pneumonia at RBWH mirror those in other hospitals in temperate Australia is currently unknown. 
 
Study cohort and endpoints in section 6.3 were chosen to reflect practical disposition decision-
making in the ED, within the context outlined above. Results endorsed the continued use of the 
SMARTCOP tool to screen for patients at risk of ICU admission either from the ED or later during 
subsequent hospitalisation. CORB (or CURB65) was found to have higher specificity therefore may 
be useful when making referrals to ICU. No score was effective in reliably identifying patients likely 
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to have a brief admission, and so scores were deemed not useful to identify potential patients for 
short-stay unit admission. 
 
Cohort and endpoint heterogeneity were identified in section 5.2 to be responsible for marked 
variation of results in studies validating general sepsis severity scores. Similar conclusions were 
reached after review of CAP severity scores in section 6.2. Although decision support regarding 
appropriate disposition for ED patients with CAP has proved a good example of severity score use 
in practice, care must be taken to choose a score validated in conditions with similar health care 
characteristics. 
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Chapter 7: Thesis conclusions 
 
The aims of this thesis have been to explore and evaluate systems to risk stratify ED patients with 
infection. The cornerstone of this work and means by which risk stratification tools have been 
assessed is a large prospective database, designed to benchmark characteristics and outcomes for 
ED patients admitted with all severities of infection, and to address some of the gaps and 
limitations in previous validation literature. The activities and findings of each thesis chapter are 
outlined below, and summarised in Figure 7.1. 
 
 Figure 7. 1: Summary of thesis papers and outcomes 
 
Figures refer to chapters, published papers in blue. ED = emergency department, SIRS – systemic 
inflammatory response syndrome, qSOFA = ‘quick’ sequential (sepsis-related) organ function assessment, 
MEDS = mortality in ED sepsis, SMARTCOP = systolic blood pressure, multilobar, albumin, respiratory rate, 
tachycardia, chest x-ray, oxygenation, arterial pH, CURB = confusion, urea, respiratory rate, blood pressure, 
CORB = confusion, oxygenation, respiratory rate, blood pressure. 
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Section 7.1 - Summary of findings 
 
Chapter one introduced two main classes of prognostication or risk stratification tools. The ‘sepsis 
syndromes’ hierarchy was first proposed by Roger Bone and colleagues in the late 1980s, and has 
been subsequently refined through several iterations, culminating to date in the recent ‘Sepsis-3’ 
proposals of 2016 [1, 2]. Each iteration has laboured with the absence of a gold standard indicator 
for infection, and with the difficulties of satisfying dual roles of clinical and research classifications 
[3]. Structured clinical prediction rules were discussed, together with the main components of 
predictive accuracy assessment (discrimination, calibration). Lastly various tools proposed for use 
in the assessment of quality and bias in validation studies were presented, including QUIPS [4], 
QUADAS-2 [5] and PROBAST [6]. Selected components of these tools were later combined as a 
custom structure for use in sections 5.2 and 6.2. 
 
After review of the potential sources of bias in observational studies, methodology of the thesis 
database was detailed in chapter two [7]. Building on characteristics established to reduce bias 
and optimise applicability to the question of risk stratification in ED patients with presumed 
infection 9,719 consecutive patient admissions were enrolled in the thesis database over three 
years. A further two years were required to check, clean and enter these data. The completed 
database was used to assess aspects of risk stratification; ‘sepsis syndromes’ were the subject of 
chapters three and four, while clinical prediction rules with established use in patients with 
infection were examined in chapters five and six. 
 
Use of a SOFA-based organ dysfunction in the thesis database facilitated an assessment of 
implications for emergency departments inherent in the recently proposed ‘sepsis-3’ proposals in 
chapter three. The associated paper [8] has raised several important issues. SIRS was defended as 
a sensitive indicator of patients at risk of organ dysfunction and mortality, and qSOFA was 
confirmed to be a specific but insensitive marker of ‘sepsis’ (defined as infection with consequent 
organ dysfunction). Since completion of chapter 3, further studies have been published with the 
aim of validating aspects of sepsis-3 proposals [9-18]. Characteristics and outcomes of studies 
published at the time of writing are summarised in Table 7.1. 
  
10 studies enrolled cohorts from non-ICU settings (mostly ED), with overall cohort mortality 
ranging from 4.4% [9, 10] to 27.5% [13]. All but two papers assessed SIRS and qSOFA in prediction 
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of (in-hospital) mortality rather than some form of organ dysfunction. Given the sepsis-3 authors’ 
stated aim of qSOFA to screen for potential ‘sepsis’ (infection with organ dysfunction) in non-ICU 
environments, the endpoint of organ dysfunction would arguably be a more appropriate endpoint 
than mortality. 
 
Chapter three of this thesis addressed aspects of the proposed sepsis-3 structure beyond 
diagnostic accuracy of qSOFA, such as the definition of organ dysfunction. As the paper comprising 
the basis of chapter three makes clear, the SOFA score requires modification and calibration for 
use in the ED environment. Additionally, the sepsis-3 requirement for an increase in total SOFA 
score of ≥2 ignores the critical prognostic and therapeutic information available if criteria for 
organ dysfunction in each of multiple systems were stipulated [19]. To date no other authors have 
acknowledged this important aspect of the proposed sepsis-3 definitions, beyond a single editorial 
[20].  
 
Chapter four focussed on the thesis cohort subgroup with septic shock, defined as per the 
inclusion criteria for early goal-directed therapy (EGDT) trials. The associated paper revealed the 
significant adverse prognostic impact of nursing home residence and limitations to therapy 
imposed in the ED [21]. While these findings are not new [22], comparison with cohorts recruited 
into controlled trials of invasive therapies with similar inclusion criteria [23-25] revealed the extent 
to which enrollment of nursing home residents (as a surrogate indicator of elderly patients with 
significant dependence and co-morbidity) varied between different countries and health-care 
systems. It is unknown whether awareness of the marginal mortality gains and forfeit of dignity, 
independence and awareness resulting from unrestrained medical management, or pragmatism 
associated with cost and availability of ICU beds underpins these stark differences [26]. Given the 
vast human and financial costs at stake, further research into acute health care decision-making 
for this high mortality subgroup across different health care systems is imperative. 
 
1
8
5 
Table 7. 1: Characteristics and results of validation studies examining qSOFA/SEPSIS-3 
Author, year Country Cohort type, period n =  outcome results Notes 
Williams 2017 
CHEST 
AUS 
 
 
 
Single-centre (Brisbane) 
prospective observational 
cohort ED patients with 
suspected infection: 2007-11 
8,871 30d mortality 3.7% 1. qSOFA≥2 vs SIRS≥2 for 
prediction of organ dysfunction. 
AUROC (0.72-0.73), SIRS 
sensitive, qSOFA specific.  
2. SOFA examined and found to 
require recalibration. 
SOFA-based definitions of 
organ dysfunction, both 
Sepsis-2 and Sepsis-3. 
Henning 2017 
Ann Emerg Med 
USA 3 prospective observational 
cohorts of ED patients with 
suspected infection: 2003-06 
7,637 In-hospital mortality 
4.4% 
1. qSOFA≥2 prediction of in-
hospital mortality: 
AUROC = 0.77 
Sens = 52%, Spec = 86% 
SIRS≥2 Sens = 83, Spec = 50% 
2. Sepsis-2 shock classified 
more high risk patients than 
sepsis-3 septic shock. 
1. qSOFA assessed in 
prediction of death, rather 
than organ dysfunction. 
2. Study organ dysfunction 
criteria not SOFA-based. 
Askim 2017 
Scand J Trauma 
Resus Emerg Med 
NOR Single-centre prospective 
cohort ED patients with 
suspected infection: 2012 
1,535 1. Severe sepsis (n = 
108, mortality 17.6%) 
2. 30d mortality 4.4% 
1. qSOFA≥2 prediction of 
(sepsis-2) severe sepsis: 
Sens 32%, Spec 98% 
2. qSOFA≥2 prediction of death 
Sens = 13%, spec = 96% 
SIRS≥2 prediction of death  
Sens = 64%, spec = 55% 
1. Severe sepsis = infection + 
SIRS + (non-SOFA) organ 
dysfunction in the ED. 
Park 2017 
J Crit Care 
KOR Single-centre retrospective 
cohort, ED patients with 
suspected infection: 2007-16 
1,009 1. Sepsis-3 based 
organ failure (n = 627 
= 62% of cohort) 
2. In-hospital 
mortality 15.8% 
1. Organ dysfunction: AUROCs 
qSOFA 0.81 vs SIRS 0.67,  
qSOFA≥2 Sens = 35, spec = 99% 
2. In-hospital mortality: AUROC 
qSOFA 0.73 Vs SIRS 0.60 
qSOFA≥2 Sens = 53, spec = 84%  
Cohort retrospectively 
identified through EMR 
combination of cultures and 
antibiotics. AVPU rather than 
GCS for CNS SOFA. Excluded 
those discharged <24h. 
Freund 2017 
JAMA 
EUR Multicentre (30 centres, 27 in 
France) European prospective 
cohort of consecutive ED 
patients with suspected 
infection: 2016 
879 In-hospital mortality 
8% 
In-hospital mortality: AUROCs 
qSOFA 0.80 vs SIRS 0.65 
qSOFA≥2 Sens = 70, spec = 79% 
SIRS≥2 Sens = 93, spec = 27% 
qSOFA assessed in prediction 
of in-hospital death, rather 
than organ dysfunction. 
Wang 2016 
Am J Emerg Med 
CHN Single-centre prospective 
observational cohort ED 
patients with suspected 
infection: 2015 (6 months) 
477 28d mortality 27.5% 
ICU admission 22.9% 
1. qSOFA prediction 28d 
mortality AUROC 0.67, 
Sens = 43% , spec = 83% 
2. qSOFA prediction ICU 
Prediction of death /ICU rather 
than ‘sepsis’, high mortality for 
ED patients with infection.  
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6 
admission AUROC 0.64 
Sens = 33%, spec = 84% 
Churpek 2017 
Am J Resp Crit Care 
Med 
USA Single-centre retrospective 
observational cohort: 
suspicion of infection, ED 
(60%) or wards, 2008-16. 
31K 1. In-hospital 
mortality 5.4% 
2. ICU admission or 
mortality 
1. AUROC for mortality: qSOFA 
0.69 vs SIRS 0.65 (p<0.01),  
qSOFA≥2 Sens = 69, spec = 64% 
SIRS≥2 Sens = 94, spec = 12% 
Similar for composite. 
qSOFA included GCS≤13 as 
originally calculated, but 
mortality outcome rather than 
organ dysfunction. 
Finkelsztein 2017 
Crit Care 
USA Prospective cohort of patients 
admitted to medical ICU, 67% 
from ED: years not specified 
152 1. In-hospital 
mortality 19% 
AUROCs for mortality: qSOFA 
0.74 vs SIRS 0.59 (p = 0.03) 
qSOFA≥2 Sens = 90, spec = 42% 
SIRS≥2 Sens = 93, spec = 12% 
Data from 8 hours before ICU 
admission, outcome mortality. 
April 2017 
J Emerg Med 
USA Retrospective chart review ED 
patients admitted to ICU with 
presumed infection: 2012-15. 
214 1. In-hospital 
mortality 18.2% 
AUROCs for mortality: qSOFA 
0.66 vs SIRS 0.65 (p = NS) 
qSOFA≥2 Sens = 27, spec = 90% 
SIRS≥2 Sens = 97, spec = 2% 
ED data for patients admitted 
to ICU. (In-hospital) mortality 
endpoint. 
Raith 2017 
JAMA  
ANZ Retrospective interrogation of 
ANZICS APD database of ICU 
admissions – included those 
with infection-related Dx: 
2000-2015 
184K 1. In-hospital 
mortality 18.7% 
2. Mortality or ICU 
admission ≥3 days 
1. AUROC for mortality: qSOFA 
0.61, SIRS 0.59, SOFA 0.75 
2. AUROC for composite endpt: 
qSOFA 0.61, SIRS 0.61, versus 
SOFA 0.74 
1. Data collected within 24h of 
ICU admission. 
2. Baseline SOFA 0 presumed 
for all patients. 
Ho 2017 
J Crit Care 
AUS Single-centre (Perth) ICU 
admissions with suspected 
infection: 2008-13. 
Shock 
422, 
sepsis 
242 
In-hospital mortality 
for larger cohort 12% 
1. qSOFA prediction of in-
hospital mortality AUROCs: 
Septic shock 0.64 (SOFA 0.68) 
Sepsis 0.60 (SOFA 0.62) 
1. Data from 1st hour in ICU 
2. Ventilated patients excluded 
 
Country codes are standard 3-character conventions except ANZ = Australia and New Zealand, and EUR = 4 European countries (France, Spain, Belgium, Switzerland), ED = 
emergency department, ICU = intensive care unit, SOFA = sequential (sepsis-related) organ function assessment, qSOFA = ‘quick’ SOFA, AUROC= area under receiver operating 
characteristic curve, Sens = sensitivity, spec = specificity, EMR = electronic medical record, AVPU = alert, voice, pain, unresponsive, GCS = Glasgow Coma Score, CNS = central 
nervous system. 
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A recruitment rate of 10.5 patients per month also contrasted with those for the recent EGDT 
studies (<0.5 patients/centre/month) emphasising the selective nature of controlled trials [27]. 
Finally, associations between interventions such as greater fluid volume and early vasopressor 
therapy and better outcome have underlined the importance and of observational studies 
recruiting a broad spectrum of subjects in furthering evidence for interventions in sepsis care. 
 
Clinical prediction rules developed for mortality risk stratification in patients with infection (MEDS, 
SOFA, ‘severe sepsis score’) or critical illness (APACHE II, SAPS II) were the subject of chapter five. 
Previous validation literature was systematically reviewed before the paper comprising section 5.3 
[28] assessed the predictive accuracy of these scores in the thesis cohort. In that study, 
assessment of different sepsis subgroups produced variation in resulting discrimination. Spectrum 
bias [29] in risk stratification scores was thus graphically demonstrated, helping to explain some of 
the substantial variation in results seen in previous validation literature.  
Despite the MEDS score achieving superb discrimination, performance suffered in subgroups less 
likely to include patients from nursing homes or at high risk of mortality from underlying co-
morbidities, such as those admitted to ICU. In further analysis using the entire cohort, plotting 
observed and predicted outcomes showed poor calibration for scores developed for use in ICU or 
other critically ill populations. In summary, this paper recommended the use of clinical prediction 
scores derived and validated in similar populations to the cohort of interest.  
 
Clinical prediction rules developed for community-acquired pneumonia (CAP) were assessed in 
chapter six. Pneumonia comprises the largest source subgroup in ED patients with infection [30] 
and provides an example of more advanced stages of prediction rule development. Several 
national guidelines have endorsed the use of clinical prediction rules for decision-making 
regarding disposition location. The paper comprising section 6.3 [31] assessed the accuracy of 
several established CAP scoring systems for prediction of ICU admission (or death) in a cohort 
thought to be suitable for unrestrained resuscitation. These requirements approximated the 
derivation purpose of several scores (SMARTCOP, IDSA/ATS 2007 criteria, CURXO) leading to 
optimal performance [32-34]. A speculative analysis of the accuracy of low CAP severity scores in 
predicting admission <48 hours was unrewarding.  
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Section 7.2 – Limitations and strengths  
 
The inherent limitations of methods used to identify the thesis cohort have been detailed in 
chapter two (thesis methods, [35]) and subsequently outlined in each publication. Rather than 
reproduce these in full here, discussion will centre on the methods used to identify patients for 
inclusion in the study cohort, and how they might have been improved. Central to the thesis aims 
was to identify a cohort of patients relevant to the issue of risk stratification for ED practitioners, 
and as such it was necessary to capture a broad, consecutive and inclusive group. Achieving this 
denominator would enable a meaningful estimate of prevalence, in turn necessary for realistic 
diagnostic accuracy measurements.  
 
Patients admitted with an ED diagnosis indicating or suggesting infection were identified daily (a 
list of the relevant ICD codes has been appended to the methods paper). Study data collectors 
then accessed each of the listed patients’ paper charts, and formally enrolled patients if both the 
ED and admitting inpatient unit concurred that infection was the most likely cause for admission.  
 
Enrollment therefore rested on the overall clinical impression of both ED and inpatient teams. 
Investigators with similar aims elsewhere have enrolled cohorts based on ED diagnosis [36] or 
admission diagnosis [37], but this author is unaware of previous studies that required concurrence 
of ED and admission team diagnosis for study inclusion. It was intended that these methods 
proved sufficiently sensitive to capture as many patients meeting study criteria as possible but also 
with sufficient specificity that enrolled non-infected patients were kept to a minimum. Study 
methods may have been strengthened by retrospective checks to ensure inclusion of specific 
identifiable groups such as bacteraemic patients, patients admitted to ICU with infection, and 
patients discharged with codes indicating infection-related diagnoses. These steps were 
impractical from the perspective of available time and funds. Ultimately, in the absence of a gold-
standard indicator or test for infection, the methods used in this thesis database would have 
caused inclusion of patients ultimately determined not to have infection, and inadvertently 
exclusion of patients with infection. 
 
Another important limitation of this study is single centre design. As such, relevance of these data 
to risk stratification and classification of patients in other centres, countries and health care 
systems is unclear. Examples of multi-centre or even multi-national studies which have recruited 
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ED patients with infection exist [9, 12, 22], however a greater level of research infrastructure  and 
funding were likely brought to bear in these instances. Emergency medicine research in Australia 
(and beyond) has yet to realise full potential [38], however promising ED based multi-centre 
collaborations in sepsis research are currently developing in this country [39-41].    
 
As an observational study, data collected from each patient’s chart and electronic databases were 
limited to those accumulated during the course of routine management. Missing data were the 
inevitable result. These effects were mitigated through the development of a modified SOFA 
framework which incorporated commonly-recorded data as an alternative to invasive tests, such 
as SpO2 cut-offs alongside arterial blood gas data for grading respiratory function. Quantity and 
consequences of missing data were reported through sensitivity analyses in published papers. An 
alternative study design in which specified data were collected for all patients would have been 
impractical and less informative; costly data collection, required consent from patients, and 
potentially un-necessary tests would have substantially reduced size and representativeness of the 
resulting cohort. 
 
Strengths of the study design should be acknowledged. They include recruitment of a large 
consecutive cohort of ED patients, collection of detailed data including demographics, co-
morbidities, acute physiology, organ dysfunction, results of biochemical, haematological and 
microbiological tests, and solid mortality outcomes. Systematic reviews (sections 5.2 and 6.2) 
facilitated awareness of deficiencies in previous validation literature, and adherence to accepted 
standards of data collection and reporting for observational studies [42, 43].  
 
Section 7.3 – Future directions 
 
7.3.1 - The evolution of risk stratification 
In an age of increasingly sophisticated and powerful computing and data storage, electronic 
medical records offer a means by which routine data are captured in real time in the course of 
each patient’s treatment. This offers the possibility of ‘real time’ risk stratification and screening, 
using inbuilt software algorithms, which enable earlier identification of high risk patients and 
earlier decision-making and interventions [44]. Through neural networks and machine learning 
(introduced in section 1.2.2), systems can be designed to self-calibrate and improve predictive 
accuracy [45, 46]. Electronic patient records also allow the rapid construction of large 
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observational datasets designed to answer specific clinical questions. Examples include the ANZICS 
Adult Patient Database and the combined US hospital dataset utilised to produce and support the 
sepsis-3 initiatives [9, 47]. 
 
Another topical area of research that may ultimately allow individual patient prognostication as 
well as therapy is novel biotests, a field which includes biomarkers, metabolomics and genomics. 
Pro- and anti- immune and inflammatory biomarkers, interleukins, cell adhesion molecules and 
other discrete soluble factors such as monocyte human leukocyte antigen-DR (mHLA-DR), 
presepsin (soluble CD14), soluble urokinase plasminogen activator receptor (suPAR) and mid-
regional pro-ADM(MR-pro-ADM) have all been associated with outcome in sepsis [48]. Concurrent 
arrays of biomarkers are likely to allow greater diagnostic accuracy [49]. Some investigators have 
added novel biomarkers to more conventional clinical prediction tools with mixed results [50-52]. 
The necessary technologies to allow these complex tests to be performed at the bedside are 
already being developed [53].  
 
The study of metabolomics in sepsis encompasses the measurement of a range of metabolic by-
products (including acylcarnitines, sphingolipids and glycerophospholipids) released as a result of 
altered cellular metabolism in disease states [54]. Patterns of gene expression have been 
associated with individual responses to sepsis and this comprises the essence of genomics [55]. 
The combination of known and yet to be discovered biomarkers, metabolomics and genomics may 
well promise an exciting future of individualised prognostic and therapeutic data for sepsis 
management. 
 
7.3.2 - Extension of this work 
This work has established that SIRS may still have a role in screening ED patients with infection for 
those at higher risk of organ dysfunction and mortality, and that qSOFA is ill-suited for this 
purpose. Despite that, it has, together with other ED-based studies [37, 56] also confirmed SIRS 
does not influence outcome in patients with organ dysfunction or shock, so should not be an 
inclusion criterion for future trails enrolling ED patients with those characteristics.  
Use of the SOFA score to signify and quantify organ dysfunction in sepsis has been proposed in the 
sepsis-3 initiatives [2]. Reference to outdated or non-evidence based therapies (dopamine, 
dobutamine), non-standard invasive tests (arterial blood gases) and data impractical to collect in 
the ED (daily urine balances) argues the SOFA score needs urgent revision for use in the ED [57]. 
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Moreover this thesis has revealed that mortality risk substantially varies between types of organ 
dysfunction using the score as currently structured. Collaboration between a network of 
committed ED-based clinicians and researchers is required to propose a modified SOFA score for 
use in the ED and thereafter instigate multi-centre observational studies to calibrate the score and 
determine evidence based thresh-holds for organ dysfunction in patients with infection. 
 
Further work on redefining shock as hypotension persisting despite a designated fluid bolus (the 
Surviving Sepsis Campaign’s current guideline recommended dose of 30 mL/kg might be a 
reasonable place to start discussion) or requirement for vasopressor therapy must also be a 
priority for further ED-based collaborations [58]. Given the demonstrated mortality burden carried 
by patients considered unsuitable for vasopressor therapy (at least in Australia), requirement for 
invasive therapies to satisfy the definition of septic shock appears inappropriate. The extent to 
which patients with extensive co-morbidity and dependence precludes invasive therapies in 
different health care settings is also another area of required research that would extend this 
thesis. 
 
The ongoing use of SMARTCOP to risk stratify patients with CAP is justified by these data. This 
work is currently being extended to determine whether SMARTCOP remains additionally an 
appropriate framework to determine spectrum of appropriate empiric antibiotic therapy. Other 
practical decision-making tools that may be derived from future multicentre observational 
databases might include tools to assess risk of bacteraemia, in immunosuppressed and non-
immunosuppressed populations. Although such tools exist [59, 60], validation and application to 
local practice is required. 
 
Section 7.4 Conclusions  
 
Risk stratification forms a key part of the management of all critical illnesses, including sepsis. 
Components of current ED risk stratification tools include demographic, historical, physiological 
and initial investigational factors – many of which may, in the future become obsolete. However 
they are the tools to hand at this time, and it remains a matter of some importance we enquire 
how best to use them. Large observational datasets such as the one on which this thesis is based 
will always be required to assess new risk stratification tools and strategies. Although electronic 
patient datasets will supplant labour-intensive data extraction from paper charts and other 
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sources, the factors that contribute to quality of data and analysis explored here are unlikely to 
change. 
 
The vast majority of steps forward in the quest to improve the quality of care supplied to our 
patients with sepsis will be almost immeasurably small ones. If even the smallest part of this work 
is viewed as such at some time, it will have been worthwhile.  
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